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ABSTRACT 
 
Background 
Activation of the innate immune system plays a key role in exacerbations of chronic 
lung disease, yet the role of fibroblasts in innate immune responses and the identity 
of danger signals (alarmins) that may contribute to their activation are still to be 
unraveled. The objectives of this study were to identify epithelial alarmins released 
during environmental insults which induce innate immune responses in lung 
fibroblasts and dissect the mechanisms responsible for this.  
Methods  
Primary human lung fibroblasts (PHLF) were treated with conditioned media from 
primary bronchial epithelial cells (PBECs) exposed to oxidant injury or endoplasmic 
reticulum stress (ER stress) and fibroblast responses assessed. The relevance of 
alarmins in-vivo was assessed clinically by measurement of relevant alarmins 
longitudinally in patients developing Bronchiolitis Obliterans Syndrome (BOS) after 
lung transplantation. 
Results 
Conditioned media from PBEC cells subjected to oxidant injury and ER stress 
contained elevated levels of alarmins. Treatment of PHLFs with conditioned media 
from damaged cells significantly upregulated IL-6, IL-8, MCP-1, GM-CSF, IL-1α and 
IL-1β expression (p<0.05). This effect was reduced with anti-IL-1α or IL-1Ra but not 
anti-IL-1β antibody. Co-stimulation with Poly I:C significantly accentuated the IL-1α 
induced inflammatory phenotype in PHLFs.  Clinically, IL-1α was increased in BAL of 
lung transplant recipients with infections and within 3 months of developing 
bronchiolitis obliterans syndrome (BOS) (p<0.001). Additionally, IL-1α levels 
positively correlated with elevated IL-8 (p<0.001) and neutrophil counts (p<0.001). 
Conclusions 
IL-1α plays a pivotal role in triggering proinflammatory responses in fibroblasts and 
this process is accentuated in the presence of viral pathogen associated molecular 
patterns. This novel pathway warrants further evaluation of its therapeutic 
potential to limit the repeated cycles of injury and exacerbation in chronic lung 
diseases.  
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CHAPTER 1 INTRODUCTION 
1.1 Wound healing and tissue fibrosis 
 
Wound healing is an immensely important physiological process, essential for 
maintaining tissue integrity and protection against various extrinsic factors including 
toxic chemicals and pathogens. Tissue injury very often leads to damage of the 
endothelial-epithelial barrier which triggers a cascade of events including platelet 
aggregation, formation of a protective fibrin-fibronectin meshwork, removal of 
dead cells by neutrophils and macrophages, angiogenesis, re-epithelization and 
reconstitution of the extracellular matrix (ECM) by activated fibroblasts secreting 
substantial amounts of collagen type III which is later replaced by the more robust 
collagen type I. In the final stage of the wound healing process – the remodeling 
phase - the excessive collagen is removed by matrix metalloproteases and the cells 
which are no longer required, such as the activated fibroblasts, undergo apoptosis 
[1] [2] [3]. However in chronic tissue injury the process of remodeling often 
becomes dysregulated leading to further activation and proliferation of fibroblasts 
which may result in scar tissue formation and development of fibrosis [4] [5] [6].  
Fibrosis is a chronic disease characterized by progressive loss of epithelium that is 
replaced by fibroblasts producing excessive collagen leading to distortion of tissue 
architecture and function [7] [8]. Fibrosis has been recognized as a major cause of 
morbidity and mortality in many chronic diseases including liver cirrhosis [9], 
Crohn’s disease [10], type II diabetes [11], chronic inflammatory lung diseases 
including chronic obstructive pulmonary disease (COPD) [12] and bronchiolitis 
obliterans syndrome (BOS) [13] and certain ageing-associated diseases eg. chronic 
renal disfunction [14]. In organs such as liver, heart, lung and kidney development 
of fibrosis is accompanied by progressive loss of organ function which may lead to 
serious clinical complications or even prove fatal. It is estimated that over 45% of 
deaths in the western world are attributed to some sort of fibrotic disease [15]. 
Fibrosis is associated with neutrophil and macrophage influx into the organ and 
upregulation of proinflammatory cytokines resulting in chronic inflammation. 
However it is unclear if prolonged inflammation is a trigger for fibrosis or whether 
these two processes only co-exist in chronically injured tissues. Martin et al. using 
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PU.1 mice lacking functional neutrophils and macrophages demonstrated that the 
fibrogenetic process may take place even in the absence of immune cell, which 
indicates that fibrosis may also develop without ongoing inflammation [16]. Some 
fibrotic diseases such as Crohn’s disease [17], rheumatoid arthritis [18] and 
scleroderma [19] are responsive to immunosupressants. Corticosteroids, however, 
proved to be ineffective in the treatment of fibrotic diseases such as idiopathic 
pulmonary fibrosis (IPF), which develops in the environment of oxidative stress 
which suppresses corticosteroid activity [20].  
Fibrotic lung diseases, such as IPF, COPD and BOS – a clinical manifestation of 
chronic post-transplant lung rejection, are characterized by chronic inflammation, 
degeneration of the respiratory epithelium and intensive fibroproliferation. The 
epithelial damage in these diseases may be triggered by oxidative stress caused by 
ROS released by activated neutrophils [21], viral [22] and bacterial [23] infections, 
cigarette smoke [24], air pollution [25] or allogenic injury [26]. Recent studied 
revealed that damaged cells may release danger signals (alarmins, damage 
associated molecular patterns – DAMPs), which may activate myeloid cells such as 
neutrophils and macrophages [27], however the interactions between epithelial 
alarmins and fibroblasts which become one of the most abundant cell type in 
fibrotic lung, have not been studied before. Therefore, the objective of this study 
was to investigate, if danger signals released by damaged human bronchial 
epithelial cells may activate human lung fibroblasts, to identify alarmins involved in 
fibroblast activation and to verify the clinical relevance of the potential findings by 
measuring the levels of the relevant alarmins in bronchoalveolar lavage (BAL) of 
lung transplant recipients who developed BOS.  
A diagram representing a simplified process of wound healing and tissue fibrosis is 
shown in figure 1. 
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Figure1 A diagram representing a simplified process of wound healing and tissue 
fibrosis 
Acute tissue injury which may be caused by infection, irritating substances or 
allogenic factors results in damage to the endothelial-epithelial barrier, followed by 
inflammation and fibroproliferation required for the remodeling and restoration of 
the tissue architecture. Repetitive tissue injury which may be caused by unresolved 
infection or prolonged exposure to irritating substances distorts the wound healing 
process, leading to chronic inflammation and tissue fibrosis. 
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1.2 Cellular mediators of fibrosis and inflammation 
1.2.1 Structural cells 
Fibroblasts 
 
Fibroblasts, which are the key drivers  of fibrogenesis, may originate from different 
sources including increased proliferation of resident fibroblasts or epithelial cells 
which upon activation by profibrotic agents such as transforming growth factor-β1 
(TGF-β1) and platelet derived growth factor (PDGF) may undergo a process called 
Epithelial to Mesenchymal Transition (EMT) and gain a new mesenchymal 
phenotype, characterized by upregulation of specific markers such as α-smooth 
muscle actin (α-SMA), desmin, vimentin and fibronectin [28]. The pool of fibrogenic 
cells may also be supported by bone marrow derived fibrocytes [29] that may be 
attracted to the site of injury by chemokines such as CXCL-12 [30]. Fibrocytes 
cultured in vitro can differentiate into myofibroblasts and gain the ability to 
produce collagen [31].  
Once the process of wound closure has been completed, the activated fibroblasts 
which are no longer required should enter the apoptotic pathway. However, in 
fibrosis, this process becomes distorted and the activated fibroblasts continue to 
proliferate and produce excessive collagen deposits. Shalamit et al. showed that in 
the murine model of bleomycin-induced fibrosis, myofibroblasts present in the lung 
become resistant to Fas-ligand mediated apoptosis and gain the ability to 
counteract Fas+ lymphocytes [32]. This observation may suggest that the 
environment of injured tissue provides factors promoting survival of the activated 
fibroblasts. Cytokine profiling conducted on BAL from IPF patients showed that a 
correlation exists between the disease and upregulation of type 2 cytokines, 
including IL-4, which stimulates fibroblast proliferation. Furthermore, a proteomic 
analysis revealed that tissue samples from IPF patients expressed increased levels of 
proteins possessing anti-proteolitic activity such as α-2 Macroglobulin which is an 
inhibitor of metalloproteases involved in the ECM remodeling [33]. In addition, a 
gene expression analysis of pulmonary fibrosis revealed upregulation of several 
antiapoptotic genes including Twist-1 which is activated by profibrotic factors such 
as PDGF, Basic Fibroblast Growth Factor (bFGF) and Epidermal Growth Factor (EGF) 
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[34]. These observations indicate that the environment in chronically injured organs 
selectively promotes fibroblast proliferation and survival. 
Until quite recently fibroblasts have been regarded as cells whose role was limited 
mainly to the restoration of tissue architecture. However an increasing number of 
studies have suggested that fibroblasts may also function as mediators of the innate 
immune responses and that they may act to modulate the switch from acute 
response to chronic inflammation which coexists with fibrosis [35]. The influence of 
a microenvironment determined by damaged epithelium, which develops in organs 
exposed to chronic injury, such as post-transplant lung, on fibroblast behavior has 
not been studied before, and therefore one of the objectives of the study was to 
determine if danger signals released from damaged human bronchial epithelial cells 
may modulate fibroblast phenotype. 
Epithelial cells 
 
Respiratory epithelium is built up with a single layer of ciliated, columnar cells based 
on a fibrous basement membrane. Three different cell types, namely ciliated cells, 
goblet cells and basal cells, can be distinguished in the epithelial layer. During 
epithelial injury, basal cells migrate to cover a site where epithelial cells get 
damaged, and differentiate to restore the epithelial structure.  
Depending on the location, the respiratory epithelium can be divided into three 
groups: nasal, bronchial and alveolar epithelial cells, amongst whom, type I and 
type II pneumocytes have been distinguished. Type I pneumocytes make up around 
96% of the alveolar surface and their main function is CO2/O2 gas exchange [36]. 
Type II pneumocytes make up the remaining 4% of ciliated epithelial cells and are 
mainly involved in the production of pulmonary surfactant which reduces surface 
tension and is required to increase pulmonary compliance (ability of the lung to 
expand) and prevent atelectasis (collapse of the lung) [37].  
Respiratory epithelium provides the first line of defense against invading pathogens 
and airborne microparticles by formation of a physical barrier, expressing a vast 
array of Pattern Recognition Receptors (PRR) and production of proinflammatory 
28 
 
factors involved in mobilization and activation of immunocytes including 
macrophages, neutrophils and T cells [38].  
Chemotaxis of inflammatory cells can be mediated by a plethora of chemotactic 
factors produced by bronchial cells, including monocyte chemotactic protein-1 and 
4 (MCP-1 and MCP-4), IL-8, eotaxin, and arachidonic acid metabolites which act as 
attractants for neutrophils, eosinophils, and monocytes and increase mucus 
production [39]. 
Moreover, the airway epithelium actively participates in pathogen clearance and 
maintaining tissue homeostasis by producing mediators such as anti-microbial 
agents including lactoferrin, lysozyme, mucins, cationic proteins and anti-proteases 
such as alpha1-protease inhibitor, secretory leukoprotease inhibitor, alpha1-anti-
chymotrypsin, alpha2-macroglobulin and tissue inhibitors of metalloproteases [40]. 
Bronchial epithelial cells are also a source of adhesion molecules such as integrins, 
selectins and cadherins which provide contact between adjacent cells and between 
cells and ECM [41].   
Additionally, bronchial epithelium secrets a variety of growth factors such as 
Epidermal Growth Factor (EGF), TGF-ß, insulin-like growth factor (IGF) and PDGF, 
which play important roles in the process of wound healing and may contribute to 
the pathogenesis of fibrotic lung diseases such as IPF or BOS [42] [43]. 
Due to their location, bronchial epithelial cells are extremely prone to injury which 
may be caused by exposure to airborne chemicals and microparticles such as 
cigarette smoke, asbestos, or smog. Epithelial damage may also occur due to 
chronic oxidative stress which may cause rupture of the cell membrane, DNA 
damage and ATP depletion. Red-ox balance is respiratory epithelium is maintained 
by anti-oxidant agents such as glutathione, superoxide dismutase, and catalase [44].  
Previous reports provide evidence that damaged cells may be a source of alarmins 
[27], however, the influence of oxidative stress on alarmin release and viability of 
primary human bronchial epithelial cells has not been investigated before. The 
interactions between primary human bronchial epithelial cells damaged with 
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oxidative stress and primary human lung fibroblast has not been studied before 
either. 
1.2.2 Immunocytes 
Macrophages 
 
Monocyte-derived phagocytes, macrophages, are involved both in innate and 
adaptive immunity. The main role of macrophages is phagocytosis of pathogens and 
cellular debris. Moreover, macrophages are a powerful source of proinflammatory 
cytokines and growth factors which support responses of lymphocytes and other 
immune cells to pathogens. Macrophages can be identified by specific markers 
including CD11b, CD14 and CD68. They also express a vast array of PRRs which 
enable them to recognize numerous PAMPs and DAMPs [45]. 
Macrophages derive from monocytes which circulate in the blood or reside in the 
spleen or bone marrow. Upon activation by certain proinflammatory cytokines or 
PAMPs, monocytes can differentiate into macrophages or dendritic cells.  
Recently it has been suggested that two subsets of macrophages, termed as M1 and 
M2, can be distinguished. The concept of M1/M2 cells derived from an observation 
that macrophages from C57BL/6 mice, which are considered as prototypical Th1 
strains, are more responsive to IFN-γ or LPS stimulation resulting in NO production 
than macrophages derived from BALB/c mice (prototypical Th2 strain). Upon LPS 
stimulation M2 macrophages start to metabolize arginine to ornithine while in M2 
cells this metabolic pathway remains switched off. In vitro, macrophages can be 
differentiated into M1 phenotype using IFNγ and M2 differentiation can be 
achieved using IL-13 and IL-4. 
M1 type of macrophage activation can also be elicit by cytokines such as TNFα and 
GM-CSF and certain PAMPs, including LPS, and is characterized by high expression 
of IL-12 and IL-23, low expression of IL-10 and enhanced production of reactive 
oxygen species and nitrogen intermediates. The biological functions of M1 
macrophages include stimulating Th1 responses and mediating resistance against 
tumors and intracellular parasites.  
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M2 macrophage phenotype is characterized by low expression of IL-12, IL-23, IL-1β 
and caspase1 and high expression of IL-10, IL-1Ra and IL-1RII. M2 cells are involved 
in promoting Th2 responses, tissue repair, remodeling and tumorigenesis [46]. 
Pulmonary macrophages are a heterogeneous population comprising of alveolar, 
interstitial and intravascular macrophages and dendritic cells. The only macrophage 
type that is exposed directly to air, are alveolar macrophages, which are located in 
the surfactant film, produced by type 2 alveolar cells. Alveolar macrophages show 
great phagocytic potential and provide defense against invading pathogens and 
airborne microparticles.  
Pulmonary interstitial macrophages are located in the lung connective tissue and 
are involved both in innate immune responses and adaptive immunity functioning 
as antigen-presenting cells. Compared to the alveolar macrophages, the interstitial 
macrophages show lower expression of cytokines such as TNFα, IFNα and IFNβ. 
Dendritic cells, which also may belong to the macrophage lineage, in the lung are 
located mainly in the connective tissue. They are characterized by low phagocytic 
potential but high expression of class II antigens and function mainly as antigen 
presenting cells. Moreover, dendritic cells express a range of PRRs and are able to 
recognize and respond to selected DAMPs and PAMPs 
Intravascular macrophages are highly phagocytic cells, located on the endothelium 
of capillaries, which participate in removing foreign bodies and pathogens entering 
the lung via bloodstream [47].   
Macrophages are considered to play pivotal role in modulating innate immune 
responses in fibrotic lung, however their responsiveness to epithelial alarmins, 
released by human bronchial epithelial cells has not been studied before. And 
therefore one of the objectives of this study was to compare the PRR epression 
profile between macrophages and lung fibroblasts and verify the responsiveness of 
alveolar macrophages to alarmins which are able to trigger innate immune 
responses in fibroblasts. 
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Neutrophils 
Neutrophils are granulocytes which along with basophils and eosinophils form the 
family of polymorphonuclear cells (PMNs). Neutrophils show a distinctive 
morphology that is characterized by a presence of a nucleus divided into 2-5 lobes.  
Neutrophils normally circulate in the bloodstream, however in response to 
chemoatractants such as IL-8, leukotriene B4, IFNγ and N-formyl-methionine- 
leucine-phenylalanine (fMLP), they are also able to migrate through blood vessels 
towards the side of infection or injury in the interstitial tissue. 
Following activation, neutrophils show a relatively short life span of approximately 5 
days in the blood stream and up to 2 days in interstitial tissues.  
Like macrophages, neutrophils participate in pathogen clearance by phagocytosis 
and production of ROS which are generated in the respiratory burst process. It has 
been suggested that ROS generated by nicotinamide adenine dinucleotide 
phosphate-oxidase (NADPH oxidase) by activated neutrophils and macrophages 
may be involved in the pathogenesis of some chronic inflammatory diseases such as 
chronic allograft rejection or arthritis. Following digestion of pathogens, neutrophils 
can be phagocytosed by macrophages which may also lead to increased production 
of ROS [48].  
Neutrophils may be a source of proteases including elastase and cathepsin G. 
Neutrophil derived proteases are believed to participate in pathogen clearance, 
however recent studied indicate that they may also be involved in proteolitic 
activation of some cytokines and growth factors such as insulin-like growth factor 
binding protein (IGFBP) [49]. It has also been suggested that elastase may 
contribute to tissue damage in chronic degenerative diseases such as emphesyma, 
sarcocidosis and IPF. Moreover Gardi et al. [50], demostrated that elastase may 
cause breakdown of collagen which may have stimulatory activity on collagen 
production by fibroblasts.  
Neutrophils express a variety of PRR, complement receptors, as well receptors for 
cytokines and chemokines and actively participate both in adaptive and innate 
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immune responses. Moreover, upon activation by DAMPs and PAMPs they can 
produce a number of cytokines and antimicrobial peptides.  
The influx of neutrophils is associates with chronic inflammatory lung diseases such 
as COPD [51] and BOS [52], and therefore one of the objectives of the study was to 
investigate if neutrophil-derived factors such as elastase and hydrogen peroxide 
(H2O2) may cause damage of human bronchial epithelial cells and to establish if 
there exist a correlation between relevant epithelial alarmins and neutrophil 
number  in vivo.   
1.3 Immune system 
 
The underlying cause of chronic inflammatory diseases is deregulation of the 
responses of the innate and adaptive immune system, caused by repetitive tissue 
injury, prolonged exposure to irritating substances, chronic infection or allogenic 
immune responses. 
The immune system is a complex set of structures and processes within a living 
organism that provides protection against and counteracts pathogenic or 
potentially hazardous agents, including viral and bacterial pathogens, parasites as 
well as injured and tumorogenic cells. Immune defense mechanisms evolved in all 
living organisms including plants and unicellular prokaryotes. Numerous studies 
indicate that basic defense mechanisms function even in bacteria, which protect 
themselves against bacteriophages with restriction enzymes that are able to cleave 
viral nucleic acids [53]. Interestingly, even some viruses developed sophisticated 
mechanisms to increase their chances of survival. It has been discovered for 
example that cholera viruses express cytosine and adenine DNA methyltransferases 
to methylate DNA which protect it from being cleaved by bacterial restriction 
enzymes [54]. Multicellular organisms, including animals and plants, developed far 
more advanced mechanisms of counteracting invasive pathogens, called the innate 
immune system. The innate immune system is orchestrated by a specialized set of 
intra- and extracellular receptors that gained the ability to recognize microbial and 
endogenous danger signals. Activation of the innate immune system leads to 
immediate but non-specific response against the invading pathogens. Target-
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orientated defense mechanisms are present only in vertebrates and are referred to 
as the adaptive immune system. Immune defense mechanisms are essential to 
counteract pathogens and tumorogenic cells. However, deregulation of these 
processes may be detrimental for the organism and may provide foundation for 
development of autoimmune and chronic degenerative diseases.  
1.3.1 Innate immune system 
 
The innate immune system is an evolutionary conserved set of mechanisms and 
structures that evolved to provide the first line of defense against invading 
pathogens. Unlike adaptive immune system, generating immunity to specific 
pathogens via target-orientated antibodies, innate immune responses provide non-
specific defense in a form of mechanical barriers and a rapid production of 
proinflammatory cytokines causing inflammation that is essential for wound healing 
and pathogen clearance. The innate immune system consists of three major 
components: anatomical barriers, activation of the complement system and 
activation of innate immune cells leading to inflammation [55].  
Both DAMPs and PAMPs are able to activate the innate immune system via PRR 
expressed on structural cells and immunocytes, however the identity of danger 
signals playing povital role in the activation of the innate immune responses in the 
lung are yet to be established. 
1.3.2 Anatomical barriers 
 
Physical protection against pathogens is provided by anatomical barriers and 
mechanical removal of invading microorganisms. Mechanical removal mechanisms 
include the cough and sneeze reflex, vomiting and diarrhea and physical flushing 
action of body fluids eg. tears, saliva or perspiration. Anatomical barriers comprise 
of tough to penetrate structures that prevent microorganisms from migration and 
colonization. Examples of anatomical barriers in animals include skin, mucous 
membranes of respiratory tract and gastrointestinal system and bony encasements.  
Mucous membranes are composed of a layer of epithelium secreting substantial 
amounts of glycoprotein, proteoglycans, peptydoglycans and lipids, providing a 
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physical barrier to trap microorganisms and chemical particles. Moreover, epithelial 
cells building mucous membranes, secrete lysozyme, an enzyme degrading 
peptidoglycal in bacterial cell walls, lactoferrin, binding iron and preventing it from 
being used by microorganisms and lactoperoxidase catalyzing red-ox reactions 
resulting in generating toxic superoxide radicals. Furthermore, epithelial cells in 
mucous membranes are constantly sloughed to remove microorganisms and 
nanoparticles that have attached to mucus.  
Protection provided by mucous membranes is of great importance in organs such as 
the lung, that are constantly exposed to the outside environment. The alveolar 
mucous membrane is the largest surface in the human body to remain in contact 
with the external environment. Due to its location and function the respiratory 
epithelium is constantly exposed to a variety of airborne bacteria, fungi, spores and 
nanoparticles. To enable removal of microorganisms and foreign bodies from the 
respiratory tract, bronchial and nasal epithelium has been equipped with cilia, that 
move actively to encourage mucus flow. Respiratory epithelium provides the first 
line of defense against airborne pathogens and pollutants, however its ability to 
fight danger agents is limited and chronic infection or prolonged exposure to 
irritating substances may result in progressive loss of the epithelial cells and 
intensive fibroproliferation causing airway obliteration. The loss or dysfunction of 
respiratory epithelium is characteristic for many chronic inflammatory and 
degenerative lung diseases including asthma, COPD, IPF and BOS [56].  
1.3.3 Pattern Recognition Receptors (PRRs) 
 
PRRs are the main mediators of the innate immune responses. The main PRR 
families have been described below. 
Toll-like receptors (TLRs) 
 
The TLRs recognize a vast array of ligands including endogenous DAMPs, (alarmins) 
such as High Mobility Group box1 (HMGB-1), S100 calcium binding protein A 
(S100A) and Heart Shock Proteins (HSPs) and PAMPs such as bacterial 
lipopolysaccharide (LPS), nonmethylated CpG-containing DNA from bacteria and 
viruses and viral RNA (34). So far 11 members of the TLR family have been 
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identified: TLR 1-10 and IL-1R. All of them contain conserved leucine-reach repeat 
domain (LRR) and a Toll/Interleukine-1 receptor domain (TIR). TLR3, 9, 7 and 8 are 
localized intracellularly in the endosome membrane whilst TLR1, 2, 4, 6 and IL-1R 
are expressed on the cell surface. All TLRs with the exception of TLR3 which 
activates TRIF kinase, signal via an adaptor molecule MyD88. TLR4 activation 
additionally requires TRAM protein. Most TLR function as homodimers, although 
TLR2 is believed to form heterodimers with TLR1 or TLR6. Moreover, TLR4 
cooperates with MD12 and CD14 co-receptors in bacterial LPS recognition. TLRs are 
upstream coordinators of several molecular pathways including Nuclear factor 
kappa-light-chain-enhancer of activated B cells (NF-κB) and Mitogen-activated 
Kinase (MAPK) pathway and regulate phosphorylation and activation of kinases 
such as c-Jun N-terminal kinases (JNK), p38 and Extracellular signal-regulated 
kinases (ERK) which are involved in cellular responses to various stress stimuli, 
including starvation, oxidative stress, radiation and infection. TLR activation leads to 
upregulation of numerous proinflammatory gene expression including IL-6, IL-8, IL-
1β, TNFα, IFNα, IFNβ, CD40 and CD80 which play important roles in immune 
response and inflammation [57].  
Accumulated evidence suggests that TLRs may serve important functions in the 
development of fibrotic diseases. Yang et al. showed that targeting TLR2 with 
specific blocking antibodies significantly decreased animal death rate and inhibited 
progression of bleomycin-induced pulmonary fibrosis in mice. Bleomycin-induced 
fibrosis is associated with upregulation of immunosuppressive cytokines such as 
Interleukin-13 (IL-13) and TGF-β1 and profibrotic alarmins including HMGB-1. The 
authors suggest that blocking TLR2 signaling may alleviate the disease by reversion 
of the immunosuppressive microenvironment brought about by bleomycin [58].  
Seki et al. using TLR4-chimeric mice demonstrated that TLR4 is engaged in 
progression of liver fibrosis by enhancing TGF-β1 signaling. Inhibiting TLR4 signaling 
resulted in attenuated secretion of chemokines by hepatic stellate cells (HSC), the 
prime precursors for the profibrotic cells in the liver, and led to downregulation of 
the decoy receptor BMP and activin membrane-bound inhibitor homolog (BAMBI) 
which functions as a TGF-β1 inhibitor. Experiments on MyD88 deficient mice 
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confirmed that BAMBI suppression is mediated by the TLR4-MyD88–NF- B axis 
[59].  
Brentano et al. showed that TLR3, which recognizes single stranded RNA (ssRNA), 
was expressed in rheumatoid arthritis (RA) synovial fibroblasts (SA) and that these 
cells when stimulated with necrotic RA synovial fluid in vitro secreted elevated 
levels of IL-6, IFNβ, Chemokine (C-C motif) ligand 5 (CCL5) and C-X-C motif 
chemokine 10 (CXCL10). Nuclease treatment suppressed the production of these 
molecules, suggesting that endogenous RNA released by damaged cells in 
rheumatoid arthritis may stimulate proinflammatory cytokine and chemokine 
production via TLR3 [60].  
TLR3 also plays an important role in immune responses to viral infections which are 
believed to be one of the factors enhancing the risk of IPF. Rudd et al. 
demonstrated that TLR3-/- mice challenged with Respiratory Syncytial Virus (RSV) 
showed increased pulmonary mucus production and enhanced type 2 cytokines 
expression in comparison to WT mice. Moreover, RSV promoted eosinophil 
accumulation in TLR3-/- but not WT mice, suggesting that TLR3 is implicated in 
maintaining homeostasis in the immune environment upon infection [61]. 
All cells have specific TLR expression profile, which determines their responsiveness 
to PAMPs and DAMPs. The TLR expression profile of primary human lung fibroblasts 
and their role in mediating innate immune responses to PAMPs and DAMPs have 
not been investigated before and therefore establishing this profiles was one of the 
objectives of this study.  
 TLR signaling is shown in figure 2. 
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Figure 2 Toll-like receptor signaling 
Toll-like receptors (TLR) may be activates by numerous damage associated 
molecular patterns such as interleukin-1alpha (IL-1α) and pathogen associated 
molecular patterns (PAMPs) including bacterial LPS, CpGDNA and flagellin, yeast 
zymosan and viral double stranded RNA (ssRNA). Ligand binding to TLRs results in 
activation of several signaling pathways inclusing NF-κB, MAP-kinase and IRF 
pathways and triggering gene expression of numerous cytokines and chemokines 
involved in processes such as inflammation, antiviral and antibacterial immune 
responses and T cell activation. Adapted from [62]. 
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Nod-like receptors  
 
The Nod-like Receptors (NLRs) are a family of cytoplasmic proteins characterized by 
the presence of a series of tandem leucine-rich repeats and central nucleotide-
binding oligomerization domain. NLRs recognize a wide array of PAMPs including 
lipopolysaccharide (LPS), mannan, zymosan, bacterial and viral nucleic acids, 
flagellin and lipoproteins and DAMPs such as Adenosine-5'-triphosphate (ATP), uric 
acid, heparin sulfate, silica, asbestos and amyloidβ. NLR activation leads to 
assembling of a Caspase-1 activation protein complex defined as an 
‘Inflammasome’. Activated Caspase-1 processes the cleavage of pro-IL-1β and pro-
IL-18 into mature IL-1β and IL-18 respectively, which are then secreted from the cell 
[63].   
So far, over 20 Nlr genes have been identified in the human genome. Mutations in 
Nlr genes have been associated with numerous autoimmune diseases. Autosomal 
dominant mutation in Nlrp3 causes several disorders collectively termed cryopyrin-
associated periodic syndromes [64], characterized by increased secretion of IL-1β 
even in the absence of any stimulation. Nlr gene mutations have also been linked to 
psoriasis and fibrostenosing disease in patients with Crohn’s syndrome [65].  
NLR are also postulated to be involved in the immune response to asbestos and 
silica which have been implicated as important risk factors in pulmonary fibrosis. 
Perkins et al showed that prolonged exposure to asbestos and silica fibers 
upregulates IL-1β secretion in human alveolar macrophages in vitro and in vivo. 
[66].  
NLRP3 has also been recognized as an important sensor for DAMPs in bleomycin-
indced pulmonary fibrosis in mice. Gasse et al showed that bleomycin-induced DNA 
damage leads to release of uric acid which is sensed by NLRP3 and stimulates IL-1β 
secretion. Inhibition of uric acid with uricase reduced IL-1β production, lung 
inflammation and fibrosis, suggesting that targeting danger signals released by 
damaged cells may be an important therapeutic target in fibrotic lung diseases [67]. 
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Receptor for advanced glycation endproducts  
 
Receptor for advanced glycation endproducts (RAGE) is a 35kDa transmembrane 
receptor belonging to the immunoglobulin family. RAGE has the ability to recognize 
advanced glycation endproducts (AGE) and certain DAMPs such as HMGB1, S100b 
proteins and amyloidβ. RAGE ligands upregulate NADPH-dependant reactive oxygen 
species production, stimulate expression of numerous genes involved in modulating 
immune responses, cell adhesion and cell communication and activate a number of 
signaling molecules including phosphoinositol-3 kinase, NF-κB and Mitogen-
activated Kinases (MAPK) including p38, Stress-activated Protein kinases (SAPK), 
Janus kinase /signal transducer and activator of transcription (JAK/STAT), 
Extracellular signal-regulated kinases 1/2 (ERK1/2; p44/p42) (59). RAGE is strongly 
expressed in the lung and it has been implicated to play an important role in certain 
chronic inflammatory diseases including IPF [68]. In vivo studies revealed that 
bleomycin caused more severe form of pulmonary fibrosis in RAGE-/- mice than in 
WT animals [69], which suggests that RAGE may play a protective function in 
chronically injured organs. Moreover, an immunohistochemical study performed on 
lung tissue specimen from IPF patients revealed diminished RAGE protein 
expression in comparison to control tissue [70].  
IL-1 receptor (IL-1R) 
 
So far, two isoforms of IL-1 receptor have been identified: IL-1RI and IL-1RII. Both 
receptors recognize IL-1α and IL-1β but only IL-1RI is capable of transmitting 
intracellular signals initiated by IL-1. Binding of IL-1α or IL-1β to the IL-1RI results in 
the recruitment of a co-receptor IL-1RAcP which forms heterodimers with IL-1RI 
which leads to the activation of TIR domain of each receptor and is followed by 
phosphorylation of MyD88 and Interleukin-1 receptor-associated kinase 1 (IRAK1). 
Activation of IL-1RI results in mobilization of several signaling pathways including 
NF-κB, MAP kinases and IRF pathway and leads to upregulation of numerous 
cytokines mediating processes such as inflammation, T-cell stimulation and anti-
viral responses.  
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IL-1RII, which is expressed mainly on macrophages and B cells, cannot pass signals 
mediated by IL-1α or IL-1β, because it lacks a cytoplasmic TIR domain and therefore 
cannot bind to MyD88 and hence it functions as a decoy receptor. Interestingly, IL-
1RII has higher affinity to IL-1β than IL-1RI which makes it an efficient negative 
regulator of IL-1 signaling. Moreover, IL-1RII inhibits IL-1RI signaling by recruiting 
and therefore decreasing the pool of free interleukin-1 receptor accessory protein 
(IL-1RAcP). IL-1RII is also expressed in a soluble form consisting only with the 
extracellular domain. In order to efficiently bind IL-1, the soluble form of IL-1RII 
requires a soluble IL-1RAcP co-receptor. Different variants of IL-1 receptors are 
translated from different splice variants of the same RNA [71]. 
The balance between IL-1, IL-1Ra and soluble IL-1RII is believed to affect the 
severity of many chronic inflammatory conditions. It has been reported that some 
anti-inflammatory drugs eg. glucocorticoids, may reduce inflammation by 
upregulating the production of IL-1RII [72], suggesting that anti-IL-1 therapies could 
be considered in the treatment of patients who do not tolerate steroid drugs .  
The importance of IL-1 antagonists in maintaining immune homeostasis can also be 
emphasized by the observations that animals immunized against their own IL-1Ra 
develop spontaneous diseases such as colitis, arthritis, psoriatic-like skin eruption or 
cancer [73].  
Moreover, it has been shown that there is an association between IL-1Ra single-
nucleotide polymorphism rs4251961, resulting in decreased levels of IL-1Ra and 
certain chronic diseases including type 2 diabetes and colon carcinoma [74].   
IL-1β was the first member of the IL-1 protein family to be identified. IL-1α was 
discovered shortly after that, however the family is still expanding and so far, in 
total, eleven members have been distinguished. Apart from IL-1α and IL-1β, the 
following proteins have been included into the IL-1 family: IL-1Ra, IL-18, IL-36Ra, IL-
36α, IL-37, IL-36β, IL-36γ, IL-38 and IL-33. The majority of the IL-1 family members, 
except for IL-1Ra and IL-36Ra, function as proinflammatory cytokines [75]. The role 
of IL-37 has not been fully described yet, however some reports indicate that it may 
exhibit anti-inflammatory properties. The members of IL-1 family have been listed 
in table 1. 
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Name Receptor Co-receptor Functions 
IL-1α IL-1RI IL-1RacP Proinflammatory 
IL-1β IL-1RI IL-1RacP Proinflammatory 
IL-1Ra  IL-1RI NA Antagonist for IL-1α, IL-1β 
IL-18 IL-18Rα IL-18Rβ Proinflammatory 
IL-36Ra  IL-1Rrp2 NA Antagonist for IL-36α, IL-36β, IL-36γ 
IL-36α  IL-1Rrp2 IL-1RAcP Proinflammatory 
IL-37  ? IL-18Rα Unknown Anti-inflammatory 
IL-36β  IL-1Rrp2 IL-1RAcP Proinflammatory 
IL-36γ  IL-1Rrp2 IL-1RAcP Proinflammatory 
IL-38  Unknown Unknown Unknown 
IL-33  ST2 IL-1RAcP Th2 responses, proinflammatory 
 
Table 1 List of cytokines belonging to the IL-1 family 
 
1.3.4 Damage associated molecular patterns 
 
Endogenous danger signals able to activate PRR are called damage associated 
molecular patterns (DAMPs) or alarmins. Alarmins are a heterogeneous group of 
molecules that are rapidly released following cell death to orchestrate so called 
‘sterile inflammation’ via recruitment and activation of innate immune cells. 
Alarmins may be secreted by many different cell types including immunocytes as 
well as by endothelial and epithelial cells that provide structural support for organs 
and which, due to their location, are largely prone to injury. Alarmins signal via a 
range of receptors including TLR, Interleukin-1 Receptor (IL-1R) and RAGE and play a 
very important role in modulating innate immune response by activating 
lymphocytes and antigen presenting cells. Recent studies revealed that some 
alarmins may also promote proliferation and activatation of fibroblasts however 
their mechanisms of action remain unclear [27]. Characterization of selected 
alarmins has been described below and summarized in in table 1. 
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Interleukin 1 alpha (IL-1α) 
 
Interleukin 1 alpha (IL-1α) is a small 18kDa protein that is formed by a cleavage of a 
31kDa precursor protein by a calcium activated cystein potease called Calpain [76]. 
IL-1α, similarly to IL-1β and IL-18, lacks a signal peptide fragment and is released via 
an unconventional secretory pathway. IL-1α is stored in intracellural compartments 
and may be released from damaged cells to act as a ‘’danger signal’’ required to 
initiate wound healing and angiogenesis. Recent studies however suggest that IL-1α 
may also be secreted from uninjured cells upon exposure to stress stimuli such as 
viral infection [77], heat shock or serum starvation via a non-classical mechanism 
requiring a formation of a tetrameric IL-1α –S100A13 complex. The IL-1α –S100A13 
complex formation requires Ca+ ions and is followed by its direct translocasion 
across the plasma membrane. Uninjured cells expressing dominant negative 
S100A13 are unable to export IL-1α upon exposure to a stress stimulus [78].  
The role of IL-1 in the pathophysiology of fibrotic diseases was confirmed by a study 
on IL-R1 deficient mice which demonstrated that IL-1 is required for the 
development of pharmacologicaly induced hepatic [79] and pulmonary [80] fibrosis. 
Furthermore Couillin et al. showed that IL-1R/MyD88 signaling upregulates IL-6, 
TNFα and IL-1β secretion and is important in elastase-induced lung inflammation 
and emphysema  [81]. 
IL-1α is also believed to play an important role in T cell polarization. A study by 
Cauciq et al. performed using a mouse model of Ovalbumin (OVA)-induced allergic 
asthma demonstrated that mice treated upon sensitization with IL-1α showed 
reduced levels of IL-5 and OVA-specific IgE as well as decreased number of 
eosinophils and significantly increased percentage of neutrophils in BALs, suggesting 
that IL-1α may attenuate Th2 responses and shift T cell polarization towards Th1 
[82]. 
IL-1α may function both as a positive and negative regulator of proliferation or 
apoptosis [83] [84]. The end result depends on cell type, dose and interactions with 
other factors. A natural inhibitor of IL-1 is IL-1 receptor antagonist (IL-1Ra). A 
synthetic variant of IL-1Ra is known under commercial name Anakinra and has been 
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successfully used in the treatment of arthritis [85]. IL-1Ra is recognized by IL-1R 
however it does not initiate signal transmission and therefore it acts as a negative 
regulator of IL-1 signaling. Upregulation of IL-1Ra as well as anti-IL-1α 
autoantibodies have been reported in several chronic conditions including IPF [86] 
which suggests that IL-1 may be one of the factors playing an important role in the 
pathogenesis of fibrotic lung diseases. IL-1R signaling is presented in figure 3. 
 
                            
Figure 3 IL-1 receptor signaling 
Activation of Interleukin 1 receptor (IL-1R) results in phosphorylation of 
downstream signaling molecules including NFκB and MAP-kinases (JNK, p38 and 
ERK) and activation of AP-1, which results in triggering expression of 
proinflammatory cytokines including IL-1β IL-6, IL-12 and TNFα. Adapted from [87]. 
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Other alarmins implicated in chronic inflammatory and fibrotic lung diseases 
 
So far several alarmins have been identified as potential mediators of inflammation 
and fibrosis. Rottoli et al. [33] in a study of proteomic profiling of IPF distinguished 
Calgranulin-1 and Galectin-1 (Gal-1) as alarmins whose expression was strongly 
upregulated in the fibrotic lung. Gal-1 belongs to a family of carbohydrate-binding 
proteins which play important roles in many processes including T-cell homeostasis 
regulation, allergies and pathogen-host interactions. Gal-1 has also been recognized 
as an important factor involved in the regeneration of neural tissue after injury [88]. 
Calgranulin-1 is a member of the calcium-binding S100 protein family, expressed in 
many different cell types including neutrophils and epithelial cells. S100 proteins 
participate in immune responses by stimulating chemokine and cytokine production 
and are upregulated in disorders such as psoriasis, multiple sclerosis and cystic 
fibrosis [89].  
Hamada et al. recognized High Mobility Group Box-1 Protein-1 (HMGB-1), one of 
the widest described DAMPs, as an alarmin whose levels were elevated in BAL from 
IPF patients. Moreover, a study on bleomycin-induced pulmonary fibrosis in mice 
revealed that upregulation of HMGB-1 gene expression in bronchiolar and alveolar 
epithelial cells was associated with the progression of the fibrogenic process. 
Furthermore, in vitro experiments showed that HMGB-1 stimulated fibroblast 
proliferation which is in agreement with previous reports suggesting that the 
environment of fibrotic organs, despite the presence of numerous proapoptotic 
molecules, promotes fibroblast survival [90]. 
Another group of alarmins that may be implicated in pulmonary fibrosis are α-
Defensins, small antimicrobial proteins which act by binding to pathogen cell 
membranes and disrupt their integrity. Yoshioka et al. discovered that IPF patients 
had elevated plasma levels of α-Defensines and showed that Human Neutrophil 
Peptide1 (HNP1), a member of the α-Defensine family, expressed mainly in 
neutrophils but found also in the epithelia of the intestine and respiratory and 
urinary tract, promoted Collagen type-1 production by human fibroblasts in vitro 
[91]. HNP-1 was also found to promote NCI-H292 (human lung mucoepidermoid 
carcinoma cell line) cell migration and proliferation and to stimulate mucin gene 
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expression in vitro, indicating that α-Defensins may be also engaged in maintaining 
the integrity of the airway epithelium [92]. 
Heat shock proteins (HSP) are the next class of alarmins whose role in fibrosis is 
under investigation. HSP are a diverse group of proteins whose expression is 
transcriptionaly upregulated in response to various stress stimuli such as heat, 
osmotic stress, toxins, starvation, infection, inflammation, hypoxia or ER stress [93]. 
They also play an important role as molecular chaperons, orchestrating protein 
folding and preventing the accumulation of unfolded and misfolded proteins by 
modulating the Unfolded Protein Response (UPR). Recent studies revealed that 
there is a correlation between pulmonary fibrosis and activation of certain markers 
of UPR, including ATF-6 and XBP-1. One of the current hypopthesis suggests that 
UPR may be activated as a result of increased production of ECM proteins in fibrotic 
tissue or due to a mutation in a highly expressed protein, such as alveolar surfactant 
[94]. It has also been shown that certain molecular chaperons, such as HSP60 may 
be released from dying cells and act as putative ligands of the TLR 4 complex – a 
target of endogenous alarmins. In addition, HSP27 and HSP70 are strongly 
upregulated in response to oxidative stress which has been proposed as a major 
factor causing epithelial cell damage in IPF. Blocking HSP27 and HSP70 increases 
epithelial cell susceptibility to H2O2-induced damage and therefore HSPs are 
believed to serve a protective function in chronic tissue injury [93].   
The alarmins believed to be implicated in chronic inflammatory lung diseases has 
been listed in table 2. 
 
 
 
 
46 
 
 
Table 2 List of alarmins implicated in chronic inflammatory lung diseases. Adapted 
from [95]. 
Alarmin Function in 
inflammation 
Other functions Receptor Role in 
fibrosis 
HMGB1 Neutrophil  
recruitment , 
chemotaxis,  
cytokine induction,  
dendritic cell 
activation,  
Maintaining chromatin 
architecture, 
 gene expression 
regulation 
RANGE 
TLR2 
TLR4  
+ 
Uric acid cytokine induction,  
dendritic cell 
activation,  
neutrophil recruitment  
Final product of purine 
metabolism 
TLR2 
TLR4 
CD14  
 
Chromatin, 
nucleosomes 
and DNA 
dendritic cells 
maturation and 
activation,  
neutrophil 
recruitment,  
B cell activation,  
cytokine induction  
Maintaining 
chromosome 
structure,  
gene expression 
regulation  
 
TLR9   
Heat  shock 
proteins 
migration of dendritic 
cells to lymph nodes 
(gp96), 
dendritic cells 
maturation (HSP70),  
cytokine induction 
(HSP60, HSP70, HSP 
90) 
Stress response 
regulation,  
protein folding control  
 
CD14 (HSP60, 
HSP70) 
CD91 (HSP90, 
HSP70,  gp96, 
calreticulin) 
TLR4 (HSP60) 
Scavenger receptors 
(HSP70, gp96, 
calreticulin) 
 
Adenosine 
and ATP 
chemotaxis, 
exacerbation of 
nephrities and 
bronchial astma 
Energy transfer 
Secondary messenger  
Coenzyme 
P1, P2X, P2Y (ATP) 
A1, A2A, A2B, A3 
(adenosine) 
 
Galectins dendritic cels 
maturation, 
monocyte recruitment, 
chemotaxis 
Cell adhesion, 
glycoprotein synthesis 
and transport 
CD2 + 
Thioredoxin Chemotaxis Redox  reactions 
regulations  
ND  
S100 
proteins 
Chemotaxis, 
neutrophil recruitment 
Protein 
phosphorylation, 
 gene expression 
regulation,  
Ca2+ homeostasis 
RAGE + 
Cathelicidins dendritic cells 
maturation, 
chemotaxis 
Antimicrobial response  
 
FPRL1 + 
Defensins DC maturation, 
Adjuvant activity 
Antimicrobial response  CCR6, TLR4 + 
N-
formylated 
peptides 
Chemotaxis, 
neutrophil recruitment 
Products of bacterial 
and mitochondrial 
protein degradation                                
FPR, FPRL1  
 
IL-1α 
Innate immune responses, 
Inflammation, 
hematopoesis, 
IL-1R ? 
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Although the majority of alarmins are proteins, other molecules such as uric acid, 
ssRNA and methylated DNA have also been classified in that group. ssRNA and 
methylated DNA which may be of exogenous (viruses, bacteria) or endogenous 
(mitochondria) origin signal via TLR3 and TLR9 respectively. Cavassani et al. showed 
that lysates from necrotic cells stimulated TLR3-mediated chemokine generation by 
macrophages and that this effect was suppressed following nuclease treatment, 
suggesting that ssRNA released by injured cells may play a role in sterile 
inflammation [96]. 
1.3.5 Pathogen associated molecular patterns 
 
Pathogen Associated Molecular Patterns (PAMPs) are pathogen derived danger 
signals, able to activate the innate immune system via specific PRRs in both plants 
and animals. From the structural point of view, PAMPs represent a heterogenous 
group of molecules comprising of sacharydes, proteins and nucleic acids. Selected 
PAMPs and their source of origin has been described below and listed in table 3. 
The role of DAMPs and PAMPs in activation of the innate immune system has been 
summarized in figure 4. 
Lipoplysacharide (LPS) 
 
Lipoplysacharide (LPS), a glycolipid composed of a hydrophilic polysaccharide and a 
hydrophobic lipid A moiety is the major constituent of the outer membrane of 
Gram-negative bacteria. LPS is recognized by the lipopolysaccharide binding protein 
(LBP) which facilitates its transfer to CD14, that is then translocated to TLR4-
associated LY96. Activation of TLR4 by LPS leads to activation of NF-κB signalling 
pathway, which results in activation of expression of numerous proinflammatory 
genes including IL-6, IL-8, TNFα and IL-1. 
Additionally, LPS may interact with several other proteins including HSP70, growth 
differentiation factor 5 (GDF5), CD11/CD18 and CXCR4 [97] 
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Poly(I:C) (Double-stranded RNA analog) 
 
Double stranded RNA is a genetic material in many viruses including Alternaviridae, 
Birnaviridae, Chrysoviridae, Cystoviridae, Endornaviridae, Hypoviridae, 
Partitiviridae, Picobirnaviridae, Reoviridae and Totiviridae. Poly I:C is a synthetic 
analog of dsRNA that is often use to induce anti-viral responses in eucariotic cells in 
vitro. dsRNA and Poly I:C are recognized by three receptors: TLR3, Melanoma 
Differentiation-Associated protein 5 (MDA5) and retinoic acid-inducible gene 1(RIG-
1). The anti-viral responses mediated by dsRNA are characterized by activation of 
several signaling pathways engaging numerous signaling molecules including PI3 
kinase, toll-like receptor adaptor molecule 1 (TICAM1), TNF receptor-associated 
factor 6 (TRAF6), IκB Kinase-epsilon (IKKε) and TANK-binding kinase 1 (TBK1) and 
Interferon regulatory factors (IRFs), which result in the production of ant-viral 
cytokines such as IFNα/β [98]. 
Other PAMPs believed to play a role in chronic inflammatory lung diseases include 
zymosan, beta glucan, muramyl dipeptide and flagellin. Selected Pathogen 
Associated Molecular Patterns and pathogens producing them have been listed in 
table 3. Role of DAMPs and PAMPs in activation of the innate immune system has 
been summarized in figure 4. 
B
ac
te
ri
a 
Gram-negative 
bacteria 
Lipopolysaccharide (LPS)  
CpG unmethilated DNA 
 
Flagellin (flagellated 
bacteria) 
Gram-positive 
bacteria 
Lipoteichoic acid 
Lipopeptide 
Lipoarabinomannan 
Fungi Chitin Glucans 
Viruses Double and single-stranded RNA 
 
Table 3 Selected Pathogen Associated Molecular Patterns and pathogens 
producing them. Adapted from [99]. 
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Figure 4 Role of Damage (DAMP) and Pathogen (PAMP) associated molecular 
patterns in activation of the innate immune system. Adapted from [99]. 
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1.3.6 Intracellular mediators of the Innate immune signaling 
NF-κB (nuclear factor kappa-light-chain-enhancer of activated B cells)  
 
NF-κB is a protein complex functioning as a transcription factor stimulating 
expression of genes involved in processes such as inflammation, apoptosis, cell 
proliferation and red-ox homeostasis. NF-κB is present in the majority of animal cell 
types and is activated in response to numerous stimuli including proinflammatory 
cytokines, DAMPs and PAMPs, ROS, oxidized LDL and UV radiation. Deregulation of 
NF-κB signaling has been implicated in several diseases including cancer, chronic 
inflammatory diseases, autoimmune diseases and septic shock.  
NF-κB can be activated via two routes known as the classical and the alternative 
pathway. Activation of the classical pathway usually takes place in response to 
inflammatory cytokines such as IL-1, TNFα and DAMPs and PAMPs of bacterial and 
viral origin and it involves phosphorylation of IKK complexes followed by 
phosphorylation, ubiquitination and degradation of an NF-κB inhibitor – IκB. 
Activation of the canonical pathway is mainly dependant on IKKβ and leads to 
activation of p50:RelA and p50:c-Rel dimers which are next translocated to the 
nucleus where they function as transcription factors stimulating expression of genes 
encoding cytokines (eg. TNFα, IL-1β, IL-1α, GM-CSF, IL-6), chemokines (IL-8, MCP-1, 
RENTES, MIP-1α), adhesion molecules (ICAM-1 VCAM-1) and enzymes (iNOS, COX2). 
The alternative pathway is triggered by stimuli involved in cell growth and 
differentiation such as lymphotoxin-α, B-cell activating factor (BAFF) or nuclear 
factor-kappaB ligand (RANKL) which cause phosphorylation of IKKα homodimers, 
followed by p52:RelB dimer activation, which is next transported to the nucleus 
where it activates expression of genes such as cytokines (BAFF), chemokines (B 
lymphocyte chemoattractant (BLC), secondary lymphoid chemokine (SLC), EBI1 
ligand chemokine (ELC), stromal cell derived factor (SDF-1)).  
In order to maintain cell homeostasis NF-κB activity must be scrupulously regulated. 
One of the main regulators of NF-κB activity are IκB kinases called IKK proteins. So 
far three IKK proteins have been indentified, namely IKK1 (IKKα), IKK2 (IKKβ) and 
IKKγ (NEMO). As mentioned above, IKK1/2/NEMO complexes are involved in 
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regulation of the canonical pathway, while IKK1 homodimers participate in the 
alternative pathway activation [100-102].  
An important role in NF-κB pathway activation plays ubiquitination which is 
required for IκB degradation. 
Ubiquitination is involved in regulation of the canonical as well as the alternative 
pathway. Ubiquitination is a covalent, reversible modification that is catalyzed by a 
group of specialized enzymes, leading to ligation of ubiquitin residues to protein.  It 
is an ATP-dependant, multi-step process requiring involvement of several enzymes 
including a ubiquitin-activating enzyme causing ubiquitin phosphorylation, 
ubiquitin-conjugating enzyme (E2 or Ubc) forming an E2-Ub thioester and a 
ubiquitin-protein ligase (E3), enabling the binding of ubiquitin to the target protein.  
Proteins labeled with a polyubiquitin chain linked through lysine-48 (K48) undergo 
proteosomal degradation. Chains linked with K-63 lysine of ubiquitin have been 
found to be involved in DNA repair and activation of protein kinases – a process that 
does not include proteasome-mediated degradation.  
The mechanism of ubiquitin-dependant prteosomal degradation of proteins is not 
yet fully understood. According to the current model, degradation of 
polyubiquitinated proteins is catalyzed by 26S proteasome which is a protein 
complex, consisting of approximately 60 subunits, and is found in the nucleus and 
cytosol of all cells. The 26S complex comprises of a 20S core structure that is linked 
to 19S regulatory subunits. Proteolitic degradation mediated by proteasome is a 
highly energy-consuming process requiring ATP hydrolysis.  
Following binding to the 19S component, the protein-polyubiquitin complex 
becomes disassembled and the protein is unfolded. The linearization of protein is 
necessary to enable its transport via the pore in the core structure in the 20S 
subunit. Within the 20S subunit, the linearized  protein is cleaved by six proteolitic 
sites. As a result small 3-25 aminoacid peptides are generated which then further 
cleaved into aminoacids by cytosolic endopeptidases and aminopeptidases [103].  
The main functions of NF-κB include production of proinflammatory mediators and 
regulation of cell death/survival.  
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The ratio of dying to proliferating cells is one of the most important aspects of 
homeostasis in tissue. Increased proliferation of cells is required in processes such 
as tissue regeneration and wound healing, however uncontrolled and intensified 
cell division rate may also lead to cancer or fibrosis.  
Inflammation – the end effect of NF-κB activation – may be associated with diseases 
characterized by increased cell proliferation such as inflammatory cancer as well as 
degenerative disorders characterized with progressive tissue damage and cell death 
such as chronic post-transplant organ rejection. 
Cell death may be either apoptotic or necrotic. Apoptosis is characterized by 
membrane rupture, shrinking of the cells and condensation of the intracellular 
organelles. Necrosis causes cell swelling, membrane disruption and cell lysis. 
Apoptosis is mainly induced in a receptor-dependant manner eg. following 
activation of TNFR while necrosis is usually mediated by ROS produced by 
mitochondria. In both cases it comes to activation of caspases which are cysteine 
proteases. Caspases are involved in protein digestion and degradation during 
programmed cell death, however they may also play regulatory functions 
proceeding cleavage of pro-proteins.  
Increased activation of caspase 1, which is required to cleavage and activation of IL-
1β, may result in enhanced production of proinflammatory cytokines and 
chemokines. Caspase 1 activation is not always associated with cell death and in 
some cells such as macrophages it is constitutively expressed which results in ability 
of these cells to produce active IL-1β following stimulation with a proinflammatory 
stimulus eg. LPS [104]. 
NF-κB may act as an inducer and inhibitor of cell death 
A study on RelA knockout mice revealed that the animals die in the mid-digestion 
age due to enhanced apoptosis of liver cells, suggesting that NF-κB suppresses 
programmed cell death [105]. The control of cell death and survival by NF-κB may 
be mediated by a cross-talk between NF-κB and JNK. JNK activates caspases and 
stimulates production of ROS – two factors that contribute to and regulate 
programmed cell death. NF-κB may inhibit JNK function [106] and stimulate 
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expression of anti-apoptotic genes including B-cell lymphoma 2 (Bcl-2) [107], 
antioxidant genes such as Manganese Superoxide Dismutase (MnSOD) [108] and 
Ferritin heavy chain (FHC) [109]. 
Mitogen-activated protein (MAP) kinases (MAP-kinases) 
 
MAP kinases are a group of serine/threonine-specific protein kinases that may be 
activated by numerous stimuli including proinflammatory cytokines eg. TNFα, IL-1, 
mitogens, heat shock and osmotic stress. MAP kinases regulate numerous 
intracellular processes including gene expression, cell differentiation, mitosis, cell 
survival and apoptosis.  
To date several MAP kinase proteins have been identified including extracellular 
signal-regulated kinases (ERK), c-Jun N-terminal kinases (JNK) and p38 isoforms. 
Extracellular signal-regulated kinases are a diverse family comprised of several ERK 
isoforms including ERK1,2,3,4 and 5. 
ERK1 and 2 (p44/p42) are activated in response to stimuli such as mitogens, growth 
factors, cytokines and phorbol ester and are involved in regulation of numerous 
processes including cell differentiation mitosis and meiosis. ERK1/2 are activated by 
phosphorylation that is preceded by initiation of a three-part protein cascade 
involving activation if a MAP kinase kinase kinase (MAPKKK or MAP3K), a MAP 
kinase kinase (MAPKK or MAP2K), and a MAP kinase (MAPK). So far multiple 
proteins, including Raf, Mos and Tpl have been included into the MAP3K family and 
MEK1 and MEK2 has been recognized as the main kinases within the MAKK 
subgroup. MEK1 and MEK2 activate ERK1/ERK2 by phosphorylating Thr202/Tyr204 
and Thr185/Tyr187, respectively. ERK1/ERK2 phosphorylation leads to activation of 
its downstream target molecules including 90 kDa ribosomal protein S6 kinase 1 
(p90RSK) and E twenty-six (ETS)-like transcription factor 1 (Elk-1). p90RSK is a 
serine/threonine protein kinase functioning as ATP and magnesium ion binding 
protein. It acts as caspase inhibitor and therefore is a negative regulator of 
apoptosis. p90RSK is phosphorylated following activation of TLR1,2,3,4 and other 
receptors whose signaling is mediated by MyD88 including IL-1R. Elk-1 functions as 
a transcription factors and plays an important role in stimulating several genes 
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including c-fos – a cellular proto-oncogene whose upregulation has been associated 
with oncogenesis [110, 111].  
ERK3 is constitutively localized in the nuclear and cytoplasmic compartments and in 
contrast to other MAP kinases, has only a single phosphorylation site at serine 189. 
The function of ERK3 still remains to be discovered however some reports suggest 
that it may play a role in cell cycle regulation.  
Unlike ERK3, ERK4 is a relatively stable protein, which amongst other, is involved in 
activation of MAPK-Activated Protein Kinase 5 (MK5) – a nuclear enzyme which 
upon activation is translocated to the cytoplasm where it interacts with p38. 
Increased activation of MK5 occurs in response to proinflammatory cytokines and 
stress stimuli. It has been shown that ERK4 may interact and form heterodimers and 
oligomers with ERK3 [112]. 
Recently identified ERK family members include ERK5,6 and 7. Their function is still 
to be investigates however some reports indicate that they may play a role in 
regulating cell proliferation [113]. 
Another class MAP kinases that are activated in response to proinflammatory 
cytokines, and stress stimuli such as UV light or heat shock, are c-Jun N-terminal 
kinases (JNKs). JNKs are activated by phosphorylation of threonine (Thr) and 
tyrosine (Tyr) residues within a co called ‘Thr-Pro-Tyr motif’ and are involved in 
processes such as T cell differentiation and apoptosis. JNK phosphorylation is 
mediated by MKK4 and MKK7 while protein Ser/Thr and Tyr phosphatases can lead 
to their inactivation. 
So far ten JNK isoforms have been identified: JNK1 (consisting of four isoforms), 
JNK2 (consisting of four isoforms) and JNK (consisting of two isoforms). JNK1 and 
JNK2 are expressed constitutively in all tissue while JNK3 expression so far has been 
confirmed in the brain, heart and testes.  
JNK activates numerous downstream molecules including c-Jun, ATF2, ELK1, 
SMAD4, p53 and HSF1 which were found to participate in processes such as cell 
proliferation, apoptosis and differentiation, tumorogenesis, embryo development, 
fibrogenesis and cell survival in response to stress stimuli. JNK may also function as 
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inhibitor of several signaling molecules including Nuclear factor of activated T-cells, 
cytoplasmic 1 and 4  (NFATC4, NFATC1) which are involved in T cell differentiation  
and STAT3, mediating signaling of factors belonging to IL-6 cytokine including IL-6, 
oncostatin M and leukemia inhibitory factor [114, 115]. 
p38 are a group of MAP kinases that, alike JNK and ERK, are activated by multiple 
proinflammatory cytokines, UV radiation and stress stimuli such as osmotic stress or 
heat shock. p38 proteins participate in numerous processes related to cell 
differentiation and survival. p38 proteins described to date include p38α (MAPK14), 
-β (MAPK11), -γ (MAPK12 / ERK6), and -δ (MAPK13 / SAPK4). 
MAPK14 (p38α) acts as a signaling molecule bridging several molecular pathways 
regulating processes such as proliferation, transcription, differentiation and 
development. MAPK14 can be activated by phosphorylation by MAP kinase kinases 
(MKKs) or as a result of autophosphorylation that may be triggered by interaction 
with MAP3K7IP1/TAB1. MAPK14 phosphorylation leads to activation of its 
downstream target molecules including ATF2, involved in regulation of 
transcription, CDC25B, functioning as a cell cycle regulator and a tumor suppressor - 
p53 protein. p38α has also been shown to play a role regulation of proliferation and 
differentiation of progenitor and stem cells in the lung. A study on mice revealed 
that inactivation of this protein kinase results in hyperproliferative epithelium that 
is highly prone to tumorigenesis. Moreover it has been shown that p38α plays an 
important role in morphogenesis in lung epithelial brunching, probably by 
regulating expression of proteins involved in regulation of cell adhesion and cell-cell 
interactions such as cadherin [116] [117].  
MAPK11 (p38β) plays similar biological functions as MAPK14 and can be activated 
by MKKs, mainly MKK6. One of the targets of MAPK11 discovered so far, is 
ATF2/CREB2, which functions as a transcription factor and histone acetyltransferase 
[118]. 
MAPK12 is also known as ERK6 or p38γ, similarly to other MAP kinases responds to 
proinflammatory cytokines and environmental stress and has been reported to play 
a role in several processes related to cell differentiation, including development of 
myotubes from myofibroblasts, and downregulation of cyclin D1 in response to 
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stress stimuli eg. hypoxia. Moreover some studies suggest that MAPK12 may act as 
an inhibitor of proliferation during cell differentiation [119].  
MAPK13 / SAPK4 also known as p38 δ is activated by dual phosphorylation on Thr-
180 and Tyr-182, which can be mediated by MAP2K3 and MAP2K6. MAPK13 has 
been reported to play a role in activation of a ATF2 transcription factor and 
stathmin, which functions as a regulator of microtubule dynamics [120].  
Since NF- B and MAP-kinase pathways may be activated both by DAMPs and 
PAMPs, the assessment of phosphorylation state of protein kinanses signaling 
within these two pathways is often used as a marker of activation of the innate 
immune system. 
1.4 Inflammation 
 
The consequence of PRR, NF B and MAP-kinase signaling pathway activation is 
triggering inflammatory responses. Inflammation can be defined as the end 
response of the body to an injurious agent such as mechanical or chemical trauma 
or infection. Inflammation comprises of various physiological reactions including 
increased release of a vast plethora of cytokines causing leucocytic migration and 
activation, seepage of plasma proteins, proximal vasodilation and distal constriction 
of blood vessels and it is required to wound healing and pathogen clearance. 
External symptoms of inflammation include swelling, redness, pain and increase in 
the body temperature. In inflamed tissues influx of immunocytes including 
neutrophils and macrophages is often observed [121].  
Inflammation can be classified as acute or chronic.  
1.4.1 Acute inflammation 
 
Acute inflammation is the initial reaction of the organism to an injury or infection. 
Symptoms of acute inflammation become apparent within minutes post exposition 
to trauma. Acute inflammation is initiated by increased movement of plasma and 
leukocytes through endothelium of blood vessels into the injured tissue and is 
mediated mainly by neutrophils migrating through blood vessels in response to the 
chemokine IL-8 which can be released by injured cells as well as activated 
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macrophages, fibroblasts, endothelial and epithelial cells. Acute inflammation is 
also mediated by cells residing in tissues, including macrophages, dendritic cells, 
and structural cells which may produce inflammatory cytokines upon activation by 
DAMPs and PAMPs. Acellular components involved in acute inflammation include 
elements of the complement system and coagulation factors present in blood 
plasma, causing blood clot formation. Recently it has also benn proposed that acute 
inflammation may be released by alarmins released from damaged epithelium. 
Acute inflammation is resolved within a few days and usually does not cause further 
complications [122].  
1.4.2 Chronic inflammation 
 
Chronic inflammation is a consequence of persistent acute inflammation which 
cannot be resolved due to non-degradable pathogens, continuous injury which may 
be caused by prolonged exposure to toxic factors, presence of foreign bodies or 
autoimmune reaction. In the context of chronic degenerative lung diseases, chronic 
inflammation is most often caused by chronic infection, cigarette smoking and 
exposure to asbestos, coal dust or smog. Chronic inflammation may also develop in 
organ transplant recipients as a result of an allogenic reaction.  
Chronic inflammation is mediated mainly by mononuclear cells such as monocytes, 
macrophages, lymphocytes, but also by structural long-living cells, such as 
fibroblasts, and is manifested by production of a vast array of proinflammatory 
factors including IFN-γ, TNFα, IL-1 and other cytokines, growth factors, reactive 
oxygen species and hydrolytic enzymes. 
Chronic inflammation may last up to months or even years and may vastly 
contribute to tissue damage and fibrosis. Chronic inflammation has been linked to 
multiple degenerative diseases including: COPD [123], IPF [124], asthma [125], 
chronic post-transplant organ rejection [126], arthritis [127], multiple sclerosis [128] 
and scleroderma [129].  
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1.4.3 Cytokines and chemokines 
 
Proinflammatory cytokines and chemokines can be released by a variety of cells 
including immunocytes and structural cells, encompassing fibroblasts, epithelial and 
endothelial cells. Their production may be triggered in response to various stimuli, 
including DAMPs and PAMPs, small signaling molecules such as nitric oxide (NO) 
and other cytokines. The main role of cytokines is providing communications 
between cells both on the paracrine and autocrine level. Cytokines are a diverse 
group of molecules encompassing proteins, peptides and glycoproteins. From the 
functional point of view they may be divided into two major groups: pro- and anti-
inflammatory. Additionally, some cytokines may function and chemotactic agents 
and growth factors [130].  
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               
The main cytokines believed to play important roles in chronic inflammatory lung 
diseases has been listed in table 4 and described in more detail below. 
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Cytokines 
Chemokines  CCL  CXCL  CX3CL  XCL  
TNF  TNFA   Lymphotoxin   TNFB/LTA   TNFC/LTB   TNFSF4   
TNFSF5/CD40LG TNFSF6   TNFSF7   TNFSF8   TNFSF9   TNFSF10   
TNFSF11   TNFSF13B   EDA 
Interleukins  Type I   chain  IL2/IL15   IL4/IL13   IL7   IL9   IL21 
Β chain  IL3  IL5  GM-CSF 
IL-6 family  IL6  IL11  IL27  IL30  IL31 
IL-12 family  IL12  IL23  IL27  IL35 
Type II  IL-10 family   
IFN family  Type 1: IFN1A  IFNA2  IFNA4 IFNA5  
IFNA6  IFNA7  IFNA8 IFNA10  IFNA13  
IFNA14  IFNA16 IFNA17  IFNA21  
IFNB1  IFNK IFNW1 
 Type 2: IFNg  
IL-1 family  IL1A/IL1F1   IL1B/IL1F2  IL1Ra/IL1F3  IL1F5  IL1F6  IL1F7  
IL1F8  IL1F9  IL1F10  33/IL1F11 18/IL1G 
IL-17 
family  
IL17/IL25 (IL17A) 
 
Table 4 Major cytokine families. Adapted from [131]. 
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1.4.4 Main cytokines implicated in chronic inflammatory lung diseases 
 
Interleukin 8 (IL-8) 
 
IL-8 is an 8 kDa non-glycosylated protein that is expressed and released by a variety 
of cells including macrophages, endothelial and epithelial cells and fibroblasts. IL-8 
is recognized by and able to activate two G protein-coupled serpentine receptors: 
CXCR1 and CXCR2.  CXCR2, apart from IL-8, is able to recognize several other CXC 
chemokines, while CXCR1 binds specifically to IL-8. Upon ligand binding, both 
receptors undergo phosphorylation, internalization and re-expression. IL-8 can exist 
in a monomeric form or it can form homodimers. IL-8 functions as a chemokine 
stimulating migration of cells such as neutrophils and granulocytes and as an 
angiogenic factor promoting blood vessel growth. Moreover IL-8 increases 
intracellular Ca2+ concentration and is involved in respiratory burst and exocytosis. 
Ca2+ mobilization, which is required for chemotactic cell movement is regulated 
both by CXCR1 and CXCR1, while respiratory burst activity and therefore the key 
anti-bacterial functions of neutrophils are mediated only by CXCR1 [132].  
Binding of IL-8 to cell surface receptors leads to upregulation of CD11b/CD18 (Mac-
1), a complement receptor able to bind to C3b and C4b. Mac-1, which is expressed 
mainly by phagocytic cells such as neutrophils, natural killer cells (NK) and 
macrophages, functions also as PRR and can recognize many molecules expressed 
on the surfaces of bacteria. Mac-1 upregulation upon IL-8 stimulation increases 
phagocytic ability of cells and plays an important role in pathogen and cell debris 
clearance [133].  
In patients with Cystic Fibrosis unopposed proteolitic activity causes cleavage of 
CXCR1 receptor which disables neutrophil bacteria-killing capacity. Interestingly, 
glycosylated fragments of CXCR1 may function as DAMPs and may stimulate IL-8 
production by activation TLR-2 expressed for example by bronchial epithelial cells 
[134]. 
IL-8 gene expression is upregulated upon activation of a variety of receptors 
including TLRs, IL-1R and TNFR. Increased levels of IL-8 have been reported in many 
diseases including chronic inflammatory diseases including chronic post-transplant 
61 
 
organ rejection [135], autoimmune diseases eg. psoriasis [136] and some metastatic 
diseases eg. lung cancer [137].  
Upregulation of IL-8 is often accompanied by oxidative stress that may be caused by 
reactive oxygen species (ROS) produced by activated neutrophils. ROS contribute to 
pathogen clearance, however their uncontrolled overproduction may result in 
damage of the host tissue [138].  
Expression of IL-8 is mediated via NF-κB signaling pathway and can be effectively 
inhibited by corticosteroids which block inflammation induced by factors such as 
TNFα, IL-1 and LPS. In vivo IL-8 induced neutrophil influx can be also abolished by 
CXCR2 antagonists eg. SB 225002 [139].  
Interleukin 6 (IL-6) 
 
IL-6 is a 22-27 kDa protein whose molecular mass may vary depending on its 
glycosylation state. IL-6 may function both as pro- and antiinflammatory cytokine. 
The proinflammatory functions of IL-6 include involvement in B cell maturation, 
monocyte activation, T-cell differentiation and its pyrogenic activity manifested by 
ability to induce fever during infection. IL-6 may also function as anti-inflammatory 
cytokine by inhibiting IL-1 and TNFα activity and upregulating production of IL-1Ra 
and IL-10. IL-6 may be secreted by several different cell types including 
macrophages, T-cells, muscle cells and fibroblasts. Increased production of IL-6 has 
been observed during infection, after trauma eg. caused by tissue damage or during 
muscle contraction. Enhanced levels of IL-6 are associated both with acute and 
chronic inflammation. During muscle contraction IL-6 is released to blood stream 
and acts to enhance the breakdown of fats which stimulates energy mobilization 
and increases body temperature. 
Expression of IL-6 can be triggered by DAMPs and PAMPs and some 
proinflammatory cytokines such as IL-1 and TNFα, suggesting that this cytokine may 
be implicated both in pathogen-induced and autoimmune inflammatory diseases. 
So far the role of IL-6 has been investigated mainly in chronic diseases and its 
importance importance been recognized in diseases such as atherosclerosis, 
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depression, diabetes, prostate cancer, Alzheimer's Disease, systemic lupus 
erythematosus and rheumatoid arthritis.  
Apart its function in inflammation IL-6 plays also an important role in liver and 
neuronal regeneration haematopoiesis, fertility and embryonal development [140]. 
IL-6 signals through a receptor complex consisting of IL-6Rα chain (CD126) which 
has the ability to recognized and bind the ligand and gp130 component (CD130) 
responsible for signal transduction. CD130 is ubiquitously expressed while CD126 
expression is restricted to certain cell types.  
Binding of IL-6 induces receptor dimerization and leads to activation of associated 
proteins called JAKs (Janus Kinases) which undergo autophosphorylation and cause 
the receptor phosphorylation. Next, the phosphorylation sites on JAKs and the 
receptor bind other signaling molecules called STATs (Signal Transducers and 
Activators of Transcription) which initiates a cascade of phospharylation events 
leading to activation numerous intracellular signaling pathways including MAP-
kinase pathway and PI3K/Akt pathway [141] . 
Monocyte chemotactic protein-1 (MCP-1)  
 
MCP-1 also known as Chemokine (C-C motif) ligand 2 (CCL2) is a small 13 kDa 
proinflammatory chemokine endoced by CCL2 gene, involved in recruitment of 
monocytes, memory T cells and dendritic cells. MCP-1 is upregulated both during 
injury and infection and can be secreted by monocytes, macrophages, dendritic 
cells and some structural cells such as fibroblasts.  
MCP-1 is bound by two receptors: CCR2 and CCR4. CCR2 (CD129) is expressed in the 
surface of monocytes, macrophages, activated memory T cells, basophiles and B 
cells and apart from MCP-1 it can also interact with CCL8 and CCL16. CCR4 
expressed on Th2 T cells and is able to recognize several cytokines including CCL3, 
CCL5, CCL17 and CCL22. CCR2 and CCR2 are G-protein coupling receptors and their 
activation leads to several intracellular reactions including release of intracellular 
calcium, formation of  inositol triphosphat, and activation of PKC [142] [143]. 
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MCP-1 expression can be triggered by a variety of factors including growth factors 
eg. PDGF, VEGF, cytokines eg. IL-1, IFN  ,IL-4, TNFα, and bacterial molecules eg. LPS 
and it has been implicated in the pathogenesis of several diseases including  
atherosclerosis, psoriasis, rheumatoid arthritis, epilepsy, brain ischemia and 
traumatic brain injury [144]. 
Moreover, recent studies indicate that MCP-1 may be also implicated in 
pathogenesis of BOS where it may play an important role in leukocyte recruitment. 
Elevated levels of MCP-1 in human bronchial lavage fluid (BALF) have been 
associated with increased risk of transformation from acute to chronic inflammation 
and development of chronic allograft rejection post lung transplantation [145]. The 
role of MCP-1 in lymphocyte recruitment is additionally supported by recent studies 
demonstrating that mice treated with neutralizing antibodies to MCP-1, showed 
significantly reduced number of macrophages following tracheal transplantation 
[146].  
MCP-1 has also been proposed as a biomarker that could be used to predict the risk 
of developing COPD in heavy smokers [147]. Increased levels of MCP-1 were also 
observed in BALs of asthmatics following allergen exposure [148] as well as patients 
suffering from chronic degenerative lung diseases such as IPF [149]. 
Granulocyte-macrophage colony-stimulating factor (GM-CSF)  
 
GM-CSF is a 14 kDa glycosylated protein cytokine that is produced by several cell 
types including macrophages, fibroblasts, mast cells and endothelial cells. 
Extracellular GM-CSF forms homodimers which are involved in stimulating stem 
cells into granulocytes (neutrophils, eosinophils, and basophils) and monocytes. 
GM-CSF concentrations in blood serum increase following bacterial, fungal, viral and 
protozoal infections. Enhanced blood levels of GM-CSF have been also detected in 
tumor-bearing animals animals. In vitro, production of this cytokine can be induced 
by proinflammatory cytokines such as IL-1 and TNFα. Increased GM-CSF levels were 
also noted following irradiation damage in bone marrow, where the cytokine plays 
an important role in the process of hematopoiesis [150]. 
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GM-CSF signals through granulocyte macrophage colony-stimulating factor receptor 
(GM-CSFR) also known as CD116 (Cluster of Differentiation 116) which is expressed 
by mature neutrophils and myeloblast. CD116 is a momodimer composed of two 
subunits namely α chain responsible for ligand recognitions and binding and a β 
chain involved in signal transduction.  α chain is specific to CD116 while β chain is 
also a component of receptors for IL-3 and IL-5. Ligand binding to the α chain leads 
to dimerisation of the α and β subunits and phosphorylation of the the β chain on 
tyrosine residues by JAK kinases. β subunit phosphorylation is followed by 
association with a Shc adaptor protein and which leads to activation of other 
downstream signaling molecules [151]. 
GM-CSF is involved in macrophage activation and is a strong chemoattractant for 
neutrophils. It stimulates microbicidal and phagocytotic activity, oxidative 
metabolism and improves cytotoxicity of both macrophages [152] and neutrophils 
[153].  
In the lung GM-CSF is believed to play an important role in surfactant homeostasis 
regulation and host defense. In mice GM-CSF deficiency or disruption in its signaling 
pathway leads to pulmonary alveolar proteinosis (PAP) which may caused by 
impaired capacity of macrophages to surfactant metabolism, phagocytosis, cell 
adhesion and pathogen killing [154].  
Interleukin 1β (IL-1β) 
 
IL-1β in humans is synthesized as a 31kDa precursor and it is activated by cleavage 
by a protease, caspase-1 between Asp116 and Ala117 resulting in a production of 
an active, 17kDa, product. Caspase-1 is a component of a multiprotein oligomer 
called inflammsome whose composition may vary depending on the activation 
factors initiating its assembly. The main molecules building inflammsome, apart 
from caspase-1, include PYCARD (Apoptosis-associated speck-like protein containing 
a CARD (C-terminal caspase-recruitment domain) or ASC (Apoptosis signal-
regulating kinase 1) a NOD-like receptor NALP and caspase5 [155].  
ASK, which acts as an adaptor protein, recruits caspase-1 via CARD activation, which 
leads to cleavage of IL-1β and IL-18 precursor proteins causing their activation. 
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Inflammasome can be activated via multiple ligands including bacterial RNA, 
triphosphate (ATP), uric-acid, asbestos and silica [156].  
IL-1β is a powerful cytokine able to trigger expression of other proinflammatory 
factors including IL-6, IL-8 and TNF-α via activation of IL-1R. It can also upregulate 
expression of its own gene resulting in formation of a positive feedback loop 
enhancing inflammatory responses. The main source of IL-1β are macrophages 
which show constitutive caspase-1 activation. IL-1β release from macrophages in 
considerably enhanced upon infection. In vitro, IL-1β release from macrophages can 
be achieved eg. via stimulation with TLR4 ligands such as bacterial lipopolisacharide 
(LPS) [157]. 
Anti-IL-1β therapies has been proposed as a clinical target in many chronic 
inflammatory and degenerative diseases including familial pyogenic arthritis [158], 
rheumatoid arthritis [159], urate crystal arthritis (gout) [160] and type 2 diabetes 
[161].    
The cytokines described above may be produced by fibroblasts of different origin, 
and therefore in the current study, their expression has been used as a marker of 
innate immune signalling activation in human lung fibroblasts.  
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Figure 5 Signaling in the innate immune system. (A) Activation of the innate 
immune system is required for efficient tissue repair and pathogen clerance. (B) 
Repetitive dissue injury or unresolved infection may cause dysregulation of this 
process leading to chronic inflammation and progressive tissue degeneration. 
Adapted from [87]. 
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1.5 Chronic degenerative lung diseases 
 
Chronic degenerative lung diseases characterized by progressive degeneration of 
the respiratory epithelium, intensive fibroproliferation and chronic inflammation 
include idiopathic pulmonary fibrosis (IPF), bronchiolitis obliterans syndrome (BOS) 
and chronic obstructive pulmonary disease (COPD). Although, all these diseases are 
associated with epithelial damage, the profile of alarmins in BALs of patients 
affected by these conditions, has not been investigated before. 
 
1.5.1 Bronchiolitis Obliterans Syndrome  
 
Bronchiolitis Obliterans Syndrome (BOS), also referred to as chronic post transplant 
rejection, is a non-reversible obstructive lung disease characterized by chronic 
inflammation and fibrosis in the small airways which is often accompanied by 
chronic lower respiratory tract infection. BOS affects approximately 50% patients 
who survive 5 years after lung transplantation and accounts for 30% of deaths 
occurring within the first three years post transplantation [162]. 
BOS is characterized by progressive loss of epithelium, excessive fibroproliferation, 
and an influx of neutrophils and macrophages that are a source of ROS and 
proteolitic enzymes which may cause damage to the bronchial epithelium. In 
addition, macrophages secrete numerous fibrogenic cytokines including TGF-β1, 
PDGF and Insuline-like Growth Factor 1 (IGF-1) that promote fibroblast activation 
and proliferation [163]. Lung biopsies from BOS patients showed presence of 
eosinophilic plagues and polyps consisting of fibromyxoid granulation tissue, which 
cause the airway obliteration [163]. 
Numerous studies revealed that changes in the balance between type 1 and type 2 
cytokines may play an important role in allograft airway remodeling. Type 1 
cytokines such as IL-2 and Interferon gamma (IFNγ) are associated with cell-
mediated immunity while type 2 cytokines, represented for example by IL-4, IL-5 
and IL-15, are involved in humoral and allergric immunity. It has been postulated 
that the type 1 immune response promotes acute rejection while the type 2 
response is implicated in chronic allograft rejection [162]. The balance between 
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type 1 and type 2 cytokines may have influence on expression pattern of TLR which 
recognize pathogen associated molecular patterns (PAMPs) and damage associated 
molecular patterns (DAMPs). TLR are involved in modulating innate immune 
response and have been proposed to play an important role in both acute and 
chronic transplant rejection. Palmer et al. showed that heterozygosity for either of 
two functional single nucleotide polymorphisms (SNPs), Asp299Gly or Thr399Ile in 
Tlr4 gene was associated with hyporesponsivness to endotoxin and decreased the 
risk of lung allograft rejection within 3 years post transplantation. TLR are also 
engaged in immune responses in chronic infections which have been implicated as 
an important risk factor for BOS [164]. 
The cellular mechanisms driving chronic rejection remain poorly elucidated but 
current consensus suggests that both alloantigen-dependent [165, 166] and 
alloantigen-independent insult to airway epithelium leads to an influx of 
inflammatory cells, chronic neutrophilic inflammation, dysregulated repair and 
resultant fibrotic plugging or the small airways presenting in the typical obliterative 
bronchiolitis (OB) lesions [167, 168]. A multitude of risk factors have been identified 
which include; HLA-mismatch [169], acute rejection episodes [170], recipient age 
[171], CMV [172], community respiratory viral infections [173], pseudomonal 
colonisation [174], lymphocytic bronchitis/bronchiolitis [175], gastro-oesophageal 
reflux [176], air pollution [177] and ischemia-reperfusion injury [178]. Additionally, 
recent observations suggest that pro-inflammatory cytokines such as IL-1 family 
members, TNFα [179] and IL-17 [180, 181] may be key pathways driving these 
insults, via subsequent induction of the potent neutophilic chemoattractant protein 
IL-8. One of the characteristics of chronic rejection is damage to the bronchial 
epithelium [163]. Previous studies have demonstrated that damage to epithelium 
may result in release of alarmins, including IL-1α, which in a paracrine manner may 
trigger expression of proinflammatory cytokines in lung fibroblasts and other 
epithelial cells [182]. However, the levels of IL-1α in BALs of patients with BOS and 
its role in the development of chronic lung rejection have not been studies before. 
Clinically, chronic rejection manifests with persistent cough, increased sputum 
production, dyspnea, coarse crackles and can be quantified functionally by a 
progressive loss of forced expiratory volume in one second (FEV1). Traditionally this 
clinical presentation would have been labeled as Bronchiolitis Obliterans Syndrome 
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(BOS) but more recently has been termed Chronic Lung Allograft Dysfunction (CLAD) 
[13, 183]. 
Surgical biopsies from normal and BOS lung has been shown in figure 6. 
 
 
                            
                         
 
Figure 6 Surgical biopsies from normal (A) and BOS (B) lung. H&E staining. 
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1.5.2 Idiopathic Pulmonary Fibrosis 
 
Idiopathic Pulmonary Fibrosis (IPF) is a disease affecting approximately 70/100 000 
people worldwide [184], characterized by progressive damage to the lung 
endothelium and epithelium, resulting in the loss of the alveolar structure and 
integrity (figure 58). The life expectancy of a patient with IPF is thought to range 
from 2 to 5 years and the only effective treatment is lung transplant [185]. IPF is 
associated with intensive fibroblast proliferation and infiltration of inflammatory 
cells including macrophages and neutrophis which not only cause chronic 
inflammation but also release a vast array of proteolotic factors including Cathepsin 
G, Elastase and Proteinase 3 which may distort cell-cell adhesion and damage cell 
membrane integrity [186]. Surgical lung biopsies from normal and IPF tissue has 
been shown in figure 7. 
 
                 
                                                    
Figure 7 Surgical lung biopsies from normal (A) and IPF (B) tissue. H&E staining. 
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Factors that may contribute to IPF include cigarette smoking, exposure to pollutants 
and irritants (asbestos, silicon fibers), viral infections and genetic disorders 
(mutation in Sftpc gene) [187], however in many cases the underlying cause of the 
disease remains unknown.  
One of the factors postulated to play an important role in provoking epithelial cell 
damage in IPF is oxidative stress. The concept of reactive oxygen species (ROS) as  a 
factor playing a crucial role in the pathogenesis of this disease is supported by the 
fact that free radicals and other oxidants such as H2O2, peroxynitrate, and 
peroxynitrite have been found to upregulate expression of TGF-β1, 
metalloproteases and proinflammatory cytokines that are implicated in IPF [188]. 
Furthermore, antioxidants such as dimethyl sulfoxide (DMSO), dimethylthiourea 
(DMTU) and dithiothreitol (DTT) attenuated release of IL-6, IL-8, IL-1β and Tumor 
Necrosis Factor alpha (TNF-α) in fibrotic lung, suggesting that oxidative stress plays 
an important role in the patophysiology of IPF [189]. 
1.5.3 Chronic Obstructive Pulmonary Disease  
 
Chronic Obstructive Pulmonary Disease (COPD) refers to two often co-existing 
diseases: emphysema and chronic bronchitis and is characterized by chronic 
inflammation, progressive degradation of lung alveolar epithelium and airway 
narrowing. The underlying cause of COPD is cigarette smoking, however heavy air 
pollution, exposure to chemicals (cadmium, coal dust) and certain genetic disorders 
(α-1-antitrypsin deficiency, Sftpd polymorfism) have also been associated with the 
disease. It is estimated that between 8 to 11% of the British population are affected 
by COPD and the mortality rates for this disease in the UK are 634/million in males 
and 323/million in females [190].  
It has been proposed that COPD, which similarly to IPF and BOS is characterized by 
increased number of fibroblasts, may be mediated by EMT which refers to a 
pathological conversion of epithelial cells into α-SMA expressing fibroblast. EMT is 
association with upregulation of specific markers such as fibronectin and vimentin 
and increased mobility of cells which gain a new mesenchymal-like phenotype. 
Kamitani et al. showed that EMT in primary bronchial epithelial cells can be 
triggered by TGF-β1 in SMAD-dependent manner and that this effect may be 
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accentuated by TNFα and to a lesser degree by IL-1β [191]. However, a role of other 
factors including BMPs and IL-8 in this process is also under investigation. 
 
1.6 The relationship between chronic inflammatory lung diseases, oxidative stress 
and the stress in the endoplasmic reticulum  (ER stress) 
 
A common pathological feature of chronic inflammatory lung diseases is epithelial 
damage, which may lead to release of alarmins (damage associated molecular 
patterns, DAMP) and trigger further inflammation and mediate recruitment of 
immunocytes to the site of injury. Epithelial damage may result from a variety of 
causes including microbial attack, proteolytic damage, the effects of bystander ROS 
[192, 193] and endoplasmic reticulum (ER) stress [194, 195]. Two factors that may 
contribute to ER stress in chronic inflammatory and fibrotic lung diseases are 
oxidative stress induced by cigarette smoke [196] and viral infections which trigger 
ER stress and unfolded protein response in an IRE1-dependant manner [197]. On 
the cellular level, ER stress is caused by accumulation of unfolded or misfolded 
proteins, which may be a consequence of a mutation or intensified translation of 
proteins, which cannot be folded in an efficient manner [198].  
Additionally, recent studies revealed that oxidative stress may also trigger the 
unfolded protein response (UPR) by upregulating glucose regulated protein 78 (GRP 
78) and protein ubiquitination [199]. ER stress activates UPR, which may trigger pro-
survival mechanisms such as ER stress associated protein degradation (ERAD) or 
may promote apoptotic mechanisms, including caspase-1 activation [199]. Although 
the activation of UPR has been demonstrated in several chronic inflammatory 
diseases including COPD [200], it is unclear as to how ER stress may contribute to 
inflammatory responses.  
The unfolded and misfolded proteins are recognized and bound by molecular 
chaperons, including Binding immunoglobulin protein (BIP) and HSPs. The 
chaperon-protein complexes are recognized by transducers of unfolded protein 
response (UPR), including PREK, IRE1α and ATF6, which are located in the ER 
membrane.  
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PREK, IRE1α and ATF6 trigger intacellular mechanism leading to activation of 
transcription factors involved in the UPR, whose main function is translation and 
transcription attenuation and degradation of accumulated unfolded proteins in a 
process called ER stress associated protein degradation (ERAD), which involves 
protein ubiquitination and their proteosomal degradation.  
In vitro, ER stress may be triggered with several drugs, including thapsigargin, which 
is a blocker of SERCA channels, tunicamycin, inhibiting protein glycosylation and 
DTT, which blocks formation of di-sulfide bond in proteins.  
Induction of ER stress may be measured by various methods, including assessment 
of activation of proteins involved in UPR and splicing of XBP-1 mRNA, which occurs 
following IRE1α activation.  
ER stress activates UPR, which may trigger prosurvival mechanisms such as ERAD or 
may promote apoptotic mechanisms, including caspase-1 activation [201].  
 
 
 
 
 
 
 
 
 
 
 
 
74 
 
GENERAL HYPOTHESIS AND MAIN AIMS 
General hypothesis: 
Alarmins released from damaged lung epithelial cells promote fibroblast activation. 
Main aims 
1. Establish an in vitro model of human bronchial epithelial cell injury 
2. Investigate the influence of conditioned media from damaged epithelial cells 
on fibroblast activation, manifested by upregulation of proinflammatory and 
fibrogenic genes and activation of PRR signaling pathways (NF B, MAP-
kineses) 
3. Establish Pattern Recognition Receptor expression profile in primary human 
lung fibroblasts 
4. Identity epithelial alarmins responsible for lung fibroblast activation 
5. Establish the responsiveness of primary human lung fibroblasts to selected 
Damage and Pathogen Associated Molecular Patterns 
6. Measure concentrations of alarmins involved in fibroblast activation in BALs 
of post-transplant patients who developed BOS. 
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Figure 8 A diagram showing a hypothetical sequence of events following tissue 
injury. 
Tissue damage caused by infection, chemical, machanical or allogenic injury leads to 
release of alarmins which activate innate immune responses in immunocytes and 
structureal cells resluting in increased production of proinflammatory factors. 
Prolonged and unresloved inflammation may cause further tissue damage .  
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CHAPTER 2 MATERIALS AND METHODS 
2.1 Patients 
Bronchoalveolar lavage (BAL) was obtained from 52 lung transplant recipients 
within 3 years of transplantation, identified from a cohort under follow up at the 
Institute of Transplantation, Freeman Hospital, Newcastle. An aliquot of BAL was 
sent for formal microbiological culture. The remaining BAL fluid was filtered to 
remove mucus and the cellular fraction was separated from the supernatant by 
centrifugation. A total and differential cell count was performed and the 
supernatant was aliquoted and stored at -80°C for subsequent cytokine 
quantification by ELISA or MSD cytokine assay. Demographics of patients 
participating in the study is shown in table 12. 
2.2 Reagents  
2.2.1 Primary antibodies 
 
     Protein             Company               Cat. No          Host   Isotype  Clonality           Application      
p38 Santa-Cruz sc-7149 Ra IgG pc WB @ 1:2000 5%Mv 
p38p Santa-Cruz sc-17852 Ra IgG pc WB @ 1:500 3%BSA 
JNK-1/2 Cell-signalling 9252 Ra IgG pc WB @ 1:1000 3%BSA 
JNK-1/2p Cell-signalling 4668 Ra IgG mc WB @ 1:1000 3%BSA 
Erk-1/2 Cell-signalling 4695 Ra IgG mc WB @ 1:1000 3%BSA 
ERK-1/2p Cell-signalling 4370 Ra IgG mc WB @ 1:1000 3%BSA 
IKKα/β Santa-Cruz sc-7607 Ra IgG pc WB @ 1:1000 3%Mv 
IKKα/βp Cell-signalling 2681 Ra IgG pc WB @ 1:1000 3%BSA 
P65 Santa-Cruz sc-109 Ra IgG pc WB @ 1:1000 3%BSA 
P65p Cell-signalling 3031 Ra IgG pc WB @ 1:1000 3%BSA 
TLR3 Imgenex IMG-315A Ms IgG mc WB @ 1:250 5% Mv 
IL-1RI R&D AF269  Go IgG pc CF @ 1μg/ml 1% BSA 
CF @ 1:100 3%BSA 
IL-1α R&D AF-200-NA Go IgG pc WB @ 0.1μg/ml Mv 
CF @ 10μg/ml 1% BSA 
Block @ 4µg/ml 
IL-1β R&D AF-201-NA Go IgG pc Block @ 4µg/ml 
Fibronectin Sigma F3648 Ra IgG pc CF@ 1:100 1%BSA 
IL-6 R&D DY206  Ms IgG mc CF@ 2µg/ml 1%BSA 
 
Ms- mouse; Ra- rabbit; Do-donkey; Go- goat; mc- monoclonal; pc- polyclonal; WB- 
western blott; CF- immunocyto/histochemistry; Block- neutralization. 
Table 5 List of primary antibodies 
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2.2.2 Secondary antibodies 
 
Company Cat. No Host Antigen Conjugate 
Sigma F2012 Go Mouse IgG FITC 
Sigma T6778 Go Rabbit IgG TRITC 
Sigma F7367 Ra Goat IgG FITC 
Sigma A3673 Go Mouse IgG HRP 
Abcam ab6721 Go Rabbit IgG HRP 
Abcam ab98513 Do Goat IgG HRP 
 
Ra- rabbit; Do-donkey; Go- goat; HRP- horseradish peroxidase; FITC- Fluorescein 
isothiocyanate; TRITC- Tetramethyl Rhodamine Isothiocyanate 
Table 6 List of secondary antibodies 
 
2.2.3 Chemical inhibitors 
 
TAK1i ((5Z)-7-Oxozeaenol) (Cat No. 499610-1MG) and IKK-2i IV (5-(p-Fluorophenyl)-
2-ureido]thiophene-3-carboxamide) (Cat No. 401481-500UG ) were purchased from 
Calbiochem.  
hrIL-1Ra was obtained from R&D systems (Cat No. 280-RA-050). 
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Primers (5’-3’) 
GENE NAME FORWARD PRIMER SEQUENCE REVERSE PRIMER SEQUENCE 
TLR1  CCTAAAGACCTATCCCAGAA ACAGTAGGGTGGCAAGAAAT 
TLR2  TTGTGGATGGTGTGGGTCTT AGGTCACTGTTGCTAATGTA 
TLR3  TATTTCCCTTGCCTCACTCC TGGTTAGGTTGAGTATGTGT 
TLR4  TTTTTCTAATCTGACCAATC TCATAGGGTTCAGGGACAGG 
TLR5  TACCCCCTTGACTATTGACA ATAACCATCTTTCAATACAG 
TLR6  TTCCATTTTGTTTGCCTTAT TTATGGGAAAGTCTCAAAAC 
TLR7  GATTTACTCCATTCAACAGC TGTCGTTCATCATCAGTTTC 
TLR8  ATGTTCCTTCAGTCGTCAAT TTTTGCTTTTTCTCATCACA 
TLR9  TACCTTGCCTGCCTTCCTAC TGTCACCAGCCTTTCCTTGT 
TLR10  TTATGACAGCAGAGGGTGATG GGAGTTGAAAAAGGAGGTTA 
IL-1R1  CCTAAAGACCTATCCCAGAA ACAGTAGGGTGGCAAGAAAT 
RAGE  TTGTGGATGGTGTGGGTCTT AGGTCACTGTTGCTAATGTA 
NLPR3  TATTTCCCTTGCCTCACTCC TGGTTAGGTTGAGTATGTGT 
IL-6  TTTTTCTAATCTGACCAATC TCATAGGGTTCAGGGACAGG 
IL-8  TACCCCCTTGACTATTGACA ATAACCATCTTTCAATACAG 
IL-1β  TTCCATTTTGTTTGCCTTAT TTATGGGAAAGTCTCAAAAC 
MCP-1  GATTTACTCCATTCAACAGC TGTCGTTCATCATCAGTTTC 
GM-CSF  ATGTTCCTTCAGTCGTCAAT TTTTGCTTTTTCTCATCACA 
IL-1α  AATGACGCCCTCAATCAAAG TGGGTATCTCAGGCATCTCC 
XBP-1 GGAGTTAAGACAGCGCTTGG  ACTGGGTCCAAGTTGTCCAG 
GAPDH  GAGTCAACGGATTTGGTCGT GACAAGCTTCCCGTTCTCAG 
 
Table 7 List of qRT-PCR primers 
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2.3 Cell culture 
2.3.1 Primary cell isolation and culture 
Human primary bronchial epithelial cells (PBEC) 
Human primary bronchial epithelial cells (PBEC) were obtained from by bronchial 
brushings from anonymous post-transplant patients and were cultured on 0.5% 
Purecol (Invitrogen) coated dishes in SAGM (Lonza) medium containing 2% FBS 
(Lonza), 100U/ml penicillin (Sigma) and 100μg/ml streptomycin (Sigma). All post-
transplant patients participating in the study gave informed consent and the study 
was approved by the local regional ethics committee (Ref. 2001/179). 
Human primary lung fibroblasts 
Human primary lung fibroblasts were isolated using collagenase type 2 digestion 
technique from parenchyma of lungs that were not used for transplantation. Lung 
tissue pieces from anonymous human donors were washed in DMEM (containing 
10% FCS, 1% penicillin/streptomycin and 1% L-glutamine) and chopped using a 
mezzaluna. The tissue pieces were washed on a 40μm filter with DMEM to remove 
debris and red cells and resuspended in 10ml serum free DMEM containing 0.1% 
BSA and 0.2% collagenase type 2. The tissue-collagenase suspension was incubated 
on a roller at room temperature for 2hrs. The tube was shaken occasionally during 
the incubation to stop the tissue from clumping. The suspension was filtered 
through a 100μm filter and the filtrate was spun down at 1200rpm for 5mins. The 
cell pellet was washed by resuspending in DMEM and spun down again. Following 
washing, the cells were resuspended in complete DMEM, counted and plated at 
80 000 cells/cm2. The cells were left to attach for 1hrs after which they were 
washed with PBS and fresh culture medium was added to the culture. The ICC 
analysis showed that the isolated cells expressed high levels of fibronectin (a 
marker of fibrogenic cells) and had characteristic for fibroblasts spindle-like shape. 
Additionally, a qRT-PCR analysis revealed that the isolated cells expressed 
transcripts for other fibroblast markers including Col1A1, Col3A3, Col4A1 and α-
SMA (data not shown). The cells were propagated in the culture and used for 
experiments at passage 1-5.  
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2.3.2 Cell line culture  
 
MRC5 cells (human fetal lung fibroblast cells) were cultured in DMEM/F12 (Sigma) 
containing 10% FBS, 1% L-glutamine, 100U/ml penicillin and 100μg/ml 
streptomycin. 
16HBE14o- (SV40 large T-antigen transformed human bronchial epithelial cell line) 
was maintained in HiClone medium (Pierce) supplemented with 10% FBS, 1% L-
glutamine, 100U/ml penicillin and 100μg/ml streptomycin. 
BEAS2B (human bronchial epithelial cells transformed with polyomavirus DNA) were 
maintained in BEGM (Lonza) media containing 2% FBS (Lonza), 100U/ml penicillin 
(Sigma) and 100μg/ml streptomycin (Sigma).   
A549 (carcinomic human alveolar basal epithelial cell line) were cultured in DMEM  
Medium (Sigma) supplemented with 10% FBS, 1% L-glutamine, 100U/ml penicillin 
and 100μg/ml streptomycin. 
THP-1 (monocytic leukemia cell line) was cultured in RPMI1640 medium (Sigma) 
supplemented with 10% FBS, 1% L-glutamine, 100U/ml penicillin and 100μg/ml 
streptomycin. 
 All cells were maintained at 37°C at an atmosphere of 5% CO2. 
When the cells reached 80-90% confluence, the monolayers were subcultured as 
follows. The growth medium was removed, cells were washed with phosphate 
buffered saline (PBS) and trypsinised with 0.05% Trypsin solution (Sigma) at 37°C. 
After cell dissociation, trypsin was neutralized with culture medium and the cells 
were pelleted by centrifugation. The cell pellets were resuspended in culture 
medium and seeded at an appropriate density. All experiments were performed on 
cell monolayers that reached 80-90% confluency.  
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2.3.3 Cell count 
 
In order to determine the cell number, 10μl of cell suspension was pipetted onto a 
hemocytometer chamber and the count was performed in 5 large size squares 
(1mm x 1mm). The cell density was determined according to the following 
equation: 
Cell density [cells/ml] =  
where: 
nC – cell number 
nB – number of large boxes (1mm x 1mm)  
d – dilution factor 
 
 
2.4 Assessment of cell viability by flow cytometry using propidium iodide (PI) 
staining. 
 
Assay principle 
Propidium iodide (PI) is a fluorescent dye (excitation wavelength 488nm) able to 
bind DNA by intercalating bases. PI is incorporated by cells whose cell membrane 
has been discontinued and it can be used to distinguish necrotic and apoptotic from 
viable cells. 
Assay procedure 
Flow cytometric analysis was performed to assess the viability of epithelial cells 
following treatment with H2O2, freeze-thaw stress, ER stress, elastase and cigarette 
smoke extract (CSE). The conditioned media from cell cultures were collected and 
stored at -80°C for ELISA analysis. The cells were pelleted and resuspended in 300µl 
DMEM phenol red free media (Gibco) and incubated for 30mins at 37°C. 
Immediately prior to analysis the cells were stained with PI at a final concentration 
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of 10 µg/ml. The analysis was performed using FACScan Cytometer and the data 
were processed with CellQuest software. All samples were analyzed in biological 
triplicates. The mean values were used to compare cell viability between samples. 
2.5 Assessment of cell viability using Trypan Blue staining  
 
Assay principle 
Trypan blue is a blue diazo dye, commonly used to distinguish between dead and 
viable cells. Trypan blue is incorporated by damaged cells. As a consequence their 
cytoplasm is colored blue and dead cells can be recognized by observation under a 
light microscope. Cells with intact membranes remain uncolored.  
Assay procedure 
The cells were pelleted and resuspended in 300µl medium. Immediately prior to 
analysis the cells were stained by addition of equal volume of with trypan blue 
(300µl). The number of dead (stained blue) and viable (unstained) cells was counted 
under a light microscope using hemocytometer and the cell viability was expressed 
as a percentage of viable cells. All samples were analyzed in biological triplicates. 
The mean values were used to compare cell viability between samples. 
2.6 XTT cytotoxicity assay 
 
Assay principle 
XTT cytotoxicity test (Roche) is based on the cleavage of the yellow tetrazolium salt 
XTT to form an orange fermazan dye by metabolically active cells.  
Assay procedure 
XTT assay was used to assess the influence of BALs from post-transplant patients on 
PBEC cell viability. PBEC cells were seeded at 2x104 cells/ml in the medium volume 
of 100ul/well in a 96 well culture plate. The cells were allowed to grow for 24hrs 
after which they were treated for 24hrs with 100μl 1:1 BAL/medium. Following the 
treatment, 10µl of XTT reagent (prepared by mixing XTT (1mg/ml) with electron 
coupling reagent (1.25mM)) was added to each well. Following 4hrs incubation the 
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formazan dye formation corresponding to the relative cell number was quantified 
using a multiwell spectrophotometer. All measurements were performed at the 
wave-length of 450nm.  
2.7 Enzyme-linked immunosorbent assay (ELISA) 
 
IL-1α, HSP60, IL-8, IL-6, IL-1β and GM-CSF concentrations were measured using 
ELISA DuoSet kit (RnD Systems) according to the manufacturer’s instructions. MCP-1 
concentrations were measured using a sandwich ELISA kit from Peprotech.  Briefly, 
96 well plates were coated with an appropriate capture antibody diluted to the 
working concentration in PBS without carrier protein. Following overnight 
incubation, the plates were blocked with 1% BSA and 100µl of an appropriate 
dilution of sample or protein standard was added to each well. Seven point 
standard curves were prepared using 2-fold serial dilutions of an adequate 
recombinant protein. All samples were analyzed in biological triplicates and 
technical duplicates. Antigen detection was performed by incubation with an 
appropriate biotynylated antibody and the plates were developed by adding HRP-
linked streptavidin producing visible signal upon addition of the substrate - 
tetramethylbenzidine. The reaction was stopped with 2M H2SO4 and the optical 
density at the wavelength of 450nm was measured using a microplate reader. The 
replicate readings for standards and samples were averaged and the zero standard 
optical density was subtracted. The standard curves were created using EXCEL 
software by plotting the mean absorbance for each standard against the 
concentration. The concentrations of samples were determined by comparing the 
absorbance to the standard curve and multiplying by the dilution factor. 
The composition of blocking buffers, wash buffers, dilution reagents and 
concentrations of the capture and detection antibodies used has been listed in table 
8. 
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Protein 
name 
Capture 
antibody 
origin and 
concentration 
Detection 
antibody origin 
and 
concentration 
 
 
Reagent 
diluent 
 
 
 
Substrate 
 
 
Detection 
range 
 
 
 
Supplier 
IL-1α Mouse anti-
human IL-1α 
2μg/ml 
Biotinylated 
goat anti-human 
IL-1α 12.5ng/ml 
1% BSA in 
PBS, pH 7.2-
7.4 
TMB 7.81-
500pg/ml 
R&D 
Systems 
HSP60 Mouse anti-
human HSP60 
2μg/ml 
Biotinylated 
mouse anti-
human HSP60 
1μg/ml 
1 mM EDTA, 
0.5% Triton 
X-100 in 
PBS, pH 7.2 - 
7.4. 
TMB 0.625-
40ng/ml 
R&D 
Systems 
IL-6 Mouse anti-
human IL-6 
2μg/ml 
Biotinylated 
goat anti-human 
IL-6 200ng/ml 
 
1% BSA in 
PBS, pH 7.2-
7.4 
TMB 31.24-
2000pg/ml 
R&D 
Systems 
IL-8 Mouse anti-
human IL-8 
4μg/ml 
Biotinylated 
goat anti-human 
IL-8 20ng/ml 
0.1% BSA in 
TBS-T 
(0,05% 
Tween20 in 
TBS), pH 7.5-
7.6 
TMB 7.81-
500pg/ml 
R&D 
Systems 
IL-1β Mouse anti-
human IL-1β 
4μg/ml 
Biotinylated 
goat anti-human 
IL-8 200ng/ml 
0.1% BSA in 
PBS-T 
(0,05% 
Tween20 in 
TBS), pH 
TMB 3.9-
250pg/ml 
R&D 
Systems 
MCP-1 Rabbit anti-
human MCP-1 
0.5μg/ml 
Biotinylated 
rabbit anti-
human IL-8 
0.5μg/ml 
0.1% BSA in 
PBS-T 
(0,05% 
Tween20 in 
TBS), pH 
ABTS 31.24-
2000pg/ml 
Peprotech 
GM-CSF Mouse anti-
human GM-
CSF 2μg/ml 
Biotinylated 
mouse anti-
human IL-8 
0.5μg/ml 
0.1% BSA in 
PBS-T 
(0,05% 
Tween20 in 
TBS), pH 
TMB 15,62-
1000pg/ml 
R&D 
System 
 
TMB- 3,3’,5,5’-Tetramethylbenzidine; ABTS-  2,2′-Azino-bis(3-ethylbenzothiazoline-
6-sulfonic acid)  
Table 8 Composition and concentrations of reagents and antibodies used in ELISA  
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Establishing sample dilution factor 
To find the optimal sample dilution factor and to ensure that the analyte 
concentration was within the range of the standard curve linearity, 2-fold serial 
dilutions of selected samples were performed prior to analysis. The sample diultions 
fitting within the linear phase of the standard curve were used to determine the 
concentrations of the protein of interests. An example standard curve has been 
shown in figure 9. 
 
Figure 9 An example of an ELISA standard curve. 
 
2.8 MSD electrochemiluminescence assay 
 
IL-1α and IL-8 concentrations in BALs were measured using MSD 
electrochemiluminescence detection kits (Meso Scale Discovery) according to the 
manufactures instructions. Briefly, 25μl of sample or an appropriate human 
recombinant cytokine was loaded in technical duplicates into each well of a 96 plate 
and subjected to an overnight incubation at 4°C. Following the incubation the plates 
were washed 3 times with 1xPBS-T and 25μl of detection antibody was added to 
each well. After 2hrs incubation the plates were washed again and 150 of 2X read 
buffer was added to each well and the plates were read immediately on a SECTOR® 
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Imager 2400 plate leader (Meso Scale Discovery). The cytokine concentrations were 
calculated against a seven point standard curve ranging from 2500 to 0 pg/ml. 
2.9 Immunocytofluorescence 
 
Cells were seeded at 2x105/ml in a 24 well plate and treated as indicated. The cells 
were fixed with 3% paraformaldehyde (Sigma) for 1hr at room temperature. To 
quench the autofluorescence the samples were incubated in 100mM glycine 
(Sigma) solution for 30mins. Cell membranes were permeabilized using 0.1% Triton 
X-100 solution (Sigma), blocked with 5% BSA (Sigma) in PBS-T and probed with 
1:100 dilution of anti-human IL-6 (mouse monoclonal, R&D Systems) or fibronectin 
(mouse monoclonal, R&D Systems) antibody. Proteins were visualized using a 
corresponding secondary antibody conjugated with FITC or TRIC respectively 
(DAKO). The cell nuclei were stained with DAPI (Vectra Shield). Samples were 
analyzed using a Leica TCS-SP-2UV confocal microscope. To determine the 
background staining, 2°Ab controls were implemented in each experiment. 
2.10 Immunohistofluorescence 
 
Lung tissue sections were embedded in paraffin and sliced using a microtome. Prior 
to the staining the specimen were dewaxed in xylens for 5mins and fixed with 74% 
ethanol for 3mins. To reduce the surface tension the slides were boiled in 1xEDTA 
for 10mins. After cooling for 20mins at room temperature the samples were 
blocked with 1% BSA in PBS-T and incubated with an appropriate concentration of 
primary antibody overnight. Following the incubation the samples were washed 3 
times with PBST and a fluorochrome-conjugated secondary antibody (DAKO) added 
for 2hrs. Cell nuclei were visualized with mounting solution containing DAPI 
(Vectashield). Samples were analyzed using a Leica TCS-SP-2UV confocal 
microscope. To determine the background staining, 2°Ab controls were 
implemented in each experiment. 
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2.11 RNA extraction 
 
Total RNA from cells was isolated using Absolutely RNA MicroPrep (Stratagen). The 
extraction method is based on the ability of nucleic acids to bind to silicon matrix 
and uses chaotropic salt guanidine thiocyanate as a strong protein denaturant 
allowing to effectively lyse cells and prevent from RNA degradation by 
ribonucleases. 
~5x105 cells were resuspended in 100µl lysis buffer containing 0.7µl β-
Mercaptoethanol and homogenized by vortexing. Next, 100ul 75% ethanol was 
added and the mixture was vortexed for 5 seconds. The cell lyset was transferred 
into RNA-Binding Spin column seating within a 2-ml collection tube and span down 
for 1 min at 12000g.  
In order to remove genomic DNA contamination, DNase treatment was performed. 
Prior to the procedure, the column was washed with 600µl 1XLow Salt Buffer and 
the matrix was dried by centrifugation for 2 mins at 12000g. Next, 30µl of DNase 
solution was added directly onto the matrix of the RNA-Binding Spin column and 
the samples were placed in a 37°C incubatior for 15 mins. 
Following the DNase treatment, the matrix was washed once with 500µl of 1xHigh 
Salt Buffer containing guanidine thiocyanate  and twice with 500 and 300µl 1xLow 
Salt Buffer and, to dry the matrix, the samples were span down for 2mins at 
12000g. 
The RNA-Binding Spin column was transferred into a new 1.5ml collection tube and, 
in order to elute the RNA, 30ul of Elution Buffer was added directly onto the matrix. 
Following 2 mins incubation at room temperature, the column was span down for 
1min at 12000g. The purified RNA solutions in Elution Buffer were stored at -80C.  
The RNA concentrations were measured spectrophotometrically at the wavelength 
of 260nm using a NanoDrop instrument. The purity of the extracted RNA was 
assessed based on the A260/A280 ratio and its quality was verified by 
electrophoresis in 2% agarose gel in 1xTAE buffer (Figure 10). 
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Figure 10 An example of RNA quality check. 20ng RNA was separated by 
electrophoresis in a 2% agarose gel containing ethidium bromide. 
 
2.12 Reverse-transcription Polymerase Chain Reaction 
 
Reverse transcription PCR was carried out with AffinityScript Multiple Temperature 
cDNA Synthesis Kit (Stratagene) using 0.5-2ug of total RNA. In order to perform the 
first strand cDNA synthesis a 15.7 μl reaction mixture containing 12.7 µl of RNA and 
3µl of random primers (0.1µg/µl) in RNase-free water was incubated for 5mins at 
65°C in a thermocycler. Following the incubation the mixture was cooled down to 
room temperature for 10mins to allow the primers to anneal to RNA. Next, 2.0 μl of 
10× AffinityScript RT Buffer, 0.8 μl of dNTP mix (25 mM each dNTP), 0.5 μl of RNase 
Block Ribonuclease Inhibitor (40 U/μl) and 1 μl of AffinityScript Multiple 
Temperature Reverse Transcriptase were added to the mixture to the total volume 
of 20μl. To extend the primers, the samples were incubated at 25°C for 10mins, 
after which the reaction temperature was increased for 60min to 55°C to allow 
cDNA synthesis. The reaction was terminated by incubating for 10mins at 70°C. 
cDNA samples were used immediately for PCR or stored at -20°C. 
 
 
M  Batch  1      2      3              
28S 
18S 
 
18 
89 
 
2.13 Polymerase Chain Reaction (PCR) 
 
PCR was performed to verify the results of the first strand cDNA synthesis and to 
confirm the site-specificity of the primers designed to anneal fragments of the 
target cDNA for gene expression analysis by qRT-PCR. PCR reactions were carried 
out in 25μl volume. Following 1min initial denaturation step at 94°C, samples were 
subjected to PCR for 35 cycles as follows: 94°C denaturation (30s), 55-60°C 
annealing (30s) and 72°C elongation (1min). The final elongation step was 
performed at 72°C for 5mins. The products of the PCR reaction were analyzed by 
electrophoresis in 2% agarose gel with 0.5μg/ml ethidium bromide in 1xTAE buffer 
containing 40 mM Tris·HOAc and 2 mM EDTA (pH ~ 8.5). 
Composition of the reaction mixture is as follows:  
5μl 5x GoTaq Flexi Reaction Buffer, 
2μl MgCl2 (25mM) 
 0.5μl dNTPs (10mM) 
 0.5μl Forward Primer (10μM) 
 0.5μl Reverse Primer (10μM) 
 15.25μl H2O 
 1μl cDNA (20ng)  
0.25μl GoTaq Flexi DNA Polymerase (0.25U) (Promega). 
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2.14 XBP-1 splicing assay 
 
1 μg total RNA was reverse-transcribed with AffinityScript Multiple Temperature 
cDNA Synthesis Kit (Agilent technologies) and 20ng of cDNA was amplified with 
JumpStart™ Taq polymerase using a pair of primers covering a 26 nucleotide intron 
(nucleotides 531-556), which is spliced out by IRE1 following ER-stress induction. 
DNA fragments were separated on 2% agarose gel. 
2.15 Real-time PCR 
 
Real-time PCR was performed using ABI PRISM 2000 instrument. GAPDH was used 
as the house-keeping gene. The reactions were performed in a 96 well plate format. 
Each well contained 6.5µl Sybr Green Master Mix (Sigma), 1µl forward and reverse 
primer mixture (10mM), 3.5µl H2O and 2µl cDNA (20ng). Each test was performed in 
duplicates with a no template control for each primer set. Results were normalized 
to the expression of the endogenous reference gene (GAPDH) and the relative gene 
expression was calculated using ΔΔCt method according to the following formula:  
ΔΔCt= 2^(Ct of reference gene – Ct of gene of interest). 
where Ct referes to a threshold cycle 
 
2.16 Determination of protein concentration using BCA (bicinchoninic acid) 
protein assay  
Assay principle 
The BCA Protein Assay is based on reduction of Cu2+ to Cu1+ by protein in an alkaline 
environment. Cuprous cations (Cu1+) are bound by bicinchoninic acid which results 
in forming a purple-blue product which exhibits a strong linear absorbance at 
562nm correlating with protein concentrations. Total protein concentration is 
calculated using an 8-point (working range = 20-2000μg/ml) standard curve 
prepared by making serial dilutions of Bovine Serum Albumin (BSA). An exemplary 
standard curve is presented in figure 11. 
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Figure 11 An example of protein standard curve used to determine protein 
concentration with BCA assay.  
 
Assay procedure 
25μL of each standard or unknown sample was pipetted in triplicates into a 
microplate well. Before loading, samples were diluted 1:16 with PBS. Next, 200μL of 
the working reagent prepared by mixing reagent A, containing sodium carbonate, 
sodium bicarbonate, bicinchoninic acid and sodium tartrate in 0.1M sodium 
hydroxide, with reagent B, containing 4% cupric sulphate, in 50:1 ration was added 
to each well and the plate was mixed thoroughly on a plate shaker for 30 seconds. 
Subsequently, the plate was covered and incubated at 37°C for 30 minutes. To 
determine the protein concentration the absorbance was measured using a plate 
reader.  
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2.17 Western bloting 
 
Protein was extracted from cells by sonication and protein concentration was 
assessed with BCA protein assay (Thermo Scientific) as described above. Aliquots 
containing equal amounts of protein were mixed at 1:6 ratio with 6 x sample 
loading buffer containing mercaptoethanol and the samples were boiled at 100°C 
for 5mins before loading on polyacrylamide gel containing SDS. Proteins were 
resolved using gradient 4-12% gels (Invitrogen) or 10% home-made acrylamide gels, 
prepared according to a recipe described in table 9. 
 
Separating gel mix 
Component Volume 
30% (w/v) acrylamide, 0.8% (w/v) bisacrylamide 3.75 ml 
1 M Tris·HCl, pH 8.9 2.813 ml 
H2O 4.654 ml 
Add after degasing: 
10% (w/v) SDS 75 μl 
10% (w/v) ammonium persulfate 33.75 μl 
TEMED 7.5 μl 
Total 11.33 ml 
Stacking gel mix 
Component Volume 
30% (w/v) acrylamide, 0.8% (w/v) bisacrylamide 0.50 ml 
1 M Tris·HCl, pH 6.8 0.938 ml 
H2O 2.323 ml 
Add after degasing: 
10% (w/v) SDS 9.375 μl 
10% (w/v) ammonium persulfate 16.88 μl 
TEMED 5.625 μl 
Total 3.795 ml 
 
Table 9 List of components used to prepare polyacylamide gels. 
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Following SDS-PAGE electrophoresis in 1xTris-glycine buffer at 100V for 1.5hrs, 
protein was transferred overnight at 4°C in 1xTris-glycin buffer containing 20% 
methanol onto PVDF membrane using X-cell Blot Module (Invitrogen). The 
membranes were blocked with 5% BSA in 0.05% TBS-T for 1hr at RT, washed 3 times 
with 0.05% TBS-T and immunobloted overnight at 4°C with an appropriate primary 
antibody diluted in 5% BSA in 0.05% TBS-T. Following the incubation, the 
membranes were washed 3 times with 0.05% TBS-T and probed for 1hr with a 
corresponding secondary HRP-conjugated antibody. Next, the membranes were 
washed 3 times with 0.05% TBS-T buffer, after which peroxidase activity was 
detected using Pierce Chemiluminescent Substrate (Thermo-Scientific) and the 
protein was visualized with Gel-Doc system or using X-ray film. The content of 
buffers and reagents used for western blotting has been listed in table 10. 
 
GEL NuPAGE Bis-Tris gradient (4-
12%) gel (Invitrogen)  
10% SDS-PADE gel 
Sample 
loading buffer  
4xLDL sample buffer + β-
mercaptoethanol (2:1) 
6xSDS-PADE sample buffer 
350 mM Tris·HCl, pH 6.8 
30% (v/v) glycerol 
10% (w/v) SDS 
0.5 g/l bromophenol blue 
2% (v/v) β-mercaptoethanol 
Running 
Buffet 
MES (0.1M 2-(N-morpholino) 
ethanesulfonic acid) 
SDS-PAGE running buffer (0.192 M 
glycine, 0.0248 M Tris, 1 g/l SDS) 
Transfer 
Buffet 
Tris-glycine buffer with 20% 
methanol  
(0.192 M glycine 
0.0248 M Tris 
20% v/v Met-OH) 
Tris-glycine buffer with 20% 
methanol  
(0.192 M glycine 
0.0248 M Tris 
20% v/v Met-OH) 
Wash buffer 0.05% TBS-T 
50 mM Tris.HCl 
150 mM NaCl 
0.1% Tween 20 
adjust pH to pH 7.4 with HCl 
0.05% TBS-T 
50 mM Tris.HCl 
150 mM NaCl 
0.1% Tween 20 
adjust pH to pH 7.4 with HCl 
 
Table 10 List of buffers and reagents used for western blotting 
94 
 
2.18 Statistical analysis 
 
Statistical analysis was performed using one-way Anova followed by un-paired 
Student –t test (for normally distributed samples) or Kruskal-Wallis test followed by 
Mann U Whitney test (for not normally distributed samples). Correlation was 
analysed using Spearman's rank correlation.  
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CHAPTER 3 ESTABLISHING AN IN-VITRO MODEL OF HUMAN BRONCHIAL 
EPITHELIAL CELL INJURY 
3.1 Background 
Innate immune signaling promotes inflammatory responses essential for tissue 
homeostasis, particularly in organs such as the lung, that are regularly challenged by 
environmental insults. Although bacterial and viral infections have been recognized 
as one of the main risk factors in chronic degenerative diseases, numerous studies 
demonstrated that chronic inflammation may also be induced by non-pathogen 
related-repetitive tissue injury which may persist even without ongoing infection. 
This phenomenon, termed ‘sterile inflammation’, is mediated by DAMPs (alarmins), 
that may be released by injured respiratory epithelium, posing the first line of 
defense against invading, exogenous agents. Chronic exposure to pathogen and 
damage associated danger signals often results in chronic inflammation and tissue 
fibrosis. Classically, myeloid cells, comprising monocytes, macrophages and 
neutrophils, are the main cellular triggers of innate immune signaling, via 
engagement of receptors recognizing DAMPs and PAMPs, However there is growing 
evidence of immune functions for tissue resident fibroblasts, whose numbers 
significantly increase in fibrotic organs [35].  
Epithelial damage associated with alarmin release is a hallmark of many chronic 
degenerative diseases including chronic lung allograft rejection, liver cirrhosis or 
arthritis. In chronic lung allograft rejection, bronchial epithelial cell injury, necrosis, 
and ulcerations of mucosa are observed. This epithelial damage is accompanied by 
infiltration of leukocytes, neutrophils and macrophages and subsequent expansion 
of myofibroblasts causing tissue scarring and airway obliteration [13].  
Although numerous alarmins have been identified so far, their potential 
involvement in the pathogenesis of chronic degenerative lung diseases remains 
unclear. The studies investigating the immunogenic potential of alarmins, that have 
been conducted to date, focused on the influence of these molecules on the 
functions of immunocytes. No studies, however, have been performed on the 
interactions between alarmins released by damaged human bronchial epithelial 
cells and fibroblasts. 
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The initial aim of this study was to establish an in vitro model of human bronchial 
epithelial cell damage and to identify alarmins released by these cells following 
injury that may be implicated in chronic fibrotic lung diseases by activating human 
lung fibroblasts. This objective has been met by establishing the influence of 
different injurious stimuli on human bronchial cell viability and alarmin release and 
investigating the changes in inflammatory and fibrotic phenotype of fibroblasts 
exposed to conditioned media from the injured epithelium.   
Since alarmins were first described in 1994 [202], in order to investigate the role of 
danger signals in different in vitro and in vivo models of chronic degenerative 
diseases, several models of cell injury have been established. 
Although, the pathophysiology of chronic degenerative diseases such as chronic 
allograft rejection has been studied for decades, the consensus as to the underlying 
cause of the progressive epithelial damage has still not been reached.  
The main injurious stimuli used to induce cell death and alarmin release in vitro, 
include freeze-thaw stress, oxidative stress, osmotic stress and cell lysis by 
sonication. 
Increased number of neutrophils, which is often observed in lung following 
transplantation, has drawn some researchers to the conclusion that another factor 
that may contribute to epithelial damage may be proteolytic enzymes such as 
elastase, that may be produced by activated neutrophils and whose main function is 
the digestion of protein components of invading pathogens [203].  
Additionally, some research indicate that cellular damage in chronic inflammatory 
diseases, which are associated with very intensive production of proinflammatory 
factors,  may be caused by stress in the endoplasmic reticulum (ER stress), which 
can be caused by accumulation of unfolded proteins. Increased production of 
proteins may occur in fibrotic and chronic inflammatory diseases which are 
characterized by intensive expression of proteins building the extracellular matrix, 
and cytokines and growth factors, which may be rapidly produced in large 
quantities [204].  
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A commonly used and well accepted animal model of pulmonary fibrosis and 
inflammation, uses bleomycin to induce epithelial damage, which initiates fibrotic 
and inflammatory changes in the lung. 
Bleomycins are a family of compounds possessing antibiotic activity that are 
produced by the bacterium Streptomyces verticillis. Bleomycin A2 and B2 found 
application in anti-cancer therapy and are used in the treatment in diseases such as 
Hodgkin's lymphoma, squamous cell carcinomas and testicular cancer. One of the 
side effects of bleomycin therapy is pulmonary toxicity which may be manifested by 
progressive lung fibrosis. This property of bleomycin has been used in an animal 
model of pulmonary fibrosis. In vitro studies revealed that bleomycin may act as an 
intercalating agent and cause DNA damage leading to cell death. The bleomycin 
molecule consists of a bithiazole component which can intercalate into the DNA 
strand and pyrimidine and imidazole components which bind iron and oxygen and 
may form oxidants causing DNA damage. Moreover bleomycin may contribute to 
cell damage by inducing lipid peroxidation. Hence, the main mechanism of 
bleomycin induced cell damage is oxidative stress which causes deregulation of the 
intracellular homeostasis leading to necrotic cell death. This property of bleomycin 
is used to reduce tumor size in anti-cancer therapy [205] [206].  
In patients and animals treated with bleomycin, damage to alveolar epithelium is 
observed. This epithelilal damage initiates influx of neutrophil and may lead to 
chronic inflammation and fibrosis. Similar changes are observed in lungs of patients 
following transplantation. The studies performed to date suggest that the 
degeneration of the respiratory epithelium post transplantation may be mediated 
by several factors including allogenic injury and oxidative stress that may be 
induced for example by activated neutrophils which are a substantial source of 
reactive oxygen species and free radicals [207] [208]. 
The mechanisms of cell death induced by the aforementioned methods differ 
significantly and therefore the choice of the cell injury technique should be carefully 
considered when designing a study.  
In lung transplant recipients, epithelial damage in the respiratory tract may be 
accentuated by environmental factors such as airborne particles, smog or cigarette 
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smoke. A recent study conducted on post-transplant patients, revealed that the 
level of air pollution may have a substantial influence on the allograft fate. The 
study demonstrated that post-transplant patients living in areas characterized by 
higher levels of air pollution were more likely to develop bronchiolities obliterans 
syndrome in comparison to allograft recipients from less polluted neighborhoods 
[209].  
Considering all the points listed above, in the present study, in order to establish an 
in vitro model of human bronchial epithelial cells damage, oxidative stress, a 
proteolitic enzyme, elastase, cigarette smoke, ER stress and freeze-thaw stress, 
have been tested as potential injurious stimuli. 
A flow chart showing the study experimental design is shown in figure 12. 
 
Figure 12 A flow chart showing the study experimental design. 
 
Primary human bronchial epithelial cells (PBECs) were used in the project to 
establish an in vitro model of epithelial injury. Primary cells are considered the best 
in vitro model to predict in vivo responses, however, their lifespan is relatively short 
(4-5 passages) and their availability is limited. Therefore it was necessary to identify 
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a cell line whose response to injury is comparable to PBECs. Cell lines tested as 
potential candidates for that role included A549, BEAS-2B and 16HBE14o-. 
To establish a lung epithelial cell injury model relevant to chronic degenerative lung 
diseases, PBECs cells and the aforementioned cell lines were exposed to the insults 
discussed above. 
The influence of the treatments listed above on PBEC cell viability was assessed by 
flow cytometry or trypan blue staining. To establish if epithelial damage was 
associated with a release of danger signals, in the initial experiments, levels of 
marker alarmins: IL-1α, HMGB-1 and HSP-60 were measured using an ELISA. The 
choice of the marker alarmins was based on previous studies showing that these 
factors may be released by damaged cells and that they are upregulated during 
infection, which is one of the major causes of exacerbations in patients affected by 
fibrotic diseases [27]. Additionally, in subsequent experiments, IL-1α was used as a 
marker of injury to identify a cell line whose behavior in response to an injurious 
stimulus resembles PBECs. Once the appropriate cell line has been indentified, and 
a method of cell injury established, the model of an in vitro epithelial cell damage 
was verified by a measurement of other marker alarmins including HMGB-1 and 
HSP-60. IL-1α and HSP-60 protein concentrations were measured using 
commercially available sandwich ELISAs. In order to estimate HMGB-1 
concentations in cell culture media, a direct home-made ELISA was developed.  
Hypotheses tested:  
1. Primary human bronchial epithelial cells (PBECs) and human lung epithelial 
cell lines (A549, 16HBE14o- and BES2B) damaged with an injurious stimulus 
such as oxidative stress, stress in the endoplasmic reticulum (ER stress), 
elastase or cigarette smoke release marker alarmins including IL-1α, HMGB-
1 and HSP60. 
2. Conditioned media from damaged human bronchial epithelial cells trigger 
gene expression of proinflammatory (eg IL-6) and fibrogenic (eg collagen 
type1) factors in human lung fibroblasts. 
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3.2 Development of direct ELISA for human HMGB-1 detection 
 
To establish optimal conditions for HMGB-1 detection by direct ELISA, titrations of 
the primary antibody (monoclonal mouse anti-human HMGB-1, RnD systems), 
secondary antibody (polyclonal biotinylated donkey anti-mouse IgG, RnD systems) 
and HRP-streptavidin (Thermo Scientific – Pierce) were performed. 96 well ELISA 
plate was coated with hrHMGB1 resuspended in PBS at a range of concentrations 
from 300 to 0.41ng/ml. Following 24hrs incubation time, the wells were washed 
three times with 1XTBS-T and blocked with 5% BSA in PBS for 2hrs. Next, the 
primary antibody in 3% BSA-PBS at three different concentrations (0.5, 2, 5μg/ml) 
was added to the plate. After 2hrs incubation period the wells were washed 3 times 
with 1XTBS-T, after which the secondary antibody in 3% BSA-PBS was added at 2 
different concentrations (1:1000, and 1:2000). The plate was incubated at RT for 
another 2hrs after which it was washed 3 times with 1XTBS-T and 100μl HRP-
strepatavidin at 3 different concentrations (1:500, 1:1000 and 1:2000) was added to 
the adequate wells. After 20 mins, the plate was washed 3 times with 1XTBS-T and 
100ul substrate solution (RnD systems) was added to each plate. The plate was 
incubated for another 20 mins in the dark, after which, to stop the reaction, 50μl of 
2M H2SO4 was added to each well and the ODs were read at 450nm with ELISA plate 
reader. The combination of the reagent concentrations which gave the lower 
background and the strongest signal (Primary Ab - 2ug/ml; Secondary Ab – 1:2000; 
HRP-Streptavidin – 1:2000) were used in all the subsequent experiments. The ELISA 
detection limit was established according to the following equation: 2.5 x mean of 
background OD + mean of standard deviation. The analysis revealed that the assay 
detection limit was 10 ng/ml. 
The tested concentrations of primary and secondary antibodies used to optimize 
HMGB-1 ELISA are listed in table 11. An example of an HMGB-1 ELISA standard 
curve is presented in figure 13. 
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Reagent Concentrations 
tested 
Incubation 
time 
 
Primary antibody - monoclonal mouse 
anti-human HMGB1, RnD systems 
 
0.5, 2, 5μg/ml 2hrs 
Secondary antibody - polyclonal 
biotinylated donkey anti-mouse IgG, 
RnD systems 
 
1:1000 
1:2000 
2hrs 
HRP- streptavidin (Pierce) 1:500 
1:1000 
1:2000 
30mins 
 
Table 11 Concentration of reagents used in the HMGB1 ELISA. 
 
               
 
Figure 13 Standard curve for HMGB1 detected using direct ELISA; 1°Ab 
concentration: 2μg/ml, 2°Ab conc. 1:2000, HRP-streptavidin conc. 1:2000 
3.3 Influence of selected injurious stimuli on PBEC cell viability and alarmin 
release. 
 
To identify the most efficient and possibly physiologically relevant method to induce 
injury of human bronchial epithelial cells, PBEC cells obtained from bronchial 
brushings were used. The cells were cultured in SAGM media until the monolayers 
reached 80-90% confluency. Next, the cells were subjected to a treatment with 
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selected injurious stimuli and the cell viability was assessed by trypan blue staining 
or flow cytometry using PI. Moreover, to establish the influence of the tested injury 
methods on danger signal release, levels of marker alarmins were measured in 
conditioned media collected from the damaged PBEC cells. 
3.4 Influence of oxidative stress on PBEC cell viability and marker alarmin (IL-1α, 
IL-1β, HMGB-1, HSP60) release. 
 
To establish the optimal dose of hydrogen peroxide, sufficient to induce PBEC cell 
damage, the cells were treated with a range of H2O2 concentrations. The medium 
was replenished after 2hrs and the cell viability assessment and conditioned media 
collection were performed after another 24hrs. The results of the experiment 
revealed marked increase in IL-1α, HSP60 and HMGB-1 release by damaged PBEC 
cells in comparison to the untreated controls. Interestingly, increase in HMGB-1 
release was associated with PBEC cell death, while elevated levels of IL-1α were 
detectable also in conditioned media from PBEC cells exposed to H2O2 doses, which 
did not have significant effect on the cell viability, suggesting that HMGB-1 may be 
considered a marker of cellular damage, while IL-1α, may function as an early 
danger signal, released by stressed cells prior to cell death. Since, according to some 
reposts, oxidative stress may trigger inflammasome activation, the levels of IL-1β, 
whose processing is caspase-1 and inflammasome dependant, were also measured 
in conditioned media from damaged cells. The ELISA analysis revealed that IL-1β 
was detectable in conditioned media following PBEC stimulation with H2O2, 
however its concentrations were approximately 5 times lower in comparison to IL-
1α (Figure 14). Therefore, to establish a model of epithelial injury, which will allow 
to identify early danger signals that may be implicated in fibroblast activation, IL-1α 
was used as a marker alarmin in all the subsequent experiments performed to 
identify a suitable cell line and type of injury.   
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Figure 14 Oxidative stress reduces primary human bronchial epithelial cell (PBEC) 
viability and induces alarmin release. PBEC were treated with the indicated 
concentrations of H2O2 for 2hrs, after which the culture medium was replenished 
and the cells were subjected to a further incubation for 24hrs. Following the 
incubation, the cell viability was assessed by flow cytometry, using PI staining and 
the levels of IL-1α, IL-1β, HMGB-1 and HSP60 were analysed by ELISA. The ELISA 
analysis revealed that oxidative stress reduced PBEC cell viability (A) and induced IL-
1α (B), HMGB-1 (D) and HSP60 (E) release. There was not significant difference in IL-
1β (C) levels in conditioned media following H2O2 treatment and IL-1β levels were 
approximately 5 times lower in comparison to IL-1α. Data represent the 
mean±S.E.M from three independent experiments performed on two biological 
replicates. Statistical analysis was performed using unpaired Student’s t test. 
*p<0.05, **p<0.01, ***p<0.001. 
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3.5 Influence of thapsigargin-induced ER stress on PBEC cell viability and IL-1α and 
HMGB-1 release.  
 
To induce ER stress, PBEC cells were exposed to 1, 10 or 50µM doses of thapsigargin 
(TG) for 2hrs, after which the culture media was replenished and the cells were re-
incubated for an additional 24hrs and the cell viability and IL-1α and release were 
assessed. Additionally, in a control experiment, the levels of HMGB-1 in conditioned 
media from TG-treated PBEC cells were also measured. Induction of unfolded 
protein response was measured 2hrs post TG treatment using XBP-1 splicing assay.  
A relatively low dose of TG (1µM) resulted in slight increase of PBEC cell viability 
and no IL-1α release. 10µM TG induced IL-1α release, but did not have a significant 
effect on PBEC cell viability, while 50µM TG significantly reduced the number of 
viable cells and resulted in IL-1α and HMGB-1 release (figure 15). 
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Figure 15 Thapsigargin-induced stress in the endoplasmic reticulum (ER stress) 
reduces PBEC cell viability and induces IL-1α and HMGB-1 release. Primary human 
bronchial epithelial cells (PBEC) were pulsed with the indicated concentrations of 
thapsigargin (TG) for 2hrs. Following the treatment, the culture medium was 
replenished and the cells were re-incubated for a further 24hrs. Next, the cell 
viability was assessed by trypan blue staining and IL-1α and HMGB-1 concentrations 
were measured with ELISA. Induction of ER stress was confirmed using XBP-1 
splicing assay (B).Treatment with 50µM TG significantly reduced PBEC cell viability 
(A) and TG doses of 50µM induced IL-1α (C) and HMGB-1 (D) release. Data 
represent the mean±S.E.M. from 3 independent experiments performed on two 
biological replicates. Statistical analysis was performed using unpaired Student’s t 
test. *p<0.05, **p<0.01, ***p<0.001.  
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3.6 Influence of human neutrophil elastase treatment on PBEC cell viability and IL-
1α release 
 
80-90% confluent PBEC cell monolayers were cultured for 2hrs in culture media 
containing the indicated concentrations of human neutrophil elastase (Sigma), after 
which the culture media was replenished and the cells were re-incubated for an 
additional 24hrs and the cell viability and IL-1α release were assessed.  The analysis 
revealed that the elastase treatment did not have a significant influence on PBEC 
cell viability or IL-1α release (figure 16). 
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Figure 16 Influence of elastase treatment on PBEC cell viability and IL-1α release 
PBEC cells were treated with the indicated concentrations of human neutrophil 
elastase for 2hrs. Following the treatment the medium was replenished and the 
cells were re-incubated for further 24hrs. Next, the cell viability was assessed using 
trypan blue staining and IL-1α protein concentration in conditioned media was 
measured using ELISA. Data represent the mean±S.E.M. from 3 independent 
experiments performed on two biological replicates. Statistical analysis was 
performed using unpaired Student’s t test. No significant differences were detected 
between samples. 
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3.7 Influence of cigarette smoke extract on PBEC cell viability and IL-1α release 
 
Cigarette smoke extract (CSE) was freshly prepared prior to the experiment by 
bubbling the mainstream of cigarette smoke directly into 20mls of the culture 
medium by constant vacuum. The CSE solution was filtrated through 0.2um filter 
and diluted down to the final concentrations of 25%, 12.5% and 6.25%. The PBEC 
cells were cultured in media containing the aforementioned concentrations of CSE 
for 2hrs, after which the culture media was replenished and the cells were re-
incubated for an additional 24hrs. Following the incubation, the cells were 
harvested and subjected to cell viability assessment by FACS and the conditioned 
media were collected and IL-1α concentrations were measured by ELISA. 
The analysis revealed that the CSE treatment did not have a significant influence on 
PBEC cell viability or IL-1α release (figure 17). 
C
e
ll
 v
ia
b
il
it
y
 [
%
]
CSE concentration [%]                                                     
0
10
20
30
40
50
60
70
80
90
100
0 6.25 12.5 25
A
CSE concentration [%]
0
50
100
150
200
250
0 6.25 12.5 25
B
NS NS
IL-1α
p
g
/m
l
 
 
Figure 17 Influence of cigarette smoke extract on PBEC cell viability and IL-1α 
release 
PBEC cells were treated with the indicated concentrations of cigarette smoke 
extract (CSE) for 2hrs. Following the tretamnet, the medium was replenished and 
the cells were re-incubated for further 24hrs. Next, the cell viability (A) was 
assessed using trypan blue staining and IL-1α protein concentration (B) in 
conditioned media was measured using ELISA. Data represent the mean±S.E.M. 
from 3 independent experiments performed on two biological replicates. Statistical 
analysis was performed using unpaired Student’s t test. No significant differences 
were detected between samples. 
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3.8 Influence of freeze-thaw stress on PBEC cell viability and IL-1α and HMGB-1 
release 
 
To establish if alarmins may be released from PBEC cells damaged without an 
intervention of chemical substances, in a control experiment, PBECs cells were 
subjected to 3 freeze-thaw (F/T) cycles at -80°C/37°C. The cells were left to recover 
for 24hrs, after which the cell viability was assessed by flow cytometry and the 
conditioned media collected for ELISA. The FACS analysis did not reveal the 
presence of viable cells in a culture following treatment. As assessed by ELISA, 
freeze-thaw stress-induced cell damage was associated with increased release of IL-
1α and HMGB-1 (figure 18). 
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Figure 18 Influence of freeze-thaw stress on PBEC cell viability and alarmin release 
PBEC cells were subjected to three cycles of freeze/thaw (F/T) at -80°C. Following 
the tretamnet the cells were re-incubated at 37°C for additional 24hrs, after which, 
the cell viability (A) was assessed using trypan blue staining and IL-1α (B) and 
HMGB-1 (C) protein concentration in conditioned media were measured using 
ELISA. Data represent the mean±S.E.M. from 3 independent experiments performed 
on two biological replicates. Statistical analysis was performed using unpaired 
Student’s t test. * p<0.05, ** p<0.01, *** p<0.001. 
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3.9 Identification of a human lung epithelial cell line that mimics behavior of PBEC 
cells in response to an injurious stimulus.  
 
Primary human bronchial epithelial cells are the most reliable in vitro model to 
investigate the behavior of respiratory epithelium in the context of chronic 
inflammatory lung diseases. However due to limited availability and relatively short 
lifespan (4-5 passage numbers) of PBEC cells, it was necessary to identify a human 
lung epithelial cell line that would mimic the behavior of PBEC cells in response to 
injurious stimuli. The cell lines appointed as the potential candidate to that role 
included: adenocarcinomic human alveolar basal epithelial cells (A549), normal 
human bronchial epithelial cells transformed with Adenovirus 12-SV40 virus (BEAS-
2B) and the SV40-transformed human bronchial lung cells (16HBE14o-). To assess 
their suitability to serve as an alternative in vitro model of epithelial injury, the 
aforementioned cell lines were subjected to treatment with H2O2-induced oxidative 
stress, after which the cell viability and IL-1α release were assessed by trypan blue 
and ELISA respectively.  
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3.10 Influence of H2O2 on A549 cell viability and IL-1α release 
 
In order to induce oxidative stress, A549 cells were treated with a range of H2O2 
doses (up to 800µM) for two hours. Following the treatment, the culture medium 
was replenished and the cells were subjected to a further incubation at 37°C for 
24hrs. Next, the conditioned media were collected and tested for IL-1α by ELISA and 
the cell viability was measured by Trypan blue staining. The analysis revealed that 
the H2O2 treatment reduced the A549 cell viability in a dose dependant manner, 
however it did not induce IL-1α release. Based on this observation, A549 cells were 
found unsuitable to be used as a cell line to establish an in vitro model of human 
lung epithelial injury (figure 19). 
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Figure 19 Influence of H2O2 on A549 cell viability and IL-1α protein release 
 
A549 cells were treated with the indicated concentrations of H2O2 for 2hrs, after 
which culture medium was replenished and cells were re-inculated for additional 
24hrs. Following the incubation the cell viability was assessed by FACS and IL-1α 
concentrations were measured by ELISA. Data represent the mean±S.E.M. from 3 
independent experiments performed on two biological replicates. Statistical 
analysis was performed unpaired Student t test. * <0.05, **<0.01, ***<0.001. 
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3.11 Influence of H2O2 on BEAS-2B cell viability and IL-1α release 
 
BEAS-2B cells were treated with H2O2 doses ranging from 0 to 800μM for 24hrs, 
after which the cell viability was assessed by trypan blue staining and the 
conditioned media collected for ELISA. Oxidative stress reduced cell viability 
however it did not have significant impact on IL-1α release (Figure 20). These results 
show that the BEAS-2B cell line’s response to oxidative stress does not resemble 
primary lung epithelial cells and therefore it would not serve as a reliable model in 
our study.   
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Figure 20 Influence of H2O2 on BEAS-2B cell viability and IL-1α protein release 
 
BEAS-2B cells were treated with the indicated concentrations of H2O2 for 2hrs, after 
which culture medium was replenished and cells were re-inculated for an additional 
24hrs. Following the incubation the cell viability was assessed by FACS and IL-1α 
concentrations were measured by ELISA. Data represent the mean±S.E.M. from 3 
independent experiments performed on two biological replicates. Statistical 
analysis was performed using unpaired Student t test. * <0.05, **<0.01, ***<0.001. 
 
3.12 Influence of H2O2 on 16HBE14o- cell viability and alarmin release. 
16HBE14o- cells were treated with decreasing doses of H2O2 ranging from 400 to 
12.5μM. Following 24hrs incubation the cell viability was assessed by trypan blue 
staining and the conditioned media collected for ELISA. H2O2-induced oxidative 
stress reduced the cell viability in a dose dependant manner and led to increased 
release of IL-1α, HSP60 and HMGB-1 (figure 21), suggesting that 16HBE14o- 
behavior in response to stress resembles PBEC responses and that it could be 
considered as a potential candidate to establish an in vitro model of human lung 
epithelium injury.   
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Figure 21 Influence of H2O2 -induced oxidative stress 16HBE-14o- cell viability and 
marker alarmin release. 
Subconfluent (80%) 16HBE-14o- cell monolayers were treated with the indicated 
doses of H2O2 for 2hrs, after which the medium was replenished and the cells were 
re-incubated for additional 24hrs. Following incubation, cell viability was assessed 
by flow cytometry and IL-1α concentrations were measured with ELISA. H2O2 – 
induced oxidative stress reduced culture viability (n=3, p<0.001) (A) and 
upregulated release of alarmins: IL-1α (n=3, p<0.001) (B), HSP60 (n=3, p<0.05) (C) 
and HMGB1 (n=3, p<0.01) (D) (asterisks correspond to the statistical significance 
between untreated controls and cells treated with 200µM H2O2 dose which was 
used to damage 16HBE-14o- cells in all subsequent experiments). Data represent 
the mean±S.E.M. from 3 independent experiments performed on two biological 
replicates. Statistical analysis was performed using unpaired Student’s t test. 
*p<0.05, **p<0.01, ***p<0.001. 
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3.13 Influence of freeze-thaw stress on 16HBE14o- cell viability and marker 
alarmin release. 
 
Since secretion of some proinflammatory cytokines has previously been attributed 
to the activity of oxidative stress, we next decided to establish whether the release 
of the marker alarmins from 16HBE14o- cells can also be achieved using an injury 
not involving any chemical substances. For that, in a control experiment, 16HBE14o- 
cell monolayers in culture media were subjected to 3 freeze (-80ºC/10 min)- thaw 
(37ºC/20min) cycles. Next, the cells were re-incubated at 37°C for a further 24hrs, 
after which the cell viability was assessed by flow cytometry and the levels of 
marker alarmins in the conditioned media were measured by ELISA. The flow 
cytometric analysis revealed only the presence of cell debris in cultures subjected to 
freeze-thaw stress. The treatment resulted in increased release of IL-1α and HMGB-
1 (Figure 22). 
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Figure 22 Influence of freeze-thaw stress on 16HBE14o- cell viability and alarmin 
release 
16HBE14o- cells were subjected to three cycles of freeze/thaw (F/T) at -80°C. 
Following the treatment the cells were re-incubated at 37°C for additional 24hrs, 
after which, the cell viability (A) was assessed using trypan blue staining and IL-1α 
(B) and HMGB-1 (C) protein concentration in conditioned media were measured 
using ELISA. The freeze-thaw treatment significantly reduced the cell viability and 
induced IL-1α and HMGB-1 release (P<0.001 in all cases). Data represent the 
mean±S.E.M. from 3 independent experiments performed on two biological 
replicates. Statistical analysis was performed using unpaired Student’s t test. 
*p<0.05, ** p<0.01, *** p<0.001. 
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3.14 Influence of conditioned media from damaged epithelial cells on fibroblast 
activation  
 
3.14.1 Optimisation of qRT-PCR reactions 
 
In order to investigate the influence of conditioned media from damaged epithelial 
cells on fibroblasts activation, a number of primers were designed to measure 
expression of various proinflammatory and fibrogenic genes by qRT-PCR. For each 
primer pair PCR reaction efficiency was assessed.   
To establish the real-time PCR reaction efficiency, serial dilutions of cDNA were 
prepared and a series of PCR reactions were run using the same concentration of 
primers. Next, titration curves were prepared by plotting Ct values on Y axis against 
log values of cDNA concentration on X axis. The reaction efficiency was calculated 
according to the following equation: Efficiency=10^(-1/-slope)-1, where slope is 
represented by the ‘a’ value in equation describing the linearised titration curve 
(y=ax+b). Efficiencies of all the primers tested in the study, were between 80-100% 
(0.8-1). An example calculation of efficiency of PCR reaction using GAPDH primers is 
presented in figure 23.  
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Figure 23 An example of qRT-PCR standard curve 
 
Slope = -3,3852 
  Efficiency=10^(-1/slope)-1 
 
Hence 
 Efficiency=0.97 or 97% 
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3.14.2 Melt curve analysis 
 
Sybr Green based amplicon detection is based on the ability of the fluorescent dye 
to bind to double stranded DNA, meaning that apart from the target template it can 
also bind to primer dimers, PCR products from misannealed primers and 
contaminating DNA. Therefore to ensure that the desired template was detected, a 
dissociation (melting) curve was generated following each PCR reaction. Melt curve 
analysis allow to establish the point of inflection which can be defined as the 
melting temperature of the amplicon. Considering, that products of different sizes 
and different nucleotide content can be distinguished based on their melting 
temperature, melt curve analysis allows to detect any by-products binding Sybr 
Green. An exemplary melting curve for GAPDH has been presented in figure 24. A 
single peak shows that during the PCR reaction only one product was amplified. 
Primer dimmers or DNA contamination would appear as additional picks.  
                         
Figure 24 An example of melting curve generated following qRT-PCR reaction 
Additionally, to assess primer specificity, the PCR products were resolved on a 2% 
agarose gel. The analysis revealed a presence of a single product on gel for all 
primer pairs, confirming, that a single PCR product is amplified (Figure 25).                                                                        
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Figure 25  Verification of primer site specificity by PCR. 200ng RNA was converted 
into cDNA and following PCR reaction, 10µl of the amplification product was 
separated by electrophoresis in 2% agarose gel containing ethidium bromide. 
 
3.15 Influence of conditioned media from damaged 16HBE14o- cells on 
proinflammatory cytokine and fibrogenic factor gene expression in MRC5 cells. 
 
To establish if alarmins released from damaged lung epithelial cells may activate 
innate immune signalling in lung fibroblasts, MRC5 cells were cultured for 5hrs in 
fresh culture media or conditioned media collected from 16HBE-14o- cells that were 
untreated or damaged with H2O2-induced oxidative stress or thapsigargin-induced 
ER stress and gene expression of proiflammatory cytokines (IL-6, IL-8, MCP-1, GM-
CSF, IL-1α, IL-1β) assessed by qRT-PCR. Fibroblast treatment with conditioned media 
from damaged epithelial cells led to an increase in expression of all of the measured 
genes, suggesting that alarmins released from damaged epithelial cells may trigger 
a proinflammatory phenotype in lung fibroblasts (figure 26 and 27).  
Additionally, to assess if factors released from damaged cells may trigger fibrogenic 
responses in fibroblasts, MRC5 cells were treated under serum free conditions for 1, 
2 or 3 days with conditioned media from 16HBE14o- cells damaged with H2O2. 
Following the treatment, the cells were harvested for RNA and gene expression of 
collagen 1A1 (Col1A1) was assessed by qRT-PCR. To confirm the responsiveness of 
fibroblasts to a fibrogenic stimulus, fibroblasts were treated for 2 days with 5ng/ml 
of TGFβ. The treatment with TGFβ resulted in marked upregulation of Col1A1 gene 
expression, however the conditioned media from damaged cells had no effect 
(figure 28).    
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Figure 26 Influence of conditioned media from 16HBE-14o- cells damaged with 
H2O2 (200µM) on proinflammatory  cytokine gene expression in MRC5 cells. 
5hrs treatment of MRC5 cells with conditioned media from 16HBE14o- cells 
damaged with 200µM H2O2 (HBE H2O2) stimulated gene expression of IL-6 (p<0.01)  
(A), IL-8 (p<0.01) (B), MCP-1 (p<0.05) (C), GM-CSF (p<0.05) (D), IL-1α (p<0.05) (E) 
and IL-1β (0.01) (F) in comparison to treatment with conditioned media from 
undamaged cells (HBE UT). Cytokine gene expression was assessed following 5hrs 
treatment by qRT-PCR using GAPDH as a reference gene. Data represent the 
mean±S.E.M. from 3 independent experiments performed on two biological 
replicates. Statistical analysis was performed using unpaired Student’s t test. 
*p<0.05, **p<0.01, ***p<0.001. 
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Figure 27 Influence of conditioned media from 16HBE-14o- cells damaged with 
50µM thapsigarging (TG) on proinflammatory cytokine gene expression in MRC5 
cells. 
5hrs treatment of MRC5 cells with conditioned media from 16HBE14o- cells 
damaged with 200µM thapsigargin (TG) stimulated gene expression of IL-6 
(p<0.001) (A), IL-8 (p<0.01) (B), MCP-1 (p<0.01) (C), GM-CSF (p=0.24) (D), IL-1α 
(p<0.001) (E) and IL-1β (p<0.01) (F) in comparison to treatment with conditioned 
media from undamaged cells (HBE UT). Cytokine gene expression was assessed 
following 5hrs treatment by qRT-PCR using GAPDH as a reference gene. Data 
represent the mean±S.E.M. from 3 independent experiments performed on two 
biological replicates. Statistical analysis  was performed using unpaired Student’s t 
test. *p<0.05, **p<0.01, ***p<0.001. 
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Figure 28 Influence of conditioned media from damaged epithelial cells on 
collagen 1A1 gene expression. 
MRC5 cells were treated with 5ng/ml of TGFβ for 2 days, or conditioned media from 
untreated (HBE UT) or damaged with H2O2 (HBE H2O2) 16HBE14o- cells for 1,2 or 3 
days, after which the cells were harvested for RNA and subject to qRT-PCR analysis 
for collagen1A1 (Col1A1) gene expression. The analysis revealed that, although 
TGFβ triggered expression of Col1A1 (p<0.05), conditioned media from damaged 
cells was with no effect. Data represent the mean±S.E.M. from 3 independent 
experiments performed on two biological replicates. Statistical analysis was 
performed using unpaired Student’s t test. *p<0.05, **p<0.01, ***p<0.001. 
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3.16 Discussion 
 
The results of the aforedescribed experiments indicate that H2O2 induced-oxidative 
stress and thapsigargin (TG)-induced ER stress may be used to trigger damage of 
human bronchial epithelial cells resulting in the release of alarmins. The epithelial 
damage was induced by pulsing the cells with H2O2 or TG for a relatively short 
period of time (2hrs), which allowed for replenishing the media when cells were still 
viable. This approach allowed for excluding the injuring agents as factors inducing 
inflammatory responses in fibroblasts following administration of conditioned 
media from damaged epithelial cells.  
Numerous studies demonstrated that oxidative stress, which may be defined as an 
imbalance between the amounts of oxidant and anti-oxidant agents, persists in 
many chronic inflammatory lung diseases such as COPD [210], BOS [211] and cystic 
fibrosis (CF) [212]. Currently it is believed that oxidative stress in the lung is induced 
by increased levels of reactive oxygen species that may be generated by activated 
macrophages and neutrophils. Activated inflammatory cells produce free oxygen 
radicals (O2.) which may be converted to H2O2 by an enzyme - superoxide 
dismutase. In a secondary reaction, hydroxyl radicals can be formed in the presence 
of Fe2+ cations in a reaction not requiring enzymatic catalysis [213].  
ROS may contribute to cellular damage by oxidizing membrane phospholipids 
resulting in formation of numerous molecules such as lipid hydroperoxide leading to 
membrane disruption, followed by DNA damage and cell death. Additionally, they 
may react with certain amino acids such as methionine, tyrosine and cysteine in 
proteins, altering their functions [214]. 
Previous studies suggest that ROS may induce inflammation in two ways: by 
activating redox-sensitive transcription factors including NF-κB and activator 
protein-1 (AP-1) leading to production of proinflammatory cytokines and by causing 
cellular damage, resulting in the release of IL-8 and inflammation-mediating danger 
signals [215]. Moreover, in order to maintain homeostasis in tissue, redox-sensitive 
transcription factors also induce expression of anti-oxidant factors such as c-
glutamylcysteine synthetase involved in glutathione production. 
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Glutathione, which is one of the main anti-oxidant agents, poses a thiol group in its 
cysteine residue which is able to reduce free radicals by donating a free electron. It 
has been shown that glutathione contributes to tissue red-ox homeostasis by 
neutralization of free radicals and reactive oxygen species and maintaining 
antioxidants such as vitamins E and C in their reduced – active state [216]. 
Additionally, other studies demonstrated that it is also involved in regulation of 
nitric oxide cycle [217], apoptosis [218], mitochondrial respiration [219] and 
remodelling of the extracellular matrix [220] .   
Decreased levels of GSH have been observed in BALs of COPD [221] and BOS [222] 
patients while increased levels of GSH have been reported in asthmatics [223]. GSH 
have been shown to be required to protect lung against cigarette smoke and 
airborne particle- induced lung injury [224].  
Interestingly this study demonstrated that there were marked differences in terms 
of the level of resistance to oxidative stress between a human bronchial epithelial 
cell line 16HBE14o- and primary human bronchial epithelial cells, which have been 
derived from brushings obtained from post-transplant patients. One of the 
limitations of this study was the restricted availability of PBEC cells from healthy 
individuals, and therefore it is difficult to speculate if the extreme resistance of 
PBEC cells to H2O2 was due to the fact that they originated from patients who have 
been subject to immunosuppressive therapy required to prevent allograft rejection 
or if PBECs are naturally equipped in mechanisms allowing them to cope with 
oxidative stress which persists in the lung due to relatively high oxygen pressure. 
The comparison of resistance to oxidative stress and glutathione levels between 
PBECs derived from healthy individuals and patients affected by chronic 
inflammatory and fibrotic lung diseases could not be performed in this study due to 
limited supply of normal PBEC cells, however it could be a subject of a follow up 
study in the future. 
Resistance to oxidative stress and production of glutathione remains under control 
of numerous factors of endogenous and exogenous origin.  
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Factors able to downregulate glutathione production include Glucocorticoids (eg. 
dexamethasone) [225], TGFβ [226] and Cyclic adenosine monophosphate (cAMP) 
[227]. 
Production of glutathione and c-glutamylcysteine synthetase may be triggered by 
numerous factors including oxidants such as hydrogen peroxide, cigarette smoke, 
ozone, nitric oxide, hyperoxia, heat shock, cytokines and growth factors including 
TNFα and IL-1, radiation, some metals such as selenium, iron, cadmium and 
mercury. Many of these substances can be inhaled with air and therefore airway 
epithelium is most prone to their influence [228]. 
It has been shown for instance that inhaled ozone, a strong oxidizing agent which 
may cause lipid peroxidation in cellular membranes leading to epithelial damage, 
may also increase neutrophil accumulation in the lung and decrease lung function 
[229].  
Airborne oxidants originating from air pollution have also been recognized as 
factors stimulating production of proinflammatory cytokines from airway epithelial 
cells [230].  
Oxidants, as well as some proinflammatory cytokines such as TNFα induce 
production of ROS by mitochondria. Proinflammatory activity of ROS involved 
activation of NF-κB which requires phosphorylation and ubiquitination followed by 
proteolitic degradation of IκB, which functions as NF-κB inhibitor. ROS are also able 
to activate a MAP-kinase JNK leading to phosphorylation of c-Jun and AP-1 
activation. Both AP-1 and NF-κB function as transcription factors modulating 
expression of numerous genes involved in maintaining red-ox homeostasis including 
c-glutamylcysteine synthetase (c-GCS), manganese superoxide dismutase (MnSOD), 
haemoxygenase-1 (HO-1), inducible nitric oxide synthase (iNOS) [231]. 
Although the direct influence of oxidative stress on activation of proinflammatory 
signaling pathways has not been investigated in this study, our data suggest that it 
may lead to release of alarmins, which may initiate a very potent inflammatory 
response. Interestingly, a dose response experiment using different concentrations 
of H2O2, revealed that oxidative stress may induce IL-1α release from cells which are 
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still viable. Interestingly, HMGB-1 release was detected only when the cells were 
damaged, suggesting that IL-1α may serve as an early danger signal  released prior 
to cell death, whereas HMGB-1 could be treated as a marker of epithelial damage. 
One of main sources of free radicals causing oxidative stress, a human lung is 
exposed to, is cigarette smoke and much research has been done on its influence on 
the activation of the innate immune system. Cigarette smoke contains numerous 
free radicals and oxidants such as nitrogen dioxide and sulphulr dioxide and remains 
the underlying cause of many chronic diseases including COPD [232]. In our study, 
cigarette smoke extract did not induce epithelial damage or alarmin release, which 
may be due to a relatively short time of treatment. Previous studies, using longer 
time of treatment, reported a link between CSE and epithelial death [233]. Such 
model, however, would not be applicable in this study, where in order to distinguish 
between the influence of injurious stimulus and released alarmins on fibroblast 
functions, the damaging factor had to be removed before epithelial damage 
occurred.  
Recent studies revealed that oxidative stress may also contribute to epithelial 
damage by inducing stress in the endoplasmic reticulum (ER stress). Gao et al., 
demonstrated that H2O2 may trigger unfolded protein response by upregulating 
glucose regulated protein 78 (GRP 78) and protein ubiquitination [234]. 
My study demonstrated that ER stress induced by thapsigargin (TG) may result in 
epithelial damage and alarmin release.  
The relationship between ER stress and chronic inflammation has been thoroughly 
investigated, and it is clear that some proinflammatory cytokines, such as IL-1β may 
cause ER stress and UPR. It is also known that ER stress may trigger 
proinflammatory responses in cells by activating the JNK pathway [235]. 
ER stress has been linked to several chronic conditions, including obesity driven 
inflammation [236], cystic fibrosis [237], cardiovascular disease [238] and COPD 
[239].  
Although the activation of UPR was demonstrated in several chronic inflammatory 
diseases, it has not been clear, how ER stress may trigger inflammatory responses. 
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My study demonstrated that cells exposed to TG released the proinflammatory 
alarmin IL-1α, even when the cell viability was not affected, which supports our 
other observations that IL-1α may function as an early danger signal, released viable 
cells exposed to a stress stimulus.  
Additionally my study demonstrated that fibroblasts treated with conditioned 
media from epithelial cells damaged with oxidative stress or ER stress show a 
proinflammatory potential manifested by increased expression of numerous 
proinflammatory cytokines, chemokines and growth factors, which have been 
recognized to play important functions in the pathophysiology of many chronic 
degenerative diseases. The proinflmmatory potential of fibroblasts is best 
pronounced by the amounts of IL-8 and IL-6 they are able to release upon 
stimulation, and which are comparable to levels generated by LPS-activated 
macrophages (data not shown). The functions and physiological importance of 
selected factors expressed by human lung fibroblasts, including IL-6, IL-8, GM-CSF 
and MCP-1 has been discussed in the introduction.  
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CHAPTER 4 PATTERN RECOGNITION RECEPTOR GENE EXPRESSION PROFILING IN 
HUMAN LUNG FIBROBLASTS AND THEIR RESPONSIVENESS TO SELECTED PRR 
LIGANDS  
4.1 Background 
 
Until quite recently fibroblasts have been regarded as cells whose role is limited to 
production of the ECM components. Recent reports however, suggest that 
fibroblasts are a substantial source of many proinflammatory and growth factors 
and that they may also function as mediators of inflammation. Comparative studies 
on fibroblasts from healthy individuals and patients with chronic arthritis 
demonstrated that the cells from the two test groups showed different cytokine 
expression patterns suggesting that fibroblasts are able to gain a new phenotype in 
chronically injured organs and that they may function as mediators of inflammation 
[240]. The molecular basis for the persistent phenotype of fibroblasts in chronically 
inflamed tissues remain unclear, however recent studies on RelB knock-out mice 
indicate that NF-κB signaling may play a crucial role in perpetuating the 
inflammatory response in chronic inflammatory diseases. Fibroblasts from 
endotoxin challenged RelB deficient mice secreted a wide array of inflammatory 
cytokines which caused accumulation of immune cells within hours. The 
proinflammatory fibroblast phenotype was attenuated following transfection with 
WT RelB, suggesting a direct link between the NF-κB pathway and fibroblast 
activation [241]. Moreover, Smith et al. showed that fibroblasts cultured in vitro in 
contact, via CD40, with hematopoetic cells secreted elevated levels of IL-6, IL-8, 
Cyclooxygenase-2 and the polysaccharide hyaluronan, which resembles interactions 
between immunocytes and antigen presenting cells [242]. Furthermore, RelB 
upregulation is associated with dendritic cell maturation, which emphasizes the 
similarity of the mechanism of activation between antigen presenting cells and 
fibroblasts [243]. Fibroblasts express a range of pattern recognition receptors 
(PRRs), including certain Toll-like receptors (TLR), Receptor for advanced glycation 
endproducts (RAGE) and NOD-like receptors (NLR), which suggests that they may 
respond to both exogenous and endogenous danger patterns. However the pattern 
of PRRs expression in different fibroblast populations has not yet been fully 
described. Therefore to better understand the role of fibroblasts in innate immune 
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signaling and fibrosis it is necessary to unravel via which molecules and receptors, 
activation of fibrogenic cells in different tissues is triggered.  
Despite several reports investigating the function of selected TLRs in human lung 
fibroblasts [244] [245], detailed PRR gene expression profile in these cells has not 
been described before. Previous reports state that normal human lung fibroblasts - 
MRC5 cells express TLR3 and TLR9 [246] [247], which may indicate that they may 
play a role in mediating innate immune responses to viral and bacterial PAMPs. 
Therefore to establish which receptors are involved in alarmin-mediated fibroblast 
activation and to identify alarmins responsible for triggering the proinflammatory 
phenotype in fibroblasts following treatment with conditioned media from 
damaged epithelial cells, we performed PRR gene expression profiling in normal 
primary human lung fibroblasts. 
Hypotheses tested: 
1. Primary human lung fibroblasts exhibit a unique and distinct from 
macrophages profile of Pattern Recognition Receptor gene expression, 
characterized by a high expression of IL-1R and TLR3 and are responsive to 
IL-1 and a TLR3 ligand, Poly I:C. 
2. Nucleic acids, which may activate TLR3 and may be released from damaged 
cells, trigger a proinflammatory phenotype in lung fibroblasts treated with 
conditioned media from injured epithelial cells. 
3. IL-1α is the key epithelial alarmin triggering innate immune responses in 
human lung fibroblasts. 
4. Human lung fibroblasts show increased expression of proinflammatory 
cytokines (IL-6 and IL-8) in response to the epithelial alarmin IL-1α and a 
TLR3 ligand, Poly I:C and these two factors may act synergistically to increase 
expression of proinflammatory factors in fibroblasts. 
5. Inflammation induced by IL-1α and Poly I:C in fibroblasts may be reduced by 
a steroid drug, dexamethasone, and chemical inhibitors targeting selected 
kinases within the IL-1R signaling pathway (IKK2i and TAK1i). 
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4.2 Pattern Recognition Receptor gene expression in primary human lung 
fibroblasts 
 
The results described in chapter 3 indicate that some factors, potentially alarmins, 
that are released by damaged epithelial cells may trigger a proinflammatory 
phenotype in fibroblasts. The influence of conditioned media from damaged cells 
on expression of selected fibrogenic genes was also investigated, however despite a 
pronounced responsiveness of fibroblasts to TGFβ in terms of collagen gene 
upregulation, these cells failed to respond to conditioned media from damaged cells 
in the same way. 
To establish which alarmins released from damaged lung epithelial cells may be 
responsible for innate immune signalling activation in lung fibroblasts, human 
primary lung fibroblast were subjected to PRR gene expression profiling by qRT-PCR. 
The analysis revealed that the cells expressed relatively high levels of TLR3 and TLR9 
and very high levels of IL-1R. TLR3 and IL-1R expression was confirmed on the 
protein level by western blotting. Additionally IL-1R expression was detected by 
immunofluorescence using an antibody specific to human IL-1R (figure 29).  
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Figure 29 Pattern Recognition Receptor (PRR) gene expression in primary human 
lung fibroblasts 
PRR gene expression profiling performed by qRT-PCR in unstimulated primary 
human lung fibroblasts isolated from 3 donor lungs revealed high levels of IL-1R and 
TLR3 and low levels of TLR2, TLR4, RAGE and NLPR3 transcripts (A). Data represent 
the mean±S.E.M, n=3. IL-1R expression was confirmed by immunocytofluorescence: 
IL-1R protein expression in primary human lung fibroblasts visualized using confocal 
incroscopy in 2D (B) and 3D (C) format; D - 2°antibody control. IL-1R (E) and TLR3 (F) 
expression was also confirmed on a protein level by western blotting. 
 
B                               C                                D                     
E    Sample    1        2                        F       Sample    1        2 
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4.3 Pattern Recognition Receptor gene expression in human lung fibroblast cell 
line MRC5 
 
To confirm the results obtained using primary human lung fibroblast, a human lung 
fibroblast cell line – MRC5 - has also been used in the study. Therefore, to establish 
if MRC5 is a suitable cell line to study innate immune responses of human lung 
fibroblasts, the cell line has also been subjected to PRR gene expression profiling by 
qRT-PCR. The analysis confirmed that MRC5 cells, like PHLF, show very high 
expression of IL-1R and relatively high expression of TLR3. The levels of TLR2, 
characteristic to macrophages were very low and gene expression for TLR4 was 
below the qRT-PCR detection level. These results indicate that MRC5 cells show 
similar pattern of TLR expression as MRC5 cells, confirming that this cell line may 
serve as a reliable model to study immune responses in human lung fibroblasts 
(Figure 30). 
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Figure 30 Pattern Recognition Receptor gene expression in MRC5 cells. 
PRR gene expression measured by qRT-PCR revealed high expression levels of TLR3 
and IL-1R in untreated MRC5 cells. GAPDH was used as a reference gene. Data 
represent the mean±S.E.M from 3 biological replicates. 
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4.4 Pattern Recognition Receptor gene expression in activated THP-1 cells. 
 
To confirm the specificity of primers used to asses PRR gene expression, PRR 
expression was also measured in THP1 cells differentiated with 20ng/ml PMA. The 
qRT-PCR analysis revealed that the cells predominantly expressed TLR2 and TLR4 – a 
pattern characteristic for mature macrophages. The expression of TLR3 and TLR9 
was relatively low in THP-1 cells, suggesting that the role of these cells, in contrast 
to fibroblasts, is focused on mediating innate immune responses to bacterial rather 
than  viral PAMPs (figure 31). 
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Figure 31 Pattern recognition receptor (PRR) gene expression in THP-1 cells 
stimulated with PMA. 
THP-1 cells were treated for 25hrs with 20ng/ml of PMA, after which they were 
harvested for RNA and subject to qRT-PCR analysis. The analysis revealed that THP-
1 cells express predominantly TLR2 and TLR4 – a pattern characteristic of activated 
macrophages. Note, to clarify the differences in expression levels between different 
PRRs in THP1 cells the data is expressed as logarithm of ΔΔCT values multiplied by a 
factor of 10000. Data represent the mean±S.E.M from 3 biological replicates. 
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4.5 Influence of selected PRR ligands on IL-6 gene expression in primary human 
lung fibroblasts 
 
To confirm the observations described above and to investigate the responsiveness 
of fibroblasts to danger signals, primary human lung fibroblasts were treated for 
6hrs with selected endogenous and exogenous PRR ligands including IL-1α (IL-1R 
ligand), Poly I:C – a synthetic analog of double stranded viral RNA (TLR3 ligand), LPS 
(TLR2 and TLR4 ligand) and HMGB-1 (TLR2, TLR4 and RAGE ligands). Following the 
treatment, the cells were harvested for RNA and subjected to qRT-PCR using IL-6 
gene expression as a marker of innate immune signaling activation. The qRT-PCR 
analysis revealed that IL-1α was the most potent inducer of IL-6 gene expression in 
these cells, resulting in a substantial, 300-fold increase in expression of the target 
gene. Poly I:C also significantly upregulated IL-6 expression, while LPS and HMGB-1 
had an insignificant or no effect on innate immune signaling activation in the human 
lung fibroblasts (Figure 32). 
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Figure 32 Influence of selected Pattern Recognition Receptor ligands on IL-6 gene 
expression in primary human lung fibroblasts 
Primary human lung fibroblasts were challenged for 5hrs with selected PRR ligands 
including IL-1α (A) and Poly I:C (B), LPS (C) and HMGB-1 (D), after which the cells 
were harvested for RNA and subjected to qRT-PCR analysis to assess IL-6 gene 
expression. The analysis revealed that IL-1α is the most potent activator of IL-6 gene 
expression in primary human lung fibroblasts. Data represent the mean±S.E.M. 
from 3 independent experiments performed on two biological replicates. Statistical 
analysis was performed using unpaired Student’s t test. *p<0.05, **p<0.01, 
***p<0.001. 
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4.6 Influence of DAMP antagonists and benzonase on innate immune signaling 
activation in human lung fibroblasts treated with conditioned media from 
damaged human bronchial epithelial cells 
 
Strong MRC5 cell responsiveness to Poly I:C suggests that TLR3 ligands may be 
involved in lung fibroblast activation. Previous reports indicate that one of the 
danger signals released from damaged cells that may activate innate immue system 
is endogenous RNA. To investigate whether TLR3 signaling in MRC5 cells may be 
triggered by endogenous RNA released by damaged epithelial cells, MRC5 cells 
were treated with the supernatants from 16HBE14o- cells injured with 200µM H2O2, 
that had been preincubated for 3hrs with or without 200U/ml nuclease (Benzonase, 
Sigma). Following the treatment, MRC5 cells were harvested for RNA and qRT-PCR 
analysis of IL-6 gene expression was performed. The analysis revealed that nuclease 
treatment did not have any influence on IL-6 gene expression when compared to 
the control (Figure 33). In a control experiment, MRC5 cells were treated with 
media containing 10ug/ml P I:C that had been preincubated for 3hrs with or without 
nuclease. The qRT-PCR analysis revealed that Benzonase treatment drastically 
reduced IL-6 gene expression in Poly I:C stimulated MRC5 cells, showing that the 
nuclease digestion was successful (Figure 34). To assess a deirect effect of 
Benzaonase on fibroblasts activation, an additional control could be perforemed 
where fibroblasts would be treated with Benzonase alone. 
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Figure 33 Validation of the efficacy of a ribonuclease, benzonase, in a functional 
assay using Poly I:C as an analog of double stranded RNA and IL-6 gene expression 
as a marker of innate immune signaling activation. 
10µg/ml of Poly I:C was treated with bensonase for 1hr. Following the treatment, 
the solution of Poly I:C and the rybonuclease was added to MRC5 cell cultures for 
5hrs. RT-PCR analysis revealed that bensonase efficiently inactivated Poly I:C and 
blocked its ability to upregulate IL-6 gene expression. Data represent the 
mean±S.E.M from 3 independent experiments performed on two biological 
replicates. Statistical analysis was performed using unpaired Student’s t test. 
*p<0.05, **p<0.01, ***p<0.001. 
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Figure 34 Influence of a Benzonase on IL-6 gene expression in MRC5 cells treated 
with conditioned media from damaged 16HBE14o- cells. 
Conditioned media from damaged 16HBE14o- cells were treated with Bensonase 
for 1hr. Following the treatment, the conditioned media were added to MRC5 cell 
cultures for 5hrs. RT-PCR analysis revealed that Bensonase had no effect on IL-6 
gene expression that was induced by conditioned media from damaged epithelial 
cells. Data represent the mean±S.E.M from 3 independent experiments performed 
on two biological replicates. Statistical analysis was performed using unpaired 
Student’s t test. *p<0.05, **p<0.01, ***p<0.001. 
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4.7 Influence of IL-1 antagonists on gene expression of selected proinflammatory 
cytokines in MRC5 cells treated with conditioned media from damaged epithelial 
cells 
 
Since IL-1R was the highest expressed PRR on human lung fibroblasts and IL-1α was 
a powerful inducer of fibroblast IL-6 gene expression I next determined the 
requirement of IL-1α/IL-1R signaling for stimulation of an inflammatory phenotype 
in fibroblasts by ROS-damaged epithelia.  MRC5 cells were treated for 5hrs with 
conditioned media collected form damaged 16HBE-14o- cells in the presence or 
absence of IL-1α blocking antibody (IL-1α BAb - 4µg/ml) or IL-1R antagonist (IL-1Ra – 
500ng/ml). To confirm IL-1α BAb specificity as a negative control a neutralizing 
antibody against IL-1β (IL-1β BAb - 4μg/ml) was used. IL-1β BAb also served as an 
isotype control (both IL-1α BAb and IL-1β BAb are IgG isotype, have been raised in 
mouse and used at the same concentration of 4µg/ml). 
The optimal doses and efficacy of IL-1Ra and IL-1α and IL-1β neutralizing antibodies 
were established in a functional assay using IL-6 gene expression as a marker of 
innate immune signaling activation in human lung fibroblasts (figure 35). In parallel, 
a cell viability study was performed to assess the possible toxic effect of the 
blocking agents. The analysis revealed that no decrease in fibroblast viability was 
observed following treatment with the indicated doses of IL-1 antagonists (data not 
shown). 
The qRT-PCR analysis revealed that IL-1α NAb and IL-1Ra significantly reduced IL-6 
gene expression in MRC5 cells challenged with media from damaged epithelial cells 
while IL-1β NAb had no effect (figure 36). 
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Figure 35 Validation of the efficacy of the IL-1α neutralizing antibody (IL-1α NAb), 
IL-1β neutralizing antibody (IL-1β NAb) and IL-1 receptor antagonist (IL-1Ra).  
The ability of IL-1α NAb, IL-1β NAb and IL-1Ra to inhibit IL-1 biological activity was 
assessed in a bioassay using IL-6 gene expression as a marker of IL-1R activation. IL-
1α and IL-1β (100 pg/ml) were incubated for 1hr at 37°C in the presence of the 
corresponding monoclonal neutralizing antibodies at various concentrations. 
Following incubation, primary human lung fibroblasts were treated for 5hrs with IL-
1α (A) or IL-1β (B) in the presence or absence of the neutralizing antibodies and 
subjected to qRT-PCR analysis to measure IL-6 gene expression. Primary human lung 
fibroblasts were treated with various concentrations of IL-1Ra for 1hr after which 
100pg/ml of IL-1 was added to the culture. Following 5 hrs incubation cells were 
harvested for total RNA and subjected to qRT-PCR analysis to measure IL-6 gene 
expression (C). All the antagonists tested reduced IL-6 gene expression in a dose 
dependant manner (n=3, p<0.001). The following concentrations of IL-1 antagonists: 
IL-1α NAb 4μg/ml, IL-1β NAb 4μg/ml, IL-1Ra 500ng/ml were used in all the 
subsequent experiments. Data represent the mean±S.E.M from 3 biological 
replicates. Statistical analysis was performed using unpaired Student’s t test. 
*p<0.05, **p<0.01, ***p<0.001. 
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Figure 36 Influence of IL-1 antagonists on IL-6 expression in MRC5 cells treated 
with conditioned media from 16HBE14o- cells damaged with 200µM H202.  
 
MRC5 cells were treated for 5hrs with conditioned media from 16HBE14o- cells 
damaged with oxidative stress in the presence or absence of IL-1α (A) or IL-1β (B) 
neutralizing antibodies (BAb) or IL-1R antagonist (IL-1Ra) (C). Treatment with 
conditioned media from damaged cells significantly induced IL-6 gene expression in 
MRC5 cells. This effect was significantly reduced by IL-1α BAb and IL-1Ra but not IL-
1β Bab. Data represent the mean±S.E.M from 3 indepenent experiments performed 
on two biological replicates. Statistical analysis was performed using unpaired 
Student’s t test. *p<0.05, **p<0.01, ***p<0.001. 
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4.8 Influence of IL-1 antagonists on gene and protein expression of selected 
proinflammatory cytokines in primary human lung fibroblasts treated with 
conditioned media from PBEC cells damaged with oxidative stress. 
 
To confirm the reproducibility of the aforedescribed results, an analogous 
experiment was performed using human primary bronchial epithelial cells derived 
from 5 patients and human primary lung fibroblasts isolated from 3 different 
patients. The qRT-PCR analysis showed that the fibroblast treatment with 
conditioned media collected from PBEC cells damaged with 1mM H2O2 led to 
upregulation of prinflammatory cytokine gene expression: IL-6, IL-8, MCP-1, GM-
CSF, IL-1α and IL-1β and that this induction was significantly reduced by IL-1α NAb 
and IL-1Ra but not by IL-1β Nab. 
To confirm the results of the qRT-PCR analysis described above on the protein level, 
primary human lung fibroblasts were treated for 5hrs with conditioned media from 
damaged epithelial cells in the presence or absence of IL-1α or IL-1β neutralizing 
antibody or IL-1Ra. Following the treatment the conditioned medium was replaced 
with fresh culture medium and the cells were incubated at 37°C for an additional 
24hrs. After the incubation, the conditioned media from fibroblasts were collected 
and subjected to ELISA for IL-6, IL-8, MCP-1 and GM-CSF. The ELISA analysis 
confirmed that IL-1α NAb and IL-1Ra but not IL-1β NAb significantly reduced IL-6, IL-
8, MCP-1 and GM-CSF protein release from lung fibroblasts pre-treated with 
conditioned media from damaged epithelial cells IL-1α and IL-1β were below the 
detection level (figures 37-42). 
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Figure 37 Influence of IL-1α (IL-1α NAb) and IL-1β (IL-1β NAb) neutralizing 
antibodies and IL-1 receptor antagonist (IL-1Ra) on IL-6 gene expression (A) and IL-
6 protein secretion (B) by primary human lung fibroblasts stimulated with 
conditioned media from PBEC cells damaged with H2O2. 
Primary human lung fibroblasts (PF) were treated for 5hrs with conditioned media 
from damaged PBECs (PBECs H2O2) that had been preincubated for 1hrs at 37°C in 
the presence or absence of IL-1α (4µg/ml) or IL-1β  (4µg/ml) neutralizing antibody. 
To inhibit IL-1R signalling, PF were pretreated for 1hrs with 500ng/ml of IL-1Ra after 
which the culture media was replaced with conditioned media from damaged 
epithelial cells containing the same concentration of IL-1Ra. Following 5hrs 
treatment samples were collected for RNA or the conditioned medium was replaced 
with fresh culture medium and the cells incubated at 37°C for additional 24hrs. 
Subsequently, the conditioned media from the fibroblasts was collected and 
subjected to ELISA. IL-1α NAb and IL-1Ra significantly reduced induction of (A) IL-6 
gene expression (90%, p<0.001 and 91% p<0.01 resp., data represented as S.E.M. 
from 5 individual experiments performed in biological triplicates). Additionally, 
conditioned media from ROS-damaged epithelial cells induced fibroblast secretion 
of (G) IL-6 (25ng/ml, data represented as S.E.M. from 3 individal experiments 
performed in biological duplicates) and that effect was significantly reduced by IL-
1α Nab and IL-1Ra but not IL-1β Nab. Statistical analysis was performed using 
Student’s t test. *p<0.05, **p<0.01, ***p<0.001. 
142 
 
         
A IL - 8
- + - - - -
- + + + +
- - + - -
- - - + -
- - - - +
0
0.5
1
1.5
2
2.5
3
3.5
NS
*** ***
0
0.2
0.4
0.6
0.8
1
1.2
1.4
µ
g
/m
l
B
NS
- + - - - -
- - + + + +
- - - + - -
- - - - + -
- - - - - +
***
PBECs 
PBECs UT
H2O2
IL- 1α NAb
IL- 1β NAb
IL-1Ra
-
-
-
-
PBECs 
PBECs UT
H2O2
IL- 1α NAb
IL- 1β NAb
IL-1Ra
IL - 8
R
e
la
ti
v
e
g
e
n
e
e
x
p
re
s
s
io
n
 
Figure 38 Influence of IL-1α (IL-1α NAb) and IL-1β (IL-1β NAb) neutralizing 
antibodies and IL-1 receptor antagonist (IL-1Ra) on IL-8 gene expression (A) and IL-
8 protein secretion (B) by primary human lung fibroblasts stimulated with 
conditioned media from PBEC cells damaged with H2O2. 
Primary human lung fibroblasts (PF) were treated for 5hrs with conditioned media 
from damaged PBECs (PBECs H2O2) that had been preincubated for 1hrs at 37°C in 
the presence or absence of IL-1α (4µg/ml) or IL-1β  (4µg/ml) neutralizing antibody. 
To inhibit IL-1R signalling, PF were pretreated for 1hrs with 500ng/ml of IL-1Ra after 
which the culture media was replaced with conditioned media from damaged 
epithelial cells containing the same concentration of IL-1Ra. Following 5hrs 
treatment samples were collected for RNA or the conditioned medium was replaced 
with fresh culture medium and the cells incubated at 37°C for additional 24hrs. 
Subsequently, the conditioned media from the fibroblasts was collected and 
subjected to ELISA. IL-1α NAb and IL-1Ra significantly reduced induction of (A) IL-8 
gene expression (93%, p<0.01 and 95%, n<0.01 resp., data represented as S.E.M. 
from 5 individual experiments performed in biological triplicates). Additionally, 
conditioned media from ROS-damaged epithelial cells induced fibroblast secretion 
of (G) IL-8 (1µg/ml, data represented as S.E.M. from 3 individal experiments 
performed in biological duplicates) and that effect was significantly reduced by IL-
1α Nab and IL-1Ra but not IL-1β Nab. Statistical analysis was performed using 
Student’s t test. *p<0.05, **p<0.01, ***p<0.001. 
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Figure 39 Influence of IL-1α (IL-1α NAb) and IL-1β (IL-1β NAb) neutralizing 
antibodies and IL-1 receptor antagonist (IL-1Ra) on GM-CSF gene expression (A) 
and GM-CSF protein secretion (B) by primary human lung fibroblasts stimulated 
with conditioned media from PBEC cells damaged with H2O2. 
Primary human lung fibroblasts (PF) were treated for 5hrs with conditioned media 
from damaged PBECs (PBECs H2O2) that had been preincubated for 1hrs at 37°C in 
the presence or absence of IL-1α (4µg/ml) or IL-1β  (4µg/ml) neutralizing antibody. 
To inhibit IL-1R signalling, PF were pretreated for 1hrs with 500ng/ml of IL-1Ra after 
which the culture media was replaced with conditioned media from damaged 
epithelial cells containing the same concentration of IL-1Ra. Following 5hrs 
treatment samples were collected for RNA or the conditioned medium was replaced 
with fresh culture medium and the cells incubated at 37°C for additional 24hrs. 
Subsequently, the conditioned media from the fibroblasts was collected and 
subjected to ELISA. IL-1α NAb and IL-1Ra significantly reduced induction of (A) GM-
CSF gene expression (95%, p<0.001 and 94%, p<0.001 resp., data represented as 
S.E.M. from 5 individual experiments performed in biological triplicates). 
Additionally, conditioned media from ROS-damaged epithelial cells induced 
fibroblast secretion of (G) GM-CSF (0.7ng/ml, data represented as S.E.M. from 3 
individal experiments performed in biological duplicates) and that effect was 
significantly reduced by IL-1α Nab and IL-1Ra but not IL-1β Nab. Statistical analysis 
was performed using Student’s t test. *p<0.05, **p<0.01, ***p<0.001. 
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Figure 40 Influence of IL-1α (IL-1α NAb) and IL-1β (IL-1β NAb) neutralizing 
antibodies and IL-1 receptor antagonist (IL-1Ra) on MCP-1 gene expression (A) and 
MCP-1 protein secretion (B) by primary human lung fibroblasts stimulated with 
conditioned media from PBEC cells damaged with H2O2. 
Primary human lung fibroblasts (PF) were treated for 5hrs with conditioned media 
from damaged PBECs (PBECs H2O2) that had been preincubated for 1hrs at 37°C in 
the presence or absence of IL-1α (4µg/ml) or IL-1β  (4µg/ml) neutralizing antibody. 
To inhibit IL-1R signalling, PF were pretreated for 1hrs with 500ng/ml of IL-1Ra after 
which the culture media was replaced with conditioned media from damaged 
epithelial cells containing the same concentration of IL-1Ra. Following 5hrs 
treatment samples were collected for RNA or the conditioned medium was replaced 
with fresh culture medium and the cells incubated at 37°C for additional 24hrs. 
Subsequently, the conditioned media from the fibroblasts was collected and 
subjected to ELISA. IL-1α NAb and IL-1Ra significantly reduced induction of (A) MCP-
1 gene expression (92%, p<0.001 and 93%, p<0.001 resp., data represented as 
S.E.M. from 5 individual experiments performed in biological triplicates). 
Additionally, conditioned media from ROS-damaged epithelial cells induced 
fibroblast secretion of (G) MCP-1 (20ng/ml, data represented as S.E.M. from 3 
individal experiments performed in biological duplicates) and that effect was 
significantly reduced by IL-1α Nab and IL-1Ra but not IL-1β Nab. Statistical analysis 
was performed using Student’s t test. *p<0.05, **p<0.01, ***p<0.001. 
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Figure 41 Influence of IL-1α (IL-1α NAb) and IL-1β (IL-1β NAb) neutralizing 
antibodies and IL-1 receptor antagonist (IL-1Ra) on IL-1α gene expression by 
primary human lung fibroblasts stimulated with conditioned media from PBEC 
cells damaged with H2O2. 
Primary human lung fibroblasts (PF) were treated for 5hrs with conditioned media 
from damaged PBECs (PBECs H2O2) that had been preincubated for 1hrs at 37°C in 
the presence or absence of IL-1α (4µg/ml) or IL-1β  (4µg/ml) neutralizing antibody. 
To inhibit IL-1R signalling, PF were pretreated for 1hrs with 500ng/ml of IL-1Ra after 
which the culture media was replaced with conditioned media from damaged 
epithelial cells containing the same concentration of IL-1Ra. Following 5hrs 
treatment samples were collected for RNA. IL-1α NAb and IL-1Ra significantly 
reduced induction of IL-1α (35%, p<0.05 and 42% p<0.05 resp., data represented as 
S.E.M. from 5 individual experiments performed in biological triplicates). Statistical 
analysis was performed using Student’s t test. *p<0.05, **p<0.01, ***p<0.001. 
 
 
 
146 
 
R
e
la
ti
v
e
g
e
n
e
e
x
p
re
s
s
io
n
H2O2
IL- 1α NAb
IL- 1β NAb
IL-1Ra
0
0.5
1
1.5
2
2.5
3
NS
*
IL-1β
*
- + - - - -
- - + + + +
- - - + - -
- - - - + -
- - - - - +
PBECs UT
PBECs
 
 
Figure 42 Influence of IL-1α (IL-1α NAb) and IL-1β (IL-1β NAb) neutralizing 
antibodies and IL-1 receptor antagonist (IL-1Ra) on IL-1β gene expression by 
primary human lung fibroblasts stimulated with conditioned media from PBEC 
cells damaged with H2O2. 
Primary human lung fibroblasts (PF) were treated for 5hrs with conditioned media 
from damaged PBECs (PBECs H2O2) that had been preincubated for 1hrs at 37°C in 
the presence or absence of IL-1α (4µg/ml) or IL-1β  (4µg/ml) neutralizing antibody. 
To inhibit IL-1R signalling, PF were pretreated for 1hrs with 500ng/ml of IL-1Ra after 
which the culture media was replaced with conditioned media from damaged 
epithelial cells containing the same concentration of IL-1Ra. Following 5hrs 
treatment samples were collected for RNA. IL-1α NAb and IL-1Ra significantly 
reduced induction of  IL-1β (77%, p<0.001 and 79%, p<0.001 resp., data represented 
as S.E.M. from 5 individual experiments performed in biological triplicates). 
Statistical analysis was performed using Student’s t test. *p<0.05, **p<0.01, 
***p<0.001. 
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4.9 Influence of IL-1 antagonists on gene expression of selected proinflammatory 
cytokines in primary human lung fibroblasts treated with conditioned media from 
16HBE14o- cells damaged with thapsigargin-induced stress in the endoplasmic 
reticulum (ER stress). 
 
To confirm the reproducibility of the results described before using a different 
model of epithelial injury, an analogous experiment was performed using 
conditioned media from 16HBE14o- damaged with 50µM thapsigargin and human 
primary lung fibroblasts. The qRT-PCR analysis showed that the fibroblast treatment 
with conditioned media collected from 16HBE14o- cells damaged with ER stress led 
to upregulation of proinflammatory and fibrogenic cytokine gene expression: IL-6, 
IL-8, MCP-1, GM-CSF, IL-1α and IL-1β, which was significantly reduced by IL-1α NAb 
and IL-1Ra but not by IL-1β Nab (Figure 43). 
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Figure 43 Influence of IL-1α (IL-1α NAb) and IL-1β (IL-1β NAb) neutralizing 
antibodies and IL-1 receptor antagonist (IL-1Ra) on proinflammatory cytokine 
gene expression by primary human lung fibroblasts stimulated with conditioned 
media from 16HBE14o- cells (HBE) damaged with 50µM thapsigargin (TG). 
Primary human lung fibroblasts (PF) were treated for 5hrs with conditioned media 
from 16HBE14o- damaged with 50µM thapsigargin (HBE TG) that had been 
preincubated for 1hrs at 37°C in the presence or absence of IL-1α (4µg/ml) or IL-1β 
(4µg/ml) neutralizing antibody. To inhibit IL-1R signalling, PHLF were pretreated for 
1hrs with 500ng/ml of IL-1Ra after which the culture media was replaced with 
conditioned media from damaged epithelial cells containing the same concentration 
of IL-1Ra. Following 5hrs treatment samples were collected for RNA. IL-1α NAb and 
IL-1Ra significantly reduced induction of IL-6, IL-8, MCP-1, GM-CSF, IL-1α and IL-1β 
induced following treatment with conditioned media from damaged epithelial cells. 
Data represent the mean±S.E.M, from 3 individual experiments performed on two 
biological replicates. Statistical analysis was performed using unpaired Student’s t 
test. *p<0.05, **p<0.01, ***p<0.001. 
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4.10 Influence of IL-1 antagonists on phosphorylation of selected PRR signaling 
molecules in primary human lung fibroblasts treated with conditioned media from 
damaged epithelial cells 
 
To investigate the influence of alarmins released from damaged epithelial cells on 
TLR signalling activation, primary human lung fibroblasts were treated for 30mins 
with conditioned media from untreated or damaged epithelial cells and 
phosphorylation of downstream TLR signalling molecules (ERK, JNK, p38, p65, IKK) 
analyzed by western blotting. The analysis revealed that the treatment with 
conditioned media from damaged cells led to MAP-kinase and NF-κB activation in 
comparison to control. Both IL-1α neutralizing antibody and IL-1Ra diminished 
phosphorylation of the kinases in response to conditioned media from 16HBE-14o- 
cells while IL-1β neutralizing antibody had no effect (Figure 44). 
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Figure 44 Influence of IL-1α (IL-1α Nab) and IL-1β (IL-1β Nab) neutralizing 
antibodies and IL-1 receptor antagonist (IL-1Ra) on phosphorylation of 
downstream TLR signaling molecules in primary human lung fibroblasts induced 
following treatment with conditioned media from H2O2 damaged 16HBE-14o- cells 
(HBE). 
Primary human lung fibroblasts (PF) were treated for 30mins with conditioned 
media from damaged  16-HBE14o- cells (HBE H2O2) that had been preincubated for 
1hrs at 37°C in the presence or absence of IL-1α (4µg/ml) or IL-1β (4µg/ml) 
neutralizing antibody. To inhibit IL-1R signalling, PF were pretreated for 1hrs with 
500ng/ml of IL-1Ra after which the culture media was replaced with conditioned 
media from damaged epithelial cells containing the same concentration of IL-1Ra. 
30mins treatment with conditioned media from damaged epithelial cells increased 
phosphorylation of downstream TLR signaling molecules including p-65, IKK2, JNK, 
ERK and p38 in primary human lung fibroblasts in comparison to treatment with 
media from undamaged cells. This effect was strongly reduced by IL-1α NAb and IL-
1Ra but not IL-1β NAb. Protein phoshorylation was assessed by western blotting. β-
actin was used as loading control (n=3). 
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4.11 Synergy between IL-1α and Poly I:C in stimulating proinflammatory cytokine 
expression in human lung fibroblasts 
 
As described above, both IL-1α and Poly I:C may stimulate expression of IL-6 in 
primary human lung fibroblasts. Therefore it may be hypothesized that there exist a 
crosstalk between IL-1R and TLR3 and that their ligands they may act synergistically 
to upregulate expression of proinflammatory cytokines. To test this hypothesis, 
human primary lung fibroblast were treated with 10μg/ml of Poly I:C or 500pg/ml of 
IL-1α or a combination of these two factors for 5 or 24hrs. Following the treatment 
the cells were harvested for RNA and subjected to qRT-PCR to assess IL-6 and IL-8 
gene expression. The analysis revealed that Poly I:C significantly accentuated IL-1α 
induced IL-6 and IL-8 gene expression and that the synergistic effect was more 
pronounced after 24hrs (figure 45). 
Since IL-6 may also be accumulated in intracellular globules, a 
immunohistochemical analysis was performed to establish if the IL-1α and Poly I:C 
may also have an effect on the levels of intracellular IL-6. The analysis showed that 
both IL-1α and Poly I:C treatment caused accumulation of IL-6 within intracellular 
granules in fibroblasts and that the stimulation with the combination of the two 
factors significantly enhanced the amount of the stored cytokine and increased the 
number of cells positively stained for IL-6 (figure 46). 
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Figure 45 Influence of IL-1α and Poly I:C on selected proinflammatory cytokine 
gene expression in primary human lung fibroblats in the course of time.  
Primary human lung fibroblasts were treated with IL-1α, Poly I:C or a combination 
of these two factors for 5 or 24hrs. Following the treatment RNA was collected and 
qRT-PCR analysis was performed to assess gene expression of IL-8 (A) and IL-6 (B). 
GAPDH was used as a reference gene. Data represent the mean±S.E.M. from 3 
individual experiments performed on two biological replicates. Statistical analysis 
was performed using Student’s t test.  *p<0.05, **p<0.01, ***p<0.001. 
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Figure 46 Influence of IL-1α and Poly I:C on of IL-6 protein acumulation in primary 
human lung fibroblasts. 
Primary human lung fibroblasts were treated for 24hrs with IL-1α (100pg/ml), Poly 
I:C (10μg/ml) or a combination of these two factors. Following treatment the cells 
were subjected to immunofluorescent staining to visualize intracellular IL-6 protein 
(n=3). Red – fibronectin, green – IL-6, blue – DAPI.  
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4.12 Influence of inhibitors of IL-1R signaling molecules on IL-α and Poly I:C 
induced inflammation. 
To investigate signaling pathways via which IL-1α and Poly I:C-induced inflammation 
is mediated, several chemical agents and commercially available drugs including 
chemical inhibitors of two major kinases mediating IL-1R and TLR3 signaling: TAK1 
and TAK1, a steroid drug, dexamethasone and a macrolide antibiotic, azithromycin, 
were tested.  
TAK1 inhibitor ((5Z)-7-Oxozeaenol) is a resorcyclic lactone of fungal origin that 
forms a covalent complex with TAK1 and inhibites both the kinase and the ATPase 
activity of TAK1. (5Z)-7-Oxozeaenol inhibits IL-1-induced activation of NF-κB (IC50 = 
83 nM) and JNK/p38.  
IKK2i (5-(p-Fluorophenyl)-2-ureido]thiophene-3-carboxamide) is an 
ureidocarboxamido thiophene compound that acts as a potent, ATP-competitive 
inhibitor of IKK-2 (IC50 = 18 nM) with selectivity over IKK-1, JNK and p38 MAPK. 
(Information obtained from the supplier (Calbiochem) datasheet). 
Human primary lung fibroblast were exposed to IKK2i (0.078-10µM), TAK1i (0.0078-
1µM) for 1hrs, after which the cells were treated with IL-1α or Poly I:C or a 
combination of these two factors for 24hrs. Following the treatment conditioned 
media from fibroblast cultures were collected for ELISA. The analysis revealed that 
IKK2i and TAK1i significantly reduced IL-6 nad IL-8 protein release form fibroblasts 
treated with IL-1α and Poly I:C (figures 44-47). Additionally, to confirm these results 
on the RNA level, an analogous experiment was performed using 1µM IKK2i or 
TAK1i and gene expression of IL-8 and IL-6 was measured by qRT-PCR. The analysis 
revealed that the treatment resulted in marked downregulation of IL-6 and IL-8 
gene expression induced by IL-1α and Poly I:C. These results were further confirmed 
on the protein level by ELISA (figures 47-54). Neither of the tested IKK2i or TAKi 
doses reduced fibroblast cell viability (data not shown). 
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Figure 47 Influence of IKK2i on IL-1α and Poly I:C induced IL-8 protein secretion by 
primary human lung fibroblasts. 
 
To establish the optimal dose of IKK2i required to inhibit IL-1α and Poly I:C- induced 
cytokine production in primary human lung fibroblasts the indicated IKK2i 
concentrations were tested in an assay using IL-8 protein secretion as markers of 
innate immune signaling activation. Primary human lung fibroblasts were treated 
with the indicated concentrations of IKK2i for 1hr after which 100pg/ml of IL-1α (A) 
or 10μg/ml of Poly I:C (B) alone or in combination were added to the culture (C). 
Following 24 hrs incubation conditioned media were collected and subjected to 
ELISA analysis   IL-8. IKK2i doses above 0.625μM were sufficient to inhibit IL-8 
secretion by >90% in response to IL-1α and Poly I:C. Consequently a 1μM IKK2i dose 
was used in subsequent experiments assessing the influence of IKK2i on IL-1α and 
Poly I:C-induced IL-8 gene expression. Data represented as S.E.M. from 3 biological 
replicates. 
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Figure 48 Influence of IKK2i on IL-1α and Poly I:C induced IL-6 protein secretion by 
primary human lung fibroblasts. 
 
To establish the optimal dose of IKK2i required to inhibit IL-1α and Poly I:C- induced 
cytokine production in primary human lung fibroblasts the indicated IKK2i 
concentrations were tested in an assay using IL-6 protein secretion as markers of 
innate immune signaling activation. Primary human lung fibroblasts were treated 
with the indicated concentrations of IKK2i for 1hr after which 100pg/ml of IL-1α (A) 
or 10μg/ml of Poly I:C (B) alone or in combination were added to the culture (C). 
Following 24 hrs incubation conditioned media were collected and subjected to 
ELISA analysis IL-6. IKK2i doses above 0.625μM were sufficient to inhibit IL-6 
secretion by >90% in response to IL-1α and Poly I:C. Consequently a 1μM IKK2i dose 
was used in subsequent experiments assessing the influence of IKK2i on IL-1α and 
Poly I:C-induced IL-6 gene expression. Data represented as S.E.M. from 3 biological 
replicates. 
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Figure 49 Influence of TAK1i on IL-1α and Poly I:C induced IL-8 protein secretion by 
primary human lung fibroblasts 
 
Optimal TAK1i dose to inhibit IL-1α and Poly I:C- induced cytokine production by 
primary human lung fibroblasts was established analogically as described in SF.6 
legend. The analysis revealed that a 1μM dose of TAK1i was sufficient to inhibit IL-8 
protein secretion by >90% in response to IL-1α and Poly I:C.  Consequently this dose 
was used in the subsequent experiments assessing the influence of TAKi on IL-1α 
and Poly I:C-induced IL-8 gene expression. Data represented as S.E.M. from 3 
biological replicates. 
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Figure 50 Influence of TAK1i on IL-1α and Poly I:C induced IL-6 protein secretion by 
primary human lung fibroblasts 
 
Optimal TAK1i dose to inhibit IL-1α and Poly I:C- induced cytokine production by 
primary human lung fibroblasts was established analogically as described in SF.6 
legend. The analysis revealed that a 1μM dose of TAK1i was sufficient to inhibit IL-6 
protein secretion by >90% in response to IL-1α and Poly I:C.  Consequently this dose 
was used in the subsequent experiments assessing the influence of TAKi on IL-1α 
and Poly I:C-induced IL-6 gene expression. Data represented as S.E.M. from 3 
biological replicates. 
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Figure 51 Influence of IKK2 inhibitor (IKK2i) on IL-6 gene expression and protein 
release from primary human lung fibroblasts in response to IL-1α and Poly I:C. 
24hrs co-treatment with IL-1α (100pg/ml) and Poly I:C (10μg/ml) markedly 
enhanced gene expression of IL-6 (A) and protein release (B) in primary human lung 
fibroblast in comparison to treatment with IL-1α or Poly I:C alone. 1hr pretreatment 
with IKK2i (1µM) inhibitor significantly reduced IL-6 gene expression and protein 
release by primary human lung fibroblasts in response to treatment with IL-1α and 
Poly I:C individually or in combination. Relative gene expression was measured by 
qRT-PCR using GAPDH as a housekeeping gene. IL-6 protein concentrations were 
analyzed by ELISA. Data represent S.E.M. from 3 individual experiments performed 
on two biological replicates. Statistical analysis was performed using Student’s t 
test.  *p<0.05, **p<0.01, ***p<0.001. 
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Figure 52 Influence of IKK2 inhibitor (IKK2i) on IL-8 gene expression and protein 
release from primary human lung fibroblasts in response to IL-1α and Poly I:C. 
24hrs co-treatment with IL-1α (100pg/ml) and Poly I:C (10μg/ml) markedly 
enhanced gene expression of IL-8 (A) and protein release (B) in primary human lung 
fibroblast in comparison to treatment with IL-1α or Poly I:C alone. 1hr pretreatment 
with IKK2i (1µM) inhibitor significantly reduced IL-8 gene expression and protein 
release by primary human lung fibroblasts in response to treatment with IL-1α and 
Poly I:C individually or in combination (n=3, p<0.001 in all cases). Relative gene 
expression was measured by qRT-PCR using GAPDH as a housekeeping gene. IL-8 
protein concentrations were analyzed by ELISA. Data represent S.E.M. from 3 
individual experiments performed on two biological replicates. Statistical analysis 
was performed using Student’s t test.  *p<0.05, **p<0.01, ***p<0.001. 
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Figure 53 Influence of TAK1 inhibitor (TAK1i) on IL-6 gene expression and protein 
release from primary human lung fibroblasts in response to IL-1α and Poly I:C. 
24hrs co-treatment with IL-1α (100pg/ml) and Poly I:C (10μg/ml) markedly 
enhanced gene expression of IL-6 (A) and protein release (B) in primary human lung 
fibroblast in comparison to treatment with IL-1α or Poly I:C alone. 1hr pretreatment 
with TAK1 (1µM) inhibitor significantly reduced IL-6 gene expression and protein 
release by primary human lung fibroblasts in response to treatment with IL-1α and 
Poly I:C individually or in combination (n=3, p<0.001 in all cases). Relative gene 
expression was measured by qRT-PCR using GAPDH as a housekeeping gene. IL-6 
protein concentrations were analyzed by ELISA. Data represent S.E.M. from 3 
individual experiments performed on two biological replicates. Statistical analysis 
was performed using Student’s t test. *p<0.05, **p<0.01, ***p<0.001. 
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Figure 54 Influence of TAK1 inhibitor (TAK1i) on IL-8 gene expression and protein 
release from primary human lung fibroblasts in response to IL-1α and Poly I:C. 
24hrs co-treatment with IL-1α (100pg/ml) and Poly I:C (10μg/ml) markedly 
enhanced gene expression of IL-8 (A) and protein release (B) in primary human lung 
fibroblast in comparison to treatment with IL-1α or Poly I:C alone. 1hr pretreatment 
with TAK1 (1µM) inhibitor significantly reduced IL-8 gene expression and protein 
release by primary human lung fibroblasts in response to treatment with IL-1α and 
Poly I:C individually or in combination (n=3, p<0.001 in all cases). Relative gene 
expression was measured by qRT-PCR using GAPDH as a housekeeping gene. IL-8 
protein concentrations were analyzed by ELISA. Statistical analysis was performed 
using unpaired Student’s t test.  *p<0.05, **p<0.01, ***p<0.001.  
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4.13 Influence of glucocorticoids and macrolide antibiotics on inflammation 
induced by IL-1α and Poly I:C 
 
Currently patients affected by chronic post-transplant lung rejection are subject to 
strict anti-inflammatory and immunosuppressive therapy, which involves drugs such 
as macrolide antibiotics including azithromycin and glucocorticois. 
In order to establish the influence of the aforementioned drugs on inflammation 
induced by IL-1α and Poly I:C, human primary lung fibroblasts were exposed to 
dexamethasone (0.1325-5µM) for 1hrs or azithromycin (0.078-5µM) for 24hrs, after 
which the cells were treated with IL-1α or Poly I:C or a combination of these two 
factors for 24hrs. 
Following the treatment the conditioned media were collected and subjected to 
ELISA form IL-8 and IL-6. 
The analysis revealed that dexamethasone significantly reduced the production of 
IL-6 and IL-8 in response to IL-1α and Poly I:C, while azithromycin was effective in 
dumping down inflammtion induced by Poly I:C but not IL-1α (figures 55-58). 
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Figure 55 Influence of Dexamethasone (DEX) on IL-1α and Poly I:C induced IL-8 
protein secretion by primary human lung fibroblasts 
 
Primary human lung fibroblasts were treated with the indicated concentrations of 
Dexamethasone (DEX) for 1hr after which 100pg/ml of IL-1α (A) or 10pg/ml of Poly 
I:C (B) alone or in combination were added (C) to the culture and the cells were 
incubated at 37°C for the further 24hrs. Following the incubation conditioned media 
were collected and subjected to ELISA analysis for IL-8. All the tested DEX doses 
significantly reduced IL-1α and Poly I:C induced IL-8 secretion. Data represented as 
S.E.M. from 3 biological replicates. 
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Figure 56 Influence of Dexamethasone (DEX) on IL-1α and Poly I:C induced IL-6 
protein secretion by primary human lung fibroblasts 
 
Primary human lung fibroblasts were treated with the indicated concentrations of 
Dexamethasone (DEX) for 1hr after which 100pg/ml of IL-1α (A) or 10pg/ml of Poly 
I:C (B) alone or in combination were added (C) to the culture and the cells were 
incubated at 37°C for the further 24hrs. Following the incubation conditioned media 
were collected and subjected to ELISA analysis for IL-6. All the tested DEX doses 
significantly reduced IL-1α and Poly I:C induced IL-6 secretion. Data represented as 
S.E.M. from 3 biological replicates. 
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Figure 57 Influence of Azithromycin (AZ) on IL-1α and Poly I:C induced IL-8 protein 
secretion by primary human lung fibroblasts 
 
Primary human lung fibroblasts were treated with the indicated concentrations of 
Azithromycin (AZ) for 24hr after which 100pg/ml of IL-1α (A) or 10pg/ml of Poly I:C 
(B) alone or in combination (C)  were added to the culture and the cells incubated at 
37°C for the further 24hrs. Following the incubation conditioned media were 
collected and subjected to ELISA analysis for IL-8. AZ partially reduced Poly I:C 
induced (B) IL-8 protein secretion but had no significant effect on the productions of 
IL-8 induced by IL-1α (A). Data represented as S.E.M. from 3 biological replicates. 
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Figure 58 Influence of Azithromycin (AZ) on IL-1α and Poly I:C induced IL-6 protein 
secretion by primary human lung fibroblasts 
 
Primary human lung fibroblasts were treated with the indicated concentrations of 
Azithromycin (AZ) for 24hr after which 100pg/ml of IL-1α (A) or 10pg/ml of Poly I:C 
(B) alone or in combination (C)  were added to the culture and the cells incubated at 
37°C for the further 24hrs. Following the incubation conditioned media were 
collected and subjected to ELISA analysis for IL-6. AZ partially reduced Poly I:C 
induced (B) IL-8 (n=3, p<0.01) protein secretion but had no significant effect on the 
productions of IL-6 induced by IL-1α (A). Data represented as S.E.M. from 3 
biological replicates. 
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4.14 Influence of IL-1α on IL-8 protein secretion in primary human alveolar 
macrophages and PBEC cells 
 
The main cellular key players involved in mediating innate immune responses in the 
lung include immune cells such as alveolar and interstitial macrophages and 
structural cells including alveolar and bronchial epithelial cells and interstitial 
fibroblasts. Therefore to establish how these cells may contribute to inflammatory 
responses mediated by IL-1α, primary human bronchial epithelial cells and human 
primary alveolar macrophages were subjected to a 24hrs treatment with a range of 
IL-1α doses, after which the conditioned media were collected for IL-8 ELISA. As a 
positive control TNFα or a lysate from Pseudomonas auriginosa were used to 
stimulate PBEC and alveolar macrophages respectively.  
The analysis revealed that, the IL-1α treatment stimulated release of IL-8 from PBEC 
cells, however not from macrophages. To evaluate this result, macrophages were 
further stimulated with a range of IL-1β doses, however this treatment did not have 
a significant impact on their activation either (figure 59 and 60). Alveolar 
macrophages used in the experiment described above were isolated by 
centrifugation from BALs of 4 anonymous lung transplant recipients.  
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Figure 59 Influence of IL-1α and IL-1β on IL-8 protein secretion by primary human 
alveolar macrophages. 
Primary human alveolar macrophages were challenged for 24hrs with the indicated 
doses of IL-1α and IL-1β, after which the conditioned media were collected and 
subject to ELISA for IL-8. As a positive control 25µl of a lysate from Pseudomonas 
aeruginosa (PA) was used. Data represent the mean±S.E.M. from 4 individual 
experiments performed on macrophages derived from 4 post-transplant patients.  
Statistical analysis was performed using Student’s t t test. 
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Figure 60 Influence of IL-1α on IL-8 protein secretion by primary human bronchial 
epithelial cells (PBEC). 
Primary human bronchial epithelial cells (PBEC) were challenged for 24hrs with the 
indicated doses of IL-1α, TNFα or 25µl of a lysate from Pseudomonas aeruginosa 
(PA), after which the conditioned media were collected and subject to ELISA for IL-8. 
Data represent the mean±S.E.M. from 3 individual experiments performed on two 
biological replicates. Statistical analysis was performed using Student’s t test. 
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4.15 Discussion 
4.15.1 Influence of IL-1α on fibroblast activation    
 
Fibroblasts represent a heterogeneous population of structural cells whose number 
significantly increases in fibrotic tissue where they may exceed 50% of the total cell 
population. Quiescent fibroblasts in normal tissues show low proliferation rate, 
limited contractibility and low expression levels of structural proteins including α-
SMA and fibronectin. In fibrotic tissues and some tumors fibroblasts become 
activated, proliferate faster, gain the ability to migrate and express significantly 
higher levels of fibrogenic proteins. The overgrowth of fibrotic tissue is usually 
accompanied by progressive degeneration of the epithelial lining [248].  
For decades, fibroblasts were regarded as cells whose role was limited to the 
production of the extracellular matrix. Therefore the majority of studies published 
to date focused on identifying factors that may stimulate fibroblasts proliferation 
and expression of fibrogenic factors in fibrotic tissues.  
In many fibrotic diseases, tissue fibrosis is accompanied by chronic inflammation, 
however the role of fibroblasts in this process has not been investigated before.  
Numerous studies investigating fibroblast biology suggest that fibroblasts are not a 
homogenous cell population, and that even fibroblasts residing in the same tissue 
may have different origin and behavior [249].  
Although previous studies suggest that alarmins released from damaged cells may 
contribute to fibrosis, we did not find a link between IL-1α or conditioned media 
from injured epithelial cells and activation of pro-fibrotic genes in human lung 
fibroblasts. Fibroblast treatment with media from damaged cells failed to 
upregulate collagen gene expression. The literature lacks information on the 
influence of IL-1α on fibrotic factor expression, suggesting that there is no a direct 
link between IL-1α and the overgrowth of fibrotic tissue.  
However previous reposts support our findings regarding the proinflammatory 
potential of IL-1α and the role of fibroblasts as mediators of chronic inflammation. 
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A study performed by Kawaguchi et al. demonstrated that endogenous IL-1α 
released by systemic sclerosis (SS) fibroblasts may stimulate production of IL-6 and 
PDGF-A in an autocrine manner [250]. Moreover the study demonstrated that 
blocking IL-6 using a specific monoclonal antibody reduced expression of 
procollagen I in SS fibroblasts. Additionally, Kawaguchi et all showed that fibroblasts 
from SS tissues produce increased levels of IL-1α when compared to fibroblasts 
from healthy individuals.  
This observation is in compliance with our results, demonstrating that IL-1α may 
upregulate expression of its own transcripts in fibroblasts, which may exacerbate 
inflammation in tissues with ongoing epithelial injury.  
Endogenous, cell bound IL-1α has also been recognized as the main factor 
responsible for upregulation of IL-6 and IL-8 in senescent fibroblasts [251]. 
Moreover senescent fibroblasts showed increased levels of IL-1α mRNA and 
intracellular protein. The number of senescent cells increases with age. Senescent 
fibroblasts are also present in some tumors and their presence is associated with 
increased production of proinflammatory cytokines.  
The role of IL-1α as the main factor stimulating production of proinflammatory 
cytokines in the tumor microenvironment was demonstrated in a study performed 
using cancer-associated fibroblasts (CAFs). The study performed by Tjomsland et al. 
has shown that coculture of pancreatic ductal adenocarcinoma (PDAC) with CAFs 
leads to IL-1α dependant upregulation of proinflammatory factor (IL-1α, IL-6, CXCL8, 
VEGF-A, CCL20, and COX-2. CAFs) gene expression in fibroblasts, suggesting that 
anti-IL-1α therapies could be implemented in pancreatic cancer treatment [252].  
The significance of IL-1α in tumor development was also confirmed in a study 
performed by Xie et al. demonstrating that fibroblasts promote squamous cell 
carcinoma cell matrigel invasive ability via a cathepsin K and IL-1α dependant 
manner [253]. 
IL-1α was also shown to promote a proinflammatory phenotype characterized by 
upregulation of IL-6, IL-8 and IL-1β gene expression in rheumatoid fibroblast-like 
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synovial cell line [254]. This process was demonstrated to be NF-κB and androgen 
receptor (AR) dependant and could be blocked by dihydrotestosterone.  
Although the relationship between primary human lung fibroblasts and IL-1α 
released from damaged bronchial epithelial cells has not been studied before, there 
are reports indicating that IL-1α may contribute to fibroblast mediated 
inflammation in injured tissues. A study performed by Turner et al. confirms that IL-
1α is capable of upregulating expression of IL-6, TNFα and IL-1β and increasing 
phosphorylation of ERK, JNK, p38 in cardiac myofibroblasts [255]. These results are 
in agreement with my observations, however primary human lung fibroblasts 
expressed insignificant levels of TNFα even after stimulation with IL-1α (data not 
shown). 
Inflammation mediated by myofibroblasts, which are the main cell type building the 
heart structure, is of great importance in conditioned such as myocardial infarction, 
which is associated with death of myocardial fibroblasts [256]. 
The results described above are in compliance with our observations, 
demonstrating that fibroblasts may be a substantial source of numerous 
proinflammatory cytokines including IL-6, IL-8, MCP-1 and GM-CSF.  
The current study revealed that upon stimulation with picogram concentrations of 
IL-1α, fibroblasts release nanogram to microgram amounts of IL-6 and IL-8, which 
resemblance the behavior of LPS-stimulated macrophages.  
Additionally, my observation, that primary human alveolar macrophages do not 
secrete increased amounts of IL-8 in response to IL-1α, suggest that fibroblasts may 
play the key role in mediating inflammation in response to IL-1α released from 
injured epithelium.  
4.15.2 Crosstalk between IL1α and TLR3 
 
The current study demonstrated that a synthetic TLR3 ligand may synergize with IL-
1α, resulting with marked upregulation of proinflammatory cytokines including IL-6 
and IL-8, which may suggest that viral infections may exacerbate inflammation 
induced following epithelial injury. 
173 
 
The synergistic effect between IL-1α and Poly I:C and the crosstalk between TLR3 
and IL-1R have not been described before. Previous studies however indicate that 
there exists a cooperation between TLR3 and IL-1R adaptor molecules: TRIF and 
MYD88. Ouyang et al. suggest that the synergistic effect between MYD88 
dependant TLR4 and TLR3 signaling upon stimulation with LPS and TLR3 ligands: 
Poly I:C or CpG-DNA, that is manifested by enhanced expression of IL-12 and IL-6 
may be mediated by IRF-5 which may directly interact with MyD88 to regulate 
expression of proinflammatory cytokines [257]. Moreover the study showed that 
the treatment with ligands of MYD88 and TRIF dependant TLRs results in a 
synergistic induction of IκBα – a regulator of NF-κB pathway. The results obtained in 
our study suggest that the synergy between IL-1α and Poly I:C which also signal via 
MYD88 and TRIF respectively may be NF-κB dependant and mediated by IKK2. 
The current study demonstrated that the inflammation induced by IL-1α and Poly 
I:C could be effectively blocked with IKK2i, TAKi and a steroid drug dexamethasone, 
which functions as an inhibitor of NF-κB signaling pathway. 
The role of IKK2 in TLR3 signaling finds confirmation is a study performed by Orita et 
all, which has shown that Poly I:C induced expression of adhesion molecules VCAM-
1 and ICAM-1 in human corneal fibroblasts can be attenuated by IKK2i and a 
selective inhibitor of PI3Ks (LY294002) [258]. 
The involvement of TAK1 in the mediation of TLR3 signaling has been confirmed in a 
study by Bhattacharyya et al., demonstrating that Poly I:C stimulates 
phosphorylation of TAK1 in mouse peritoneal macrophages, and this effect can be 
substantially attenuated by pretreatment with dexamethasone [259]. 
Additionally, Yao et all, has shown that both TAK1 and IKK2 are phosphorylated 
following IL-1R activation, and that this process is proceeded by IRAK1 
phosphorylation and ubiquitin-dependant degradation, suggesting that IKK2 and 
TAK1 also participate in IL-1 induced signal transduction [260]. 
The role of IKK2 in IL-1R signaling also finds confirmation in studies by Salmerón et 
al [261] and Schwabe et al [262]. 
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Although the crosstalk between IL-1R and TLR3 has not been investigated before, 
the studies exemplified above confirm our observations that signals triggered by 
both IL-1α and Poly I:C may be transduced by IKK2 and TAK1, and that it can be 
blocked using glucocorticoid drugs.  
4.15.3 Role of viral infections in chronic post-transplant lung rejection 
 
My study demonstrated that Poly I:C an analog of viral dsRNA ma activate innate 
immune responses in primary human lung fibroblasts.  
Viral infections have been recognized as an important factor contributing to the 
pathogenesis of many chronic inflammatory diseases.  
Following infection viruses replicate inside cells and therefore TLRs sensing viral 
PAMPs are located intracellularly. Two main TLRs capable to recognize viral danger 
signals include TLR3, sensing double stranded viral RNA and TLR7, able to bind 
single stranded viral RNA. Both TLR3 [263] and TLR7 [264] are located cytosolically 
in the endosomal membrane. 
Another two receptors implicated in the recognition of double stranded viral RNA 
include RIG-I (retinoic-acid-inducible protein I/Ddx58) and MDA5 (melanoma-
differentiation-associated gene 5/Ifih1). Although, both of these receptors are able 
to bind double stranded RNA, a study performed by Kato et al, demonstrated that 
there are differential roles of RIG-I and MDA5 in the recognition of RNA viruses. 
Using RIG-I-/- and MDA5-/- mice, Kato and al, have shown that RIG-I is required for 
the interferon production following infection with paramyxoviruses, influenza virus 
and Japanese encephalitis virus, while MAD5 is essential for picornavirus detection. 
Moreover the study revealed that RIG-I and MAD5 deficiency in mice was 
associated with increased susceptibility to viral infections in comparison to the 
control (WT) group [265]. 
These results suggest that intacellular receptors able to recognize double stranded 
RNA are essential for effective clearance of viral pathogens. One of the main 
mechanisms involved in counteracting viral infections in production of type I 
interferons, which inhibit cell division. Activation of TLR3 [266], RIG-I [267] and 
MAD5 [268] leads to increased expression of type I interferons, which may inhibit 
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cell proliferation as well as many other proinflammatory cytokines including IL-8 
and IL-6.  
Upregulation of type I interferons and proinflammatory cytokines is essential for 
viral pathogen clearance during acute infection. However unresolved or repetitive 
infections may lead to chronic inflammation causing tissue injury and progressive 
degeneration of the respiratory epithelium.   
Viral infections have been associated with the pathogenesis of several chronic lung 
diseases including BOS [173], IPF [269] and lung cancer [270]. 
A retrospective study on 259 adult lung transplant recipients performed over a 5 
year period, demonstrated that patients with community-acquired respiratory viral 
(CARV) infections were more likely to develop BOS and BOS-related death [173].  
These observations were confirmed in another study performed by Billings et al, 
which demonstrated that patients with the lower respiratory tract infection with 
CARV showed predisposition to high-grade BOS development. Moreover the study 
has shown that patients BOS patients were predisposed to CARV infections, which 
may be due to immunosuppressive therapy that the lung transplant recipients are 
subjected to [271]. 
These results found confirmation in an animal study performed by Kuo et al, who 
have shown that infections with Sendai virus (SdV) can lead to enhanced tracheal 
allograft rejection in mouse and that this effect could be prevented by 
pretransplant immunization against SdV infection [272]. 
The results described above are in agreement with our observations that Poly I:C, a  
synthetic analog of double stranded viral RNA, accentuated fibroblast-mediated 
production of proinflammatory cytokines induced by IL-1α, suggesting that viral 
infection may exacerbate inflammation triggered by epithelial damage. This 
observation may explain why lung transplant recipients are more susceptible to 
viral infections. 
Apart from enhancing inflammatory responses, viral infections may contribute to 
fibrosis, which is characteristic for many degenerative diseases including BOS and 
IPF.  
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The relationship between viral infections and pulmonary fibrosis was confirmed in a 
study conducted by Qiao et al, revealing that mice infected with H5N1virus have 
developed interstitial and intra-alveolar fibrosis, thickened and collapsed alveoli, 
had elevated hydroxyproline levels and significantly increased dry lung-to-body 
weight ratio compared to the control group [273]. 
Although viral infections have been recognized as an important risk factor 
increasing the likelihood of complications following lung transplantation, coming in 
contact with viral pathogens is not a prerequisite for BOS development. 
Despite impaired immune system, whose functions in post-transplant patients are 
substantially limited by the immunosupresive therapy, viral infections are often  
effectively combated and cleared in BOS patients. There is however a vast spectrum 
of viruses which developed sophisticated mechanisms which allow them to 
effectively multiply in the immunosupressed microenvironment.  
One of the mechanisms allowing selected viruses for more effective succession is 
the encoding of the nonstructural proteins NS1 and NS2, which regulate cellular 
RNA transport, splicing and translation and acts as interferon inhibitors. Genes 
encoding NS1 and NS2 proteins have been found in RNA of viruses such as influenza 
virus H5N1 [274] and human respiratory syncytial virus (RSV), that has been 
implicated as an important risk factor in BOS [275]. 
Considering that type I interferons by suppressing viral replication, provide the main 
mechanism of defense against viruses, NS1 and NS2-dependant inhibition of 
interferon activity may have serious implications in patients whose functions of the 
immune system has been compromised by the immunosupresive therapy.  
Although the exact mechanism of NS1 and NS2-dependant inhibition of interferon 
function is unclear, several lines of evidence suggest that it may be executed by the 
supression of Stat2 expression, which acts as a signaling molecule within Interferon-
α/β receptor (IFNAR) signaling pathway [275]. 
Another virus that often affects lung transplant recipients is cytomegalovirus (CMV), 
however its role in BOS pathogenesis is controversial [276]. 
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Studies performed by Paraskeva et al [172] and Danziger-Isakov et al [277], suggest 
that there is an association between CMV infection and BOS development.  
4.15.4 Steroid and macrolide resistance in chronic lung allograft rejection  
 
Current immunosuppressive drugs used in lung transplant recipients include 
calcineurin inhibitors such as cyclosporine or  tacrolimus and corticosteroids such as 
prednisolone and therapies in bronchiolitis obliterans syndrome include macrolide 
antibiotics, mainly azithromycin [183]. Our study revealed that inflammation 
induced by IL-1α in fibroblasts can be partially blocked by the corticosteroid drug, 
dexamethasone, but not with azithromycin. Interestingly, both drugs were able to 
partially inhibit production of proinflammatory cytokines triggered by Poly I:C. 
Glucocorticoid drugs, including dexamtethasone, act via a cytoplasmic, 
glucocorticoid receptor (GR) [278]. Upon ligand binding, GR is translocated from 
cytoplasm to nucleus, where it functions as a transcription factor activating a vast 
array of anti-inflammatory genes including lipocortin I and p11/calpactin binding 
protein, downregulating release of arachidonic acid [279], secretory leucocyte 
protease inhibitor (SLPI) [280], and the decoy IL-1 type II receptor [281]. 
Steroids are effective anti-inflammatory drugs, however a large number of patients 
affected by chronic inflammatory diseases develop steroid resistance [282]. 
Glucocorticoid resistance has been recognized as a major obstacle in the treatment 
of a vast array of diseases including COPD [283], acute respiratory distress 
syndrome [284], asthma [285], rheumatoid arthritis [286], and inflammatory bowel 
disease [287]. Extensive studies identified several potential mechanisms responsible 
for this process, with the most probable being: activation of (MAP) kinase pathways 
by certain proinflammatory cytokines [288], upregulation of macrophage migration 
inhibitory factor (MIF) [289], increased activation of the transcription factor 
activator protein 1 (AP-1) [290], reduced histone deacetylase-2 (HDAC2) expression 
[291], and increased P-glycoprotein-mediated drug efflux [292]. 
Patients who developed steroid resistance may be subject to alternative anti-
inflammatory therapies using inhibitors of calcineurin [293], phosphodiesterase 4 
[294] or NFκB [295], although these drugs are associated with severe side effects.  
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My study demonstrated that inflammation induced by IL-1α can be effectively 
reduced using glucocorticoids. Therefore, anti-IL-1α therapies using IL-1Ra or 
monoclonal anti-IL-1α antibodies could be considered as potential treatment to 
reduce inflammation in patients who do not respond to glucocorticoids. IL-1Ra has 
been clinically tested and its use is not associated with major side effects, which 
makes it a promising candidate for an anti-inflammatory drug to treat long-lasting  
conditions [296].  
Additionally, the current study demonstrated that inflammation induced by a 
suboptimal dose of 100pg/ml of IL-1α could not be effectively reduced by 
azithromycin, which is commonly used to treat chronic post-transplant lung 
rejection. It is estimated that azithromycin is effective in approximately 50% of 
post-transplant patients who develop BOS. The exact mechanism of action of this 
macrolide antibiotic is still to be unraveled, however according to some studies 
azithromycin reduces inflammation by inhibiting production of proinflammatory 
cytokines. Interestingly, azithromycin was shown to be effective also in BOS patients 
who remained infection free, suggesting that its mechanism of action is not 
narrowed down to anti-microbial properties. Although azithromycin was 
demonstrated to be beneficial for a significant number of patients who developed 
chronic post-transplant lung rejection, many subjects do not respond to macrolides, 
which is a significant obstacle in the treatment of BOS. 
Many bacteria commonly found in post-transplant patients, including Streptococci 
spp., eg. Streptococcus pneumoniae, Staphylococcus aureus and nontuberculous 
mycobacteria may develop resistance to macrolides, which partially explains the 
basis of azithromycin resistance. [297].The results described in the current study 
suggest that anti-IL-1α compounds could be considered as a potential anti-
inflammatory therapy for post-transplant patients who are unresponsive to 
azithromycin.   
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4.15.5 PRR expression and responsivenes to Damage and Pathogen Associated 
Molecular Patterns of cells participating in mediating innate immunity in the lung 
 
The pattern of PRR expression is cell and tissue specific.  High expression of the 
majority of PRR has been found in alveolar macrophages and neutrophils, which are 
responsible mainly for mediating inflammatory responses to bacterial danger 
signals. Interestingly, my study revealed that primary human alveolar macrophages, 
in contrary to primary human lung fibroblasts and bronchial epithelial cells, do not 
respond to IL-1α or IL-1β, suggesting that the inflammatory responses to IL-1R 
ligands are mediated by structural rather than immune cells. However, one of the 
limitations of the study was the fact that the only available source of primary 
human alveolar macrophages were BALs from post-transplant patients, and 
therefore it cannot be rulled out that macrophages derived from airways of healthy 
subjects could respond to IL-1 treatment in a different way. 
The primary macrophages used in the study responded positively to PA treatment, 
which indicates that these cells exhibit functional TLR2 and TLR4 signaling. 
TLR2 is able to recognize a vast array of bacterial wall components including 
peptidoglycan and lipoarabinomannan, which is a glycolipid derived from 
Mycobacterium tuberculosis [298], while TLR4 ligands LPS (a cell wall component of 
gramm-negative bacteria) [299], respiratory syncytial virus protein F [300], and 
Taxol, a plant derived product, possessing anti-mitotic properties that is currently 
used in anti-cancer therapy [301]. Another TLR that is able to recognize bacterial 
danger signals is TLR5, which may bind flagellin, a structural protein present in the 
flagellum of almost all flagellated bacteria including Helicobacter pylori and 
Esterichia coli [302]. TLRs expressed in the lung are also able to recognize 
endogenous danger signals including β-defensins (recognized by TLR4) [303], HSP60 
(a TLR2 ligand) [304] and fibronectin fragments (TLR4 ligands) [305] that are 
generated in response to tissue injury.  
Although alveolar macrophages has been considered to be the key mediators of 
innate immune responses in the lung, increasing evidence, including the present 
study, suggests that also structural cells may play an important role in this process.  
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Type II human alveolar epithelial cells were found to express TLR2 mRNA transcripts 
and protein, suggesting that the respiratory epithelium may be involved in 
mediating infalammatory responses to mycobacterial PAMPs such as peptidoglycan, 
lipoteichoic acid, lipoproteins, and lipoarabinomannan [306]. Moreover TLR2 and 
TLR4 were demonstrated to be involved in pathogen clearance following infection 
with Mycobacterium tuberculosis, the causative agent of the majority of 
tuberculosis cases [307].  
Innate immune responses to pathogen derived danger signals may also be mediated 
by bronchial epithelial cells that showed increased levels of β-defensins and IL-8 
following treatment with E. coli derived LPS [308]. A detailed information on the 
TLR expression pattern in primary human bronchial epithelial cells has been 
provided by study performed by Mayer et al, who report that these cells express 
functional TLR1-6 and TLR9. Moreover the authors have demonstrated that PBEC 
cells respond much stronger to Gram positive than Gram negative bacteria, which 
may be due to the lack of expression of CD36, which functions of a co-receptor 
supporting TLR2 signaling [309]. 
Additionally, my study demonstrated that primary human bronchial epithelial cells 
are responsive to IL-1α, suggesting that damage to epithelium may trigger the 
inflammatory responses in adjacent epithelial cells in a paracrine manner.  
Bronchial and alveolar epithelial cells pose the first line of defense against invading 
pathogens and microparticles in the lung. However in many chronic inflammatory 
lung diseases the respiratory epithelium undergoes a progressive degenerative 
process and becomes replaced by intensively proliferating myofibroblasts which 
may take over the role of the innate immune response mediators.  
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CHAPTER 5 IL-1α AND OTHER PROINFLAMMATORY CYTOKINE PROTEIN PROFILING 
IN LUNG ALLOGRAFT RECIPIENTS 
 
5.1 Background 
 
Chronic lung allograft dysfunction produces a significant loss of function of the 
transplanted lung and is believed to represent the process of chronic rejection and 
accounts for the limited long term survival after lung transplant [13]. When the 
process affects the small and medium sized airways causing airflow limitation it is 
referred to as bronchiolitis obliterans syndrome (BOS). BOS is commonly a 
progressive condition and is often accompanied by repeated or chronic lower 
respiratory tract infection. Histologically, BOS is characterized by progressive loss of 
bronchial epithelium, neutrophil influx, chronic inflammation and fibroproliferation 
causing small airway obliteration. Interestingly, small airway scarring may also occur 
in non-transplant patients suggesting that allogenic reaction is not a prerequisite for 
epithelial degeneration [310]. Numerous studies suggest that specific viral or 
bacterial infections significantly increase the risk of developing BOS both in post-
transplant and non-transplant patients [310, 311]. Continuous tissue injury that may 
be caused by repeated or unresolved infection which may lead to release of 
alarmins, activation of innate immunity and attraction of ROS-producing neutrophils 
that drive the vicious cycle of chronic inflammation [95]. 
Chronic inflammation and progressive fibroproliferation are the two characteristic 
features of BOS [312]. The relevance of IL-1α in BOS has not been evaluated before 
and therefore to address the clinical relevance of this alarmin in BOS, IL-1α 
concentrations were measured in BALs of 52 post-transplant patients patients who 
developed BOS or remained stable. Additionally, a correlation between IL-1α levels, 
IL-8 and neutrophil percentage was assessed.  
The levels of IL-1α and other selected peoinflammatory cytokines were also 
measured in BALs of post-transplant who developed different phenotypes of 
chronic post-transplant lung rejection. 
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Hypotheses tested: 
1. Increased IL-1α levels in BALs of lung transplant recipients are associated 
with development of BOS. 
2. IL-1α levels positively correlate with IL-8 concentrations and neutrophil 
percentage in BALs of post-transplant patients. 
3. Neutrophilic phenotypes of chronic post-transplant lung rejection (ARAD - 
Azithromycin reversible allograft dysfunction and PAN - persistent airway 
neutrophilia), are characterized by increased IL-1α levels in BALs. 
 
 
5.2 Characteristics of patients participating in the study 
 
Fifty two lung transplant recipients within 3 years of transplantation were identified 
from a cohort under follow up at the Institute of Transplantation, Freeman Hospital, 
Newcastle (table 5). These included 26 who developed chronic lung allograft 
dysfunction as BOS (16 Male and 10 Female) and 26 who remained stable and BOS-
free (21 Male and 5 Female). All recipients had undergone surveillance 
bronchoscopic evaluation at 1, 3, 6 and 12 months post transplant and again at the 
time BOS was suspected or diagnosed.  A standardized bronchoalveolar lavage (BAL) 
comprising 180mls of sterile normal saline was performed from a subsegment of 
the right middle or lower lobe or left lower lobe.  119 BAL samples were collected 
from the group who developed BOS and 94 BAL samples were collected from the 
stable group.  
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BOS group 
No. of Patients    n=26  
Median Age    46 years  
Age range    23 - 63 years  
Sex distribution    10 Female : 16 Male  
Underlying 
condition  
COPD (n=9), Cystic Fibrosis (n=7), Fibrotic Lung Disease (n=5), alpha-1 
anti-  trypsin deficiency (n=2), Asthma (n=1), Hystiocytosis X (n=1), 
Lymphangioleiomyomatosis (n=1) 
Mean BAL 
samples  
5 / patient  
Type of 
Transplant  
17 Bilateral Lung : 9 Single Lung  
Organisms 
cultured from 
BAL  
Pseudomonas Aeruginosa (n=19), Candida Albicans (n=13), Aspergillus 
fumigatus (n=6), Proteus Mirabilis (n=4), Stenotrophomonas maltophilia 
(n=4), Staph Aureus (n=2), Acinetobacter baumannii (n=1), Enterobacter 
cloacae (n=1), Haemophilus influenza (n=1), Serratia (n=1), Klebsiella 
pneumonia (n=1) 
 
 
non-BOS group 
 
 
No. of Patients    n=26  
Median Age    45 years  
 Age range    19 - 64 years  
Sex distribution    5 Female : 21 Male  
Underlying 
condition  
  Cystic Fibrosis (12), Fibrotic Lung Disease (8), COPD (2), alpha-1 anti-
trypsin deficiency (2), Primary Pulmonary Hypertension (1), 
Bronchiectasis (1) 
Mean BAL 
samples  
  3.62 / patient  
 Type of 
Transplant  
18 Bilateral Lung, 7 Single Lung and 1 Heart-Lung  
Organisms 
cultured from 
BAL  
Pseudomonas Aeruginosa (14), Candida Albicans (18), Proteus Mirabilis 
(), Aspergillus fumigatus (7), MRSA (7), Staph Aureus (4), E. Coli (2), 
Serratia (1), Burkholderia cepacia complex (1), Exophiala sp (1). 
 
Table 12 Demographics of lung transplant recipients participating in the study  
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5.3 Levels of IL-1α in BALs of post-transplant patients in lead up to BOS diagnosis  
 
To evaluate the clinical relevance of the investigated alarmins as mediators of 
inflammation in human degenerative lung disease, IL-1α and HMGB-1 levels were 
measured in bronchoalveolar lavage (BAL) fluid collected longitudinally from 26 lung 
transplant recipients in follow up to BOS diagnosis. An MSD and ELISA analysis 
revealed that in patients, HMGB-1 levels did not change (data not shown) in the 
lead up to BOS whereas levels of IL-1α were significantly higher upon BOS diagnosis 
(4.71 (1.12-14.67) pg/ml) than when measured at least 3 months before the disease 
was recognized (2.01 (0-14.67) pg/ml) (Figure 61).  
One of the risk factors, significantly increasing the risk of developing BOS post 
transplantation are bacterial, viral and fungal infections. Invading pathogens not 
only contribute to chronic inflammation, but may also cause tissue damage. 
Therefore to assess the effect of pathogen-induced airway injury on IL-1α 
concentration, the influence of bacterial infections on inflammatory parameters 
was examined in 26 lung transplant recipients who developed BOS and an age 
matched control group of 26 who remained free from BOS. The MSD analysis 
revealed that lung transplant recipients with positive BAL bacterial cultures had 
higher BAL concentrations of IL-1α (BOS 4.38 (0.64-40.11); non-BOS 3.36 (0-63) 
pg/ml) compared to patients whose BAL cultures were negative for bacteria (IL-1α: 
BOS 2.41 (0-19.08); non-BOS 1.42 (0-17.41) pg/ml) (figure 61). The same pattern 
was also observed for IL-8 (figure 63). 
The expression of IL-1α protein in human bronchial and alveolar epithelium was 
confirmed using immunohistofluorescence (figure 62). This observation confirms 
that injured respiratory epithelium may be one of the potential sources of IL-1α in 
BAL. 
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Figure 61 IL-1α levels in BALs of post-transplant patients in lead up to BOS 
diagnosis. 
IL-1α (A) concentrations in BALs of lung transplant recipients who develop BOS:  
Group 1: BAL samples taken >3 months before BOS diagnosis (>3 months before 
BOS), group 2: BAL samples taken in the 3 months before and after BOS diagnosis 
(<3 months before BOS). IL-1α (B) concentrations in culture positive (+ve) and 
culture negative (-ve) BAL from post-lung transplant recipients who went on to 
develop BOS (BOS) or remained stable (non-BOS). IL-1α concentrations were 
measured using MSD assay. Data was analyzed using Mann-Whitney U test and is 
presented as median.  *p<0.05, **p<0.01, ***p<0.001. 
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Figure 62 IL-1α protein expression in human (A) bronchial and (B) alveolar 
epithelium visualized with immunohistofluorescence using anti-human IL-1α 
antibody. (C) Secondary antibody control (staining performed in the presence of 
the secondary antibody conjugated with FITC but in the absence of the primary 
antibody). Magnification: x20. 
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Figure 63 IL-8 levels in BALs of post-transplant patients in lead up to BOS 
diagnosis. 
IL-8 (A) concentrations in BALs of lung transplant recipients who develop BOS:  
Group 1: BAL samples taken >3 months before BOS diagnosis (>3 months before 
BOS), group 2: BAL samples taken in the 3 months before and after BOS diagnosis 
(<3 months before BOS). IL-8 (B) concentrations in culture positive (+ve) and culture 
negative (-ve) BAL from post-lung transplant recipients who went on to develop 
BOS (BOS) or remained stable (non-BOS). Data was analyzed using Mann-Whitney U 
test and is presented as median.  *p<0.05, **p<0.01, ***p<0.001. 
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5.4 Correlation between IL-1α, IL-8 concentrations and neutrophil percentage in 
BALs of post-transplant patients who developed BOS 
 
One of characteristic clinical features of BOS is increased number of neutrophils in 
BAL. Neutrohils may occur as an aftermath of infection or tissue damage and their 
main role is to fight invading pathogens and to help restore tissue architecture. 
Unresolved inflammation may result in accumulation of neutrophils in the lung, 
which may lead to further epithelial damage. The main chemotactic cytokine 
promoting neutrophil migration is IL-8. 
Therefore to establish if there is a relationship between the levels of IL-1α, IL-8 and 
neutrophil percentage in BAL of post-transplant patients, a correlation analysis was 
performed using Spearman’rank correlation coefficient. The analysis revealed that 
there was a positive and statistically significant correlation between IL-1α 
concentrations and neutrophil percentage (figure 64) and IL-1α and IL-8 levels 
(figure 65). 
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Figure 64 Correlation between IL-1α concentrations and neutrophil percentage in 
BALs of post-transplant patients who developed  BOS. 
Correlation between IL-1α concentrations in BALs of BOS patients and percentage 
of neutrophils over total cell number. Correlation was tested using Spearman rank 
correlation coefficient. 
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Figure 65 Correlation between IL-1α and IL-8 concentrations in BALs of post-
transplant patients who developed  BOS. 
Correlation between IL-1α and IL-8 concentrations in BALs of BOS patients was 
tested using Spearman rank correlation coefficient. Note, Y axis is in logarithmic 
scale. 
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5.5 Correlation between IL-1α levels and selected proinflammatory cytokine 
protein concentrations in BALs of post-transplant patients 
 
The in vitro experiments conducted during the study demonstrated that IL-1α 
released from damaged epithelial cells is able to significantly increase expression of 
numerous proinflammatory cytokines including IL-8, IL-6, MCP-1 and GM-CSF. All 
these cytokines may be produced by activated fibroblasts. IL-8 is a potent 
chemokine, attracting neutrophils to the site of injury, which may explain a positive 
correlation between IL-1α concentrations and neutrophil percentage described in 
above. MCP-1 and GM-CSF function as activations and cheoattractants for 
macrophages which are a powerful source of proinflammatory cytokines such as 
TNFα and IL-1β. Therefore it may be hypothesized that a positive correlation could 
also be observed in BALs between IL-1α and TNFα and IL-1β even though they are 
directly not produced  by fibroblasts. 
To test this hypothesis, the levels of IL-1α and selected proinflammatory cytokines 
including IL-8, IL-6, TNFα and IL-1β were measured in BALs of two individual cohorts 
of post-transplant patients (Newcastle study n=26, Leuven study n=70) and a 
correlation analysis using Spearman’rank correlation coefficient was performed. 
The analysis revealed that here was a positive and statistically significant correlation 
between IL-1α concentrations and the levels of all the measured cytokines in both 
patient cohorts (figure 66 and 67). 
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Figure 66 Correlation between IL-1α levels and selected proinflammatory cytokine 
protein concentrations in BALs of post-transplant patients (Newcastle study). 
 
Concentrations of selected IL-1α, IL-1β, IL-6, TNFα were measured in BALs of post-
transplant patients using MSD. Correlations were tested using Spearman rank 
correlation coefficient.  
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Figure 67 Correlation between IL-1α levels and selected proinflammatory cytokine 
protein concentrations in BALs of post-transplant patients (Leuven study). 
 
Concentrations of selected proinflammatory cytokines were measured in BALs of 
post-transplant patients using MSD assay. Correlations were tested using Spearman 
rank correlation coefficient.  
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5.6 IL-1α and other proinflammatory cytokine protein profiles in different 
phenotypes of chronic lung allograft rejection  
 
Recently it has been suggested that chronic post-transplant lung rejection does not 
have a uniform pathophysiology, but in fact it can be divided into several different 
phenotypes depending on the magnitude of fibrotic changes, inflammation, 
deformations in tissue architecture and responsiveness to commonly used 
therapies including macrolide treatment [313] [314] [315]. Taking under 
consideration these parameters, the following BOS phenotypes have been 
proposed: ARAD (Azithromycin reversible allograft dysfunction), PAN (persistent 
airway neutrophilia), fBOS (fibroproliferative BOS) and RAS (restrictive allograft 
dysfunction). The ARAD and PAN are characterized by relatively high percentage of 
neutrophils in BAL and high levels of inflammation but very moderate level of 
fibrosis. fBOS patients show lower levels of BAL neutrophils and inflammation but 
very severe fibrosis causing airway obliteration. The RAS phenotype is characterized 
by relatively low levels of inflammation and limited presence of fibrotic lesions in 
the lung parenchyma, yet very substantial decline in lung function (FEV1). The 
proposed phenotypic dichotomy of chronic lung allograft dysfunction is presented 
in figure 68. 
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Figure 68 Phenotypic dichotomy of chronic lung allograft dysfunction 
Cytokine and alarmin profile of different chronic lung allograft dysfunction (CLAD) 
phenotypes have not been determined before, and therefore to address this issue 
levels of IL-1α, TNFα, IL-1β, IL-6 and IL-8 were measured with MSD in BALs of 50 
post-transplant patients who has been classified according to the criteria described 
above. 
The analysis revealed significant differences in the levels of the measured factors 
between the groups. The highest levels of IL-1α, IL-1β, TNFα, IL-8 and IL-6 were 
detected in the PAN group, while the concentrations of this cytokines in the fBOS 
group were comparable the control group (post-transplant patients who did not 
develop chronic lung allograft dysfunction). Increased levels of IL-6 were also 
observed in the RAS group, however this increase was not associated with 
upregulation of IL-1α, IL-1β or TNFα, suggesting that an alternative mechanism may 
be responsible for promoting IL-6 expression in this group (figure 69). 
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Figure 69 Proinflammatory cytokine protein concentrations in BALs of lung 
transplant recipients who developed different BOS phenotypes. 
ARAD (Azithromycin reversible allograft dysfunction), PAN (persistent airway 
neutrophilia), fBOS (fibroproliferative BOS) and RAS (restrictive allograft 
dysfunction). Data was analyzed using Mann-Whitney U test and is presented as 
median. 
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5.7 Influence of BALs from lung transplant recipients who developed distinctive 
phenotypes of chronic lung allograft rejection on PBEC cell viability 
 
One of the characteristics of chronic lung allograft dysfunction is progressive 
damage to bronchial epithelium. However this issue has not been studied in the 
context of different BOS phenotypes before. Therefore, to establish if any 
association exists between epithelial damage and different BOS phenotypes, 
primary bronchial epithelial cells were subjected to a 24hrs treatment with BALs 
(1:1 BAL to medium) collected from the 70 post-transplant patients who has been 
classified as ARAD, PAN, fBOS and RAS. Following the treatment, PBEC cell viability 
was assessed using XTT toxicity assay.  
The analysis revealed there was a significant decrease in viability of PBEC cells 
cultured in the presence of BALs collected from PAN patients (figure 70). 
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Figure 70 Primary human bronchial epithelial cell (PBEC) viability in reponse to 
BALs from lung transplant recipients who developed different BOS phenotypes 
 
PBEC cells were treated with 1:1 culture medium/BALs from lung transplant 
recipients who developed different BOS phenotypes for 24hrs, after which the cell 
viability was assessed by XTT assay. Data was analyzed using Mann-Whitney U test 
and is presented as mean ± S.M.E. 
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5.8 Correlation between IL-1α and other proinflammatory cytokine concentrations 
in BALs of post-transplant patients and PBEC cell viability in response to these 
BALs 
 
To further evaluate if there is any association between PBEC cell death and 
concentration of IL-1α and other proinflammatory cytokines present in BALs used to 
treat PBEC cells, a Spearman’s rank correlation coefficient was calculated. The 
analysis revealed that there was a negative correlation between IL-1α, IL-1β, IL-6, IL-
8 and TNFα levels in BALs and PBEC cell viability, suggesting that increased 
inflammation may be associated with epithelial damage (figure 71). 
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Figure 71 Correlation between PBEC cell viability and the levels of 
proinflammatory cytokines in BALs of lung transplant recipients 
PBEC cells were treated with 1:1 culture medium/BALs from lung transplant 
recipients who developed different BOS phenotypes for 24hrs, after which the cell 
viability was assessed by XTT assay. The correlation between relative cell viability 
expressed as OD and cytokine concentrations in BALs was assessed using Spearman 
rank correlation coefficient. 
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5.9 Discussion 
5.9.1 Role of IL-1α in the pathogenesis of chronic inflammatory lung diseases 
 
Previous and the current study demonstrated that IL-1α and IL-1β are potent 
inducers of a vast plethora of proinflammatory cytokines including IL-6, IL-8, GM-
CSF, MCP-1 and TNFα, which modulate numerous processes including T cell 
maturation and polarization, macrophage and neutrophil chemotaxis and wound 
healing. IL-1α and IL-1β may also upregulate the expression of their own genes, 
exacerbating the inflammatory responses.  
All these cytokines are upregulated in many chronic inflammatory diseases 
including chronic post-transplant lung rejection and COPD [162] [135]. Macrophage 
and neutrophil influx is a hallmark of many injury- and pathogen-induces chronic 
diseases, and prolonged presence of these cells in the lung may cause the 
degeneration of the respiratory epithelium.  
The role of IL-1β in the pathogenesis of chronic inflammatory lung diseases has 
been relatively widely described. However the implication of IL-1α in this process 
has not yet been insightfully investigated, and our study for the first time 
demonstrated that there is a relationship between the progression of bronchilitis 
obliterans syndrome post lung transplantation and IL-1α concentrations in BALs. 
Although, the relevance of IL-1α has not been studied in the context of BOS before, 
there are reports linking IL-1α to neutrophilia in the COPD model of cigarette smoke 
induced inflammation in mice. Using IL-1α-/-, IL-1β-/- and IL-1R-/- mice, Botelho et 
all demonstrated that mice deficient in IL-1α and IL-1R showed decreased 
neutrophil influx to the lung following exposure to cigarette smoke. Interestingly, 
this process was independent of IL-1β and caspase-1 activation, suggesting that IL-
1α is the main inducer of neutrophil influx post exposition to cigarette smoke [316]. 
These results were confirmed by Pauwels et al, who demonstrated that cigarette 
smoke-induced inflammation in mouse is IL-1α dependant. Interestingly, in this 
study also IL-1β deficiency resulted in decreased production of proinflammatory 
factors, however this process was independent of inflammasome activation [317]. 
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Both IL-1α but not IL-1β may stimulate secretion of IL-8 from cells such as 
fibroblasts, epithelial and endothelial cells. The fact that in the two above described 
models of lung injury neutrophilia was IL-1α and not IL-1β dependant, may be 
explained by the different mechanisms underlying the release of these two 
cytokines.  
My study demonstrated that IL-1α and not IL-1β is predominantly released by 
damaged normal human bronchial epithelial cells. Using a sensitive MSD analysis we 
established that detectable levels of IL-1α and IL-1β were present in BALs of lung 
transplant recipients who developed BOS (the current study and [179]). We also 
showed that although IL-1α upregulated IL-1β mRNA expression in fibroblasts it did 
not cause IL-1β protein release (data not shown).  
Previous studies have shown that one of the main sources of IL-1β in inflamed 
tissues are macrophages [318] which tend to colonize chronically inflamed organs, 
and whose number in the lung tissue and BALs is significantly higher in COPD [319] 
and BOS [320] patients compared to healthy controls, which may indicate that IL-1β 
levels in the lung increase following macrophage influx. IL-1α release form damaged 
cells may therefore precede IL-1β secretion from macrophages invading the injured 
organ afterwards, which may explain why IL-1α and not IL-1β deficiency is sufficient 
to reduce neutrophil influx following tissue injury.  
Moreover, my study demonstrated that IL-1α may stimulate secretion of GM-CSF 
and MCP-1 from fibroblasts. These two cytokines function as macrophage 
chemokines and activating factors respectively, suggesting that IL-1α may also be 
involved in mediating macrophage influx to the lung.  
Although I did not investigate the relationship between IL-1α and macrophage 
percentage in BALs of post-transplant patients, previous reports suggest that there 
is a positive correlation between these two factors in the lung [321]. 
Additionally a study performed by Fitzgerald et al., confirmed my observation that 
fibroblasts may function as a source of GM-CSF, which can mediate macrophage 
migration. In this study, fibroblasts gained the ability to produce GM-CSF following 
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exposure to TNFα and IL-1β or conditioned media from activated macrophages, 
which are a powerful source of these two cytokines [322].  
These results are in compliance with my observations, that fibroblasts may produce 
proinflammatory cytokines in response to TNFα, suggesting that they may also 
function as important mediators of inflammation at the later stages of disease, 
when the production of proinflammatory factors is mediated mainly by 
macrophages, colonizing the inflamed lung.  
One of the underlying causes of chronic inflammatory lung diseases is unresolved 
bacterial or viral infection. Pathogen-induced inflammation is mediated mainly by 
immunocytes with macrophages being the key players in this process. One of the 
cytokines released by macrophages activated by PAMPs is IL-1β, which similarly to 
IL-1α is a powerful inducer of proinflmmatory factor expression. The role of IL-1β in 
pathogen clearance during lung infection has been confirmed in a study performed 
by Kafka et all, who demonstrated that mice deficient in IL-1β show higher mortality 
rate following Streptococcus pneumoniae infection in comparison to WT controls or 
IL-1α-/- mice [323]. This observation indicates that IL-1β and not IL-1α plays a 
pivotal role in bacteria clearance during infection. Since IL-1β is strongly 
upregulated in chronic inflammatory lung diseases such as COPD and BOS, it has 
previously been suggested that anti-IL-1β therapies could be considered as a 
treatment in this diseases. However, the known role of IL-1β in the process of 
pathogen clearance, raised a question of the potential hazardous implications, that 
anti-IL-1β therapies may have in patients affected by bacterial infections.  
The study conducted by Kafka et al, suggests that blocking IL-1α does not 
significantly affect the ability of the pulmonary immune system to fight infection, 
indicating that anti-IL-1α therapies could be used to dampen down inflammation 
induced by epithelial injury in patients suffering from bacterial infections. 
Safe and effective inflammation management in post-transplant patients is a matter 
of great importance. Until quite recently, one of the most popular anti-
inflammatory strategies post-transplantation was corticosteroid therapy. However 
this kind of treatment is associated with many side effects and a large percentage of 
patients suffering from chronic inflammation develop steroid resistance. Currently, 
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patients affected by chronic post-transplant lung rejection are subjected to 
macrolide antibiotic treatment, however this therapy is effective only in approx. 
50% of cases [324]. Anti-IL-1α treatment has not been tested on BOS patients yet, 
however our and previous studies, suggest that this kind of treatment could allow 
to manage inflammation induced following epithelial injury, relatively safely, with 
minimal side effects and without the risk of uncontrolled infection.  
The role of IL-1 was also investigated in the context of viral respiratory infection in 
mouse induced by influenza virus. Using IL-1R-/- mice, Schmitz et al demonstrated 
that IL-1 is required for neutrophil and CD4+ cell influx following influenza infection, 
however it does not have a major impact on virus titrate. The study however did not 
address the individual role of IL-1α in this process [325]. 
My study revelaed that there is an association between increased levels of IL-1α in 
BALs and bacterial infections. One of the limitations of the current study is its 
retrospective character and the lack of data on viral infections in the examined 
cohort of patients. To address these issues, a re-designed prospective study could 
be performed in the future.  
 
5.9.2 Role of bacterial infections in chronic post-transplant lung rejection 
 
Bacterial infections have been recognized as an important risk factor of many 
chronic degenerative diseases, including chronic post-transplant lung rejection. The 
immunosuppressive drug regime, that lung transplant recipients must adhere to, 
makes this group of patients highly prone to both viral and bacterial infections.  
My study demonstrated that bacterial infections in lung transplant recipients who 
developed BOS were associated with significantly higher levels of proinflammatory 
cytokines including IL-8, when compared to post-transplant patients who remained 
stable, which may be due to significantly higher levels of IL-1α in BALs of BOS 
patients who were culture positive.  
The association between high levels of IL-1α and bacterial colonization, finds 
explanation in several studies demonstrating that bacterial PAMPs such as LPS may 
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stimulate expression of IL-1α [326] [327]. Moreover bacterial pathogens invading 
lung may cause damage to the bronchial and alveolar epithelium, inducing IL-1α 
release from injured epithelial cells. Unresolved bacterial infections, which are a 
common complication in patients subjected to a strict immunosuppressive regime, 
may therefore exacerbate inflammation by triggering production of 
proinflammatory cytokines directly via interactions between PAMPs and 
corresponding TLRs and indirectly via upregulation of IL-1α expression and the 
induction of its release by injuring the epithelial layer.  
Bacterial pneumonia is a frequent complication following lung transplantation. 
Recent studies demonstrated that bacterial microbes were isolated in up to 80% of 
lung transplant recipients [328]. A multicenter prospective study performed within 
the period of 2 years on a cohort of 236 lung transplant recipients (LT), revealed 
that the incidence of bacterial infections in this group was 72 episodes per 100 
LT/year. Pseudomonas aeruginosa was isolated in 24.6%, Acinetobacter baumannii 
and Staphylococcus aureus each in 14%, Escherichia coli, Klebsiella pneumoniae, 
and Stenotrophomonas maltophilia each in 5.3%, Pseudomonas putida, Serratia 
marcescens, and Burkholderia cepacia each in 1.8%, and Mycobycterial infections 
were found in 5.3% of cases [328].  
Pseudomonas aeruginosa is the most frequently isolated bacteria from lung 
following transplantation. Several studies demonstrated that lung transplant 
recipients with cystic fibrosis show higher susceptibility to infection caused by this 
bacteria, which may spread from extrapulmonary reservoirs of the recipient [329] 
[174]. 
Moreover, two independent studies [174] [330] demonstrated that the frequency 
of lung colonization with Pseudomonas aeruginosa can be associated with BOS. 
Increased incidence of BOS has also been reported in lung transplant recipients 
affected by infections with Burkholderia cepacia [331], Chlamydia pneumonia [332] 
and Mycobacterium tuberculosis [333]. 
Apart from pulmonary infections, another common complication affecting lung 
transplant recipients is bacteremia, defined as a presence of bacteria in blood. 
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A prospective, multicentre study performed between 2000-2004, revealed that 
bacteremia was documented in 56 of lung transplant recipients and that multiple 
antibiotic resistance was registered in 48% of the isolates. The most frequent 
isolates included P. aeruginosa (14/56), S. aureus (9/56) B. cepacia (5/56), 
Enterococcus faecalis (5/56), Staphylococcus epidermidis (4/56), and Klebsiella 
pneumoniae (4/56) [334]. 
Complications following lung transplantation have also been attributed to fungal 
infection, which are estimated to affect 15 to 35% lung allograft recipients. It has 
been established that 80% of all fungal infections post transplantation is caused by 
Aspergillus spp. and Candida spp. [335].  
A study by Saïd-Sadier demonstrated that inflammatory responses to conidia and 
hyphae of Aspergillus fumigates may be NLRP3 and inflmmasome dependant and 
are manifested by caspase-1 activation and increased secretion of IL-1β by 
monocytes [336]. 
This data is in compliance our recent onservations showing that bacterial infections 
are associated with upregulation of proinflammatory cytokines including IL-1α, 
TNFα, IL-1β and IL-8 in BALs of post-transplant patients who developed BOS (the 
current study and [179]).  
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CHAPTER 6 SUMMARY DISCUSSION 
6.1 Fibroblasts as mediators of immune responses 
 
Although fibroblasts are historically considered as cells whose main role is the 
production of the components of the extracellular matrix and tissue contraction 
during the wound healing process, emerging evidence suggests that fibroblasts may 
also function as important mediators of immune responses. Our study revealed that 
primary human lung fibroblasts express high levels of IL-1R and TLR3, suggesting 
that they may mediate immunity induced by IL-1α, IL-1β as well as by viral double 
stranded RNA and endogenous RNA, which may also be released from injured cell 
[337]. 
Primary human lung fibroblasts expressed also low levels of transcripts for TLR2 and 
TLR4, however they did not respond to LPS or HMGB-1, which distinguishes them 
form macrophages, which very strongly respond to TLR2 and TLR4 ligands.  
Human lung fibroblasts responsiveness to IL-1 and a synthetic TLR3 ligand – Poly I:C, 
suggest that these cells may play a pivotal role as inflammation mediators during 
tissue injury and viral but potentially not bacterial infections. Progressive tissue 
degeneration is characteristic for many chronic diseases including chronic post-
transplant lung rejection. Viral infections have been recognized as one of potential 
risk factors, increasing the probability of developing BOS post transplantation. 
Considering that fibroblasts become one of the most abundant cell type is fibrotic 
tissues, it may be therefore hypothesized that they play an important role in 
mediating chronic inflammation in BOS patients affected by viral infections.  
Fibroblasts are also a source of type I interferons, which inhibit proliferation of 
virus-infected cells. This fibroblasts characteristic not only is of significant 
physiological importance,  but it also found a practical implication, as fibroblasts 
induced with riboinosinic-ribocytidylic acid are used to produce human interferon 
for clinical use [338].  
The TLR gene expression profile in primary human lung fibroblasts have not been 
described in literature before. There are however reports investigating PRR gene 
expression in human gingival, synovial and skin fibroblasts.  
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According to the study performed by Uehara et al, human gingival fibroblasts 
express mRNA for TLR1-9 and respond to selected PAMPs including FSL-1 (a 
synthetic lipoprotein derived from Mycoplasma salivarium functioning as TLR2/TLR6 
ligand), Poly I:C (TLR3 agonist), lipid A (a component of LPS, activating TLR2 and 
TLR4), ssPolyU (TLR8 agonist) and CpG DNA (TLR9 ligand), suggesting that these cells 
may play an important function in promoting inflammatory responses to viral and 
bacterial danger signals [339]. 
The skin and synovial fibroblasts were found to express transcripts for TLR1-6, with 
TLR2 and TLR3 being significantly higher in the synovial fibroblasts. Moreover both 
skin and synovial fibroblasts responded positively to bacterial lipopeptide, poly (I:C), 
lipopolysaccharide and flagellin by producing increased amounts of MMP1, MMP3, 
MMP9 and MMP13, suggesting these cells may participate in tissue remodeling 
following viral and bacterial infections [340].   
Moreover, synovial fibroblasts were found to produce a vast array of 
proinflammatory cytokines including granulocyte chemotactic protein (GCP)-2, 
RANTES, monocyte chemoattractant protein (MCP)-2, IL-8, growth-related 
oncogene-2, macrophage-inflammatory protein 1alpha, MCP-1, EXODUS, and CXCL-
16. GCP-2 and RANTES in response to bacterial the TLR-2 ligand bacterial 
peptidoglycan, suggesting that similarly to human lung fibroblasts, the synovial 
fibroblasts also may function as mediators of inflammation [341]. 
Interestingly, in my study, unlike synovial fibroblasts, neither MRC5 cells nor 
primary fibroblasts isolated from human lung tissues responded to TLR2 agonist 
treatment, indicating that there are distinctive differences between fibroblasts 
originating from different tissues.  
The role of human and lung fibroblast in mediating inflammation has recently been 
described in an elegant study performed by Kitamura et al, who demonstrated that 
mouse and human lung fibroblasts may regulate dendritic cell trafficking, airway 
inflammation, and fibrosis via integrin αvβ8–mediated activation of TGF-β.  
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The study revealed that conditional deletion of lung fibroblast αvβ8 led to inhibition 
of airway inflammation, and a reduction in innate and adaptive immune responses 
and fibrosis induced by adenovirus and IL-1β.  
Moreover the study demonstrated that human lung fibroblasts derived from COPD 
lung show increased responsiveness to IL-1β in terms of αvβ8-dependent TGF-β 
activation, collagen expression, and proinflammatory gene expression when 
compared with normal lung fibroblasts, suggesting that the microenvironment of 
tissue exposed to injurious stimuli may modulate fibroblast behavior [342]. 
Additionally, Saalbach et al., demonstrated that human dermal fibroblasts may 
interact with dendritic cells (DC) in a β2 integrins -Thy-1 (CD90)/ ICAM-1 dependant 
manner, leading to upregulation of CD83, CD86, CD80, and HLA-DR in DC. The study 
also demonstrated that fibroblast-induced DC may modulate T cells activation via 
induction of CD25 expression [343].  
The modulation of T cell responses by fibroblasts may be also performed via 
stimulation of IL-23 protein secretion by DC, which is required for Th17 cell 
differentiation [344]. 
All the studies cited above and the results described in this report suggest that 
fibroblasts may play pivotal role in regulating innate and adaptive immune 
responses, during tissue injury and infection. 
6.2 IL-1α as mediator of innate immune responses and its role in chronic 
inflammatory diseases and wound healing  
 
IL-1, initially named as LAF (lymphocyte-activating factor) was discovered in 1972 by 
Gery et al. [345]. However it was not until 1985, that it was recognized that IL-1 
consists of two different proteins, currently known as IL-1α and IL-1β [346]. The 
majority of studies, published since then, focused on the biology of IL-1β. One of 
the reasons behind this, was that the concentrations of IL-1β during inflammation 
induced by injury or infection, are significantly higher compared to IL-1α levels. 
The functions and origin of IL-1β have been thoroughly investigated and now it is 
clear that activated macrophages are one of the main sources of this protein during 
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inflammation. IL-1β, alike other members of IL-1 family, lacks a signal peptide and 
cannot be conventionally secreted to the extracellular space. IL-1β is expressed as a 
pro-peptide, which requires a proteolitic cleavage by caspase-1. One of the 
characteristic properties of macrophages is constitutive expression of caspase-1, 
meaning that these cells are able to secret active IL-1β without inflammasome 
activation. Macrophage stimulation with LPS is sufficient to promote these cells to 
IL-1β secretion. However, the same stimulus will not induce IL-1β release from 
epithelial cells or fibroblasts.  
Little however is known about the potential sources of IL-1α in tissue and the role of 
this IL-1 family member in the pathogenesis of chronic inflammatory lung diseases.  
The clinical relevance of IL-1α in BOS has not been investigated before. In the 
current study we demonstrated, that elevated levels of IL-1α and IL-1β can be 
detected in BALs of post-transplant patients who developed chronic post-transplant 
lung rejection. The concentrations of IL-1α were significantly lower than IL-1β (data 
not shown), however, after correction for the BAL dilution factor, they were 
sufficient to trigger expression of proinflammatory cytokines in fibroblasts. 
Moreover, I demonstrated that high IL-1α levels were associated with decreased 
PBEC cell viability following BAL administration, suggesting that there is a 
correlation between epithelial injury and IL-1α release.  
Since epithelial degeneration is characteristic for many chronic inflammatory 
diseases, many studies have been performed in order to identify alarmins 
responsible for mediating inflammatory responses under these conditions [347]. 
These studies however, mainly aimed at identification of DAMPs released from 
immune cells such as macrophages or neutrophils, based on assumption that the 
danger signals originate from immunocytes undergoing apoptosis following 
pathogen/cell debris engulfment.   
However, emerging evidence suggests that alarmins may also originate from 
damaged epithelium. Using primary bronchial epithelial cells (PBECs) and a human 
bronchial epithelial cell line (16HBE14o-), we demonstrated that damaged epithelial 
cells may be a source of alarmins including HMGB-1 and IL-1α. These results were 
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confirmed using three different types of injury, including H2O2- induced oxidative 
stress, freeze/thaw damage and thapsigarging-induced ER stress. Oxidative stress 
and ER stress may module gene expression and change the metabolic state of cells. 
Freeze/thaw damage however, results in a very rapid, necrotic cell injury and 
therefore may serve as a reliable control, confirming that the alarmin release is a 
result of cell death, rather than a consequence of the cell exposition to a chemical 
stimulus.  
Additionally, the observation, that epithelial cells release IL-1α following injury 
induced by thapsigarging, which functions as an ER stress inducer and translation 
inhibitor, suggests that the mechanism of IL-1α release from damaged cells is 
translation-independent.  
One of the characteristic features of alarmins is that they are stored in intracellular 
compartments and can be rapidly released following cell injury. Using an 
immunofluorescent staining technique, we demonstrated that substantial amounts 
of intracellular IL-1α protein are present in the cytoplasm of bronchial and alveolar 
epithelium of histological sections of normal human lung. This observation, suggests 
that IL-1α may be rapidly released from damaged respiratory epithelium, which 
poses the first line of defense against the invading pathogens and exogenous 
chemicals and therefore is prone to injury. 
The observations described above are in compliance with previous studied 
demonstrating that IL-1α may function as an alarmin and can be rapidly released 
from damaged cells [182]. Moreover it has been demonstrated that the precursor 
form of IL-1α may act as a transcription factor, which can be translocated to the 
nucleus of macrophages upon stimulation with LPS and promote transcription of 
proinflammatory genes including IL-8 and IL-6 [348]. 
The role of IL-1α in the pathogenesis of chronic inflammatory lung diseases has 
been highlighted in several previous studies. For indtance, Yazdi et al., 
demonstrated that nano-TiO provoked lung inflammation was substantially 
suppressed in IL-1R or IL-1α deficient mice compared to the wild type.  
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Nanoparticles may activate innate immune responses via two distinct mechanisms. 
Namely, they can activated inflammasome via specific receptors such as Nod-like 
receptors, leading to IL-1β processing and release, and they can cause cellular 
damage, leading to spontaneous IL-1α release [349]. 
Although, the mechanism of IL-1β processing has been relatively widely described, 
the exact way in which IL-1α enters the extracellular space remains unclear. 
This issue has recently been addressed in a study performed by Gross el all, who 
suggests that IL-1α release from murine BMDC (bone marrow derived dendritic 
cells) cells may be both inflammasome-dependanat and independent. The authors 
propose that the deciding factor in this case is the type of stimulus. According to the 
study, caspase-1 independent IL-1α processing can be induces by stimulus such as 
Ca2+ influx, whereas caspase-1 dependant IL-1α release can be induced by NLRP3, 
NLRP1 or AIM2 ligands. Moreover, Ca2+ was shown to be involved in calpain-like 
protein-dependant IL-1α cleavage [350]. 
Caspase-1 is constitutively active in macrophages, which are able to secret IL-1β 
without inflammasome activation. In our study, however PMA-primed THP-1 cells 
failed to release IL-1α following LPS stimulation (data not shown). These 
observations and the results described in the aforementioned study [350], suggest, 
that the cell ability to release IL-1α and IL-1β may depend on the cell type and its 
metabolic state.  
Numerous PAMPs and DAMPs, including IL-1α, may upregulate IL-1α and IL-1β gene 
expression. Therefore it may be hypothesized, that during infection or repetitive 
tissue injury, the potential of cells to release IL-1α may increase. However, the fact 
that significant amounts of IL-1α but not IL-1β can be rapidly released from 
epithelial cells not subjected to any pre-stimulation with proinflammatory factors, 
suggests that IL-1α is the initial danger signal initiating inflammation. 
Although my study was performed in a context of chronic 
inflammatory/degenerative lung diseases, it is worth highlighting that the rapid IL-
1α release following epithelial injury may also serve very important physiological 
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function. One of the physiological processed where IL-1α may play a significant role 
is wound healing.  
Damage to the epithelial barrier initiates a cascade of events leading to macrophage 
and neutrophil recruitment, which by clearing the dead cell debris enable the 
subsequent regeneration of the damaged epithelium. Inflammation occurs rapidly 
post injury, and IL-1α which is stored inside cells may be released as the prime 
danger signal, initiating proinflammatory responses required for effective wound 
healing. Our study demonstrated that apart from fibroblasts, another cell type able 
to respond to IL-1α are epithelial cells, suggesting that paracrine interactions 
between damaged and undamaged epithelium may also significantly contribute to 
inflammation following injury. 
In conclusion, the data obtained in this study suggests, that IL-1α is the initial 
danger signal released from injured epithelial cells, which may activate innate 
immune responses in lung fibroblasts, which by producing substantial amounts of 
chemokines and cytokines such as IL-8 and GM-CSF may potentially attract 
neutrophils and macrophages to the site of injury. Repetitive insult to the 
epithelium may therefore result in chronic inflammation mediated by IL-1α, which 
can additionaly be accentuated by viral PAMPs. Hence anti-IL-1α therapies could be 
considered as a novel therapeutic strategy to target chronic inflammatory lung 
diseases. A proposed sequence of events following epithelial injury in the lung has 
been shown in figure 72. 
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Figure 72 Model of injury induced inflammation in the lung 
 
Diagram showing a proposed sequence of events following epithelial injury in the 
lung. Chemical, pathogenic or allogenic insult to epithelium causes release of 
alarmins including IL-1α which activates fibroblasts to release IL-8 attracting 
neutrophils to the site of injury. ROS producing neutrophils cause further damage to 
epithelium perpetuating the vicious circle of IL-1α-induced chronic inflammation.  
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6.3 Summary of main achievements  
 
Repetitive damage to the airway or alveolar epithelium, associated with 
inflammation and tissue remodeling are common features of many chronic 
respiratory diseases. Chronic inflammation, characterized by intensive protein 
production may also cause ER stress and an unfolded protein response, which may 
lead to programmed cell death. Additionally, the lung epithelium is the first point of 
contact for inhaled oxidants/free radicals and these species are normally 
neutralized by antioxidants present in epithelial lining fluid. Defining how oxidant 
and ER-stress-induced epithelial cell damage stimulates inflammation and 
identifying the molecular mediators that cross-talk between damaged and dying 
epithelial cells and the immune system are important goals necessary to improve 
our knowledge of the pathophysiological events that underlie chronic pulmonary 
disease.   
My work described here, makes the case for a new paradigm, that damaged 
bronchial epithelium can induce sterile innate immune signaling in lung fibroblasts 
resulting in a phenotypic switch towards a highly proinflammatory state.  
In this study I was able to show that a single alarmin IL-1α, is both necessary and 
sufficient for the epithelial damage-induced phenotypic switch of lung fibroblasts to 
their inflammatory state. Blockade of IL-1α signaling completely inhibited the 
induction of proinflammatory cytokines by damaged epithelial cells as well as the 
intracellular signaling events namely IKK2/NF-κB activation that transduce IL-1R 
triggered signals to the transcriptional machinery of the fibroblast. I also 
demonstrated that there is a positive correlation between elevated levels of IL-1α, 
IL-8 and neutrophils in the chronic inflammatory lung disease, BOS after lung 
transplantation.  
Additionally, my observation that TLR3 is the predominant TLR expressed in lung 
fibroblasts, and its ligation acts in synergy with IL-1α, raises the intriguing possibility 
that the degree to which fibroblasts impact on lung inflammation may be influenced 
by respiratory viral infections. The combined effects of IL-1α and TLR3 ligation on IL-
8 and IL-6 expression were suppressed by DEX and inhibitors of IKK2 and its 
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upstream kinase TAK1. In contrast, the neomacrolide, Azithromycin, which has been 
shown to have anti-inflammatory properties and improve lung function in some 
patients with BOS (24) did not have major anti—inflammatory effect on IL-8 and IL-
6 expression in fibroblasts in response to IL-1α. This may be an important 
observation as more than 50% of patients who develop BOS fail to respond to the 
anti-inflammatory actions of Azithromycin. 
One of the main advantages of my study was the confirmation of the role of the 
epithelial alarmin IL-1α in triggering a proinflammatory phenotype in fibroblasts 
using primary human lung fibroblasts from a normal lung and two in vitro models of 
injury of human bronchial epithelial cells (oxidative stress and ER stress). However, 
all in vitro models have their limitations and one of the main drawbacks of this 
study was a limited access to PBEC cells from normal lung (the cells used in the 
study came from bronchial brushings obtained from stable post-transplant 
patients). Also, the behaviour of PBEC cells from diseased lung has not been 
investigated in this project.  
The objective of my project was to identify alarmins that are released from injured 
bronchial epithelium and trigger sterile inflammation and fibroblast activation in the 
lung. However, normal lung is not sterile. Lungs are constantly exposed to airborne 
pathogens which are ‘kept at bay’ by the immune system. Therefore it may be 
assumed that all primary bronchial cells, unless obtained from a foetal tissue, have 
been primed with microbial and viral PAMPs. From that perspective the 
physiological relevance of the two models of epithelial injury used in the study can 
be questioned and therefore it would be beneficial to confirm the main results 
using a model of epithelial injury induced by viral or bacterial infection.  
Additionally, from the clinical point of view it would be advantageous to measure 
the levels of IL-1α as well as to establish the ratio of total and pro-IL-1β in BALs of 
patients with BOS. My study revealed that the development of BOS was associated 
with increased concentrations of both IL-1α and total IL-1β (data not shown), 
however the levels of active IL-1β in BALs of these patients have not been 
established, and therefore it remains unclear which one of the aforementioned IL-1 
family members may be implicated in the pathogenesis of BOS. 
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Interestingly my study revealed that IL-1α released from damaged epithelial cells 
triggers gene expression of both IL-1α and IL-1β which was not followed by IL-1α or 
IL-1β protein release. IL-1α also induced gene expression of another alarmin, IL-33 
(data not shown) and resulted in accumulation of IL-6 proteins in intacellular 
granules. These properties of IL-1α and the fact that it is released not only from 
damaged but also still viable but stressed cells, suggests that this alarmin may 
function as the initial danger signal priming and preparing the adjacent cells to rapid 
innate immune response to agents which may potentially damage the bronchial 
epithelium. To confirm this hypothesis, another experiment could be performed 
where release of different alarmins would be measured from cells that were first 
primed with IL-1α and then damaged with different injurious stimuli.  
Taken together, these observations build a case for investigating the therapeutic 
potential of biologics that attenuate IL-1α/IL-1R signaling in these chronic lung 
diseases which are associated with significant morbidity and premature mortality.        
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6.4 Possible future work 
 
1. Confirm the role of fibroblasts and IL-1α as mediators of inflammation in 
vivo using an animal model of pulmonary fibrosis. 
The current study resulted in identification of IL-1α as the key epithelial alarmin 
responsible for triggering a proinflammatory phenotype in primary human lung 
fibroblasts, however it did not provide an evidence that fibroblasts are important 
contributors to proinflmmatory responses in the microenvironment of injured 
tissue. To determine whether IL-1α-induced inflammation is mainly controlled by 
hemopoietic or nonhemopoietic cells in vivo, bone marrow (BM) chimeric mice 
between IL-1R and IL-1R-/- and IL-1a and IL-1a-/- mice could be generated and 
subjected to bleomycin-induced lung injury. This experiment could be next repeated 
using a more physiologically relevant model of virus-induced lung injury. 
Additionally, to distinguish between the role of epithelial cells and fibroblasts Cre-
loxP-based mouse model for conditional knockdown of IL-1R in collagen-expressing 
cells could be used. 
2. Confirm the role of IL-1α in activating innate immune responses in primary 
human lung fibroblasts using a model of rhinovirus (RV)-induced epithelial 
injury. 
In the current study, in vitro models of oxidative stress and ER stress-induced-cell 
injury models were used to evaluate the role of epithelium-derived IL-1α in the 
activation of primary human lung fibroblasts. Both oxidative stress and ER stress 
have been associated with chronic inflammation, however the in vitro models using 
relatively high doses of H2O2 and thapsigargin are difficult to translate into an in 
vivo situation. Another factor that largerly contributes to exacerbations in chronic 
inflammatory lung diseases are viral infections, and therefore to evaluate the 
results obtained in the current study, the key experiments could be repeated using 
an in vitro model of epithelial injury induced by rhinovirus (RV), which has been 
recognized as a risk factor in BOS. 
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3. Investigate the interplay between damaged epithelial cells, fibroblasts and T 
cells. 
The characteristic features of chronic post-transplant lung rejection include damage 
to the respiratory epithelium, fibroproliferation and influx of inflammatory cells 
including macrophages, neutrophils and T cells. Interaction between these type of 
cells and cytokines released by them, determine the microenvironment of the 
injured tissue. In a fibrotic tissue the balance between the number of these cellular 
components and their activation state becomes distorted. Evaluating how the 
interations between different immune and non-immune cellular components affect 
their phenotypes might increase the current understading of the relationship 
between fibrogenesis and activation of the innate and adaptive immune system.  
4. Analyze the profile of cytokines expressed by human primary lung 
fibroblasts upon stimulation with IL-1α by MSD multiplex assay or a PCR 
microarray. 
The current study revealed that IL-1α released by damaged human bronchial 
epithelial cells triggers a pro-inflammatory phenotype in fibroblasts characterized 
by increased gene expression of marker cytokines including IL-8, IL-6, MCP-1, GM-
CSF, IL-1α and IL-1β. To fully unravel the proinflammatory potential of primary 
human lung fibroblasts, a profile of cytokines released by these cells upon 
stimulation with IL-1α could be evaluated by MSD multiplex assay and a PCR 
microarray. 
5. Compare cytokine expression profile in normal primary human lung 
fibroblasts and fibroblasts derived from diseased tissue (derived from 
patients with COPD or BOS). 
The experiments described in the current study were performed using normal 
human lung fibroblasts (MRC5) or primary human lung fibroblasts derived from 
normal/healthy tissues. To evelaute if there are phenotypic differences between 
normal fibroblasts and fibroblasts diseased lung, cytokine expression profile in 
normal fibroblasts and fibroblasts derived derived from patients with COPD or BOS 
could be evaluated using a PCR microarray or MSD multiplex assay. 
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6. Perform a prospective study to investigate the association between IL-1α 
concentrations in BALs, development of BOS and the incidence of bacterial 
and viral infections in post-transplant patients.  
One of the limitations of the current study is its retrospective character. The time of 
BAL sampling was driven by clinical need and was not per pre-defined protocol 
which resulted in the difference in the number of samples collected from BOS and 
stable patients. Another limitation of this study is the lack of data on viral infections 
in the examined cohort of patients. To address these issues, a re-designed 
prospective study could be performed in the future.  
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6.5 Publications and presentations 
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Crosstalk between lung fibroblasts and T-lymphocytes: implications for anti-viral 
responses in chronic lung disease (poster presentation) 
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Borthwick, Derek A Mann, Andrew J Fisher 
 
2013 British Association of Lung Research, Summer Conference  
Transforming growth factor beta (TGFβ) and interleukin-1α (IL-1α) drive opposing 
functional phenotypes in primary human lung fibroblasts (PHLF) (poster 
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2013 American Thoracic Society Conference, Philadelphia 
Interleukin-1 alpha released from airway epithelium in response to endoplasmic 
reticulum stress promotes induction of a pro-inflammatory lung fibroblast 
phenotype (poster presentation) 
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Nicola J Green, Monika I Suwara, Lee A Borthwick, Derek A Mann and Andrew J 
Fisher 
 
2011 The International Society for Lung and Heart Transplantation Conference, 
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bronchiolitis obliterans syndrome (BOS) (poster presentation) 
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